CINXE.COM

<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/><script>window.clientEnvVars = {"SITE_KEY":"COM","GTM":"GTM-N67QVH3","LD_CLIENT_SIDE":"63779209b9abad1176b1c8de","ONETRUST":"5ba9840f-2af3-4f28-b54d-b9d55e0175d5","SCRIPTS_HEAD":"","IMG_OPTIM":true}</script><script>window.clientSideID='63779209b9abad1176b1c8de';window.ssrFlags={ "onepagerv2-ar-cache": true, "onepagerv2-ar-preview": true, "onepagerv2-at-cache": true, "onepagerv2-at-preview": true, "onepagerv2-au-cache": true, "onepagerv2-au-preview": true, "onepagerv2-be-cache": true, "onepagerv2-be-preview": true, "onepagerv2-ca-cache": true, "onepagerv2-ca-preview": true, "onepagerv2-ch-cache": true, "onepagerv2-ch-preview": true, "onepagerv2-ci-cache": true, "onepagerv2-ci-preview": true, "onepagerv2-cl-cache": true, "onepagerv2-cl-preview": true, "onepagerv2-co-cache": true, "onepagerv2-co-preview": true, "onepagerv2-cz-cache": true, "onepagerv2-cz-preview": true, "onepagerv2-dk-cache": true, "onepagerv2-dk-preview": true, "onepagerv2-dz-cache": true, "onepagerv2-dz-preview": true, "onepagerv2-eg-cache": true, "onepagerv2-eg-preview": true, "onepagerv2-es-cache": true, "onepagerv2-es-preview": true, "onepagerv2-fi-cache": true, "onepagerv2-fi-preview": true, "onepagerv2-gr-cache": true, "onepagerv2-gr-preview": true, "onepagerv2-hk-cache": true, "onepagerv2-hk-preview": true, "onepagerv2-hu-cache": true, "onepagerv2-hu-preview": true, "onepagerv2-ie-cache": true, "onepagerv2-ie-preview": true, "onepagerv2-il-cache": true, "onepagerv2-il-preview": true, "onepagerv2-in-cache": true, "onepagerv2-in-preview": true, "onepagerv2-it-cache": true, "onepagerv2-it-preview": true, "onepagerv2-kr-cache": true, "onepagerv2-kr-preview": true, "onepagerv2-lb-cache": true, "onepagerv2-lb-preview": true, "onepagerv2-ma-cache": true, "onepagerv2-ma-preview": true, "onepagerv2-mx-cache": true, "onepagerv2-mx-preview": true, "onepagerv2-my-cache": true, "onepagerv2-my-preview": true, "onepagerv2-nl-cache": true, "onepagerv2-nl-preview": true, "onepagerv2-no-cache": true, "onepagerv2-no-preview": true, "onepagerv2-pa-cache": true, "onepagerv2-pa-preview": true, "onepagerv2-pe-cache": true, "onepagerv2-pe-preview": true, "onepagerv2-pl-cache": true, "onepagerv2-pl-preview": true, "onepagerv2-pt-cache": true, "onepagerv2-pt-preview": true, "onepagerv2-py-cache": true, "onepagerv2-py-preview": true, "onepagerv2-ro-cache": true, "onepagerv2-ro-preview": true, "onepagerv2-ru-cache": true, "onepagerv2-ru-preview": true, "onepagerv2-sa-cache": true, "onepagerv2-sa-preview": true, "onepagerv2-se-cache": true, "onepagerv2-se-preview": true, "onepagerv2-sg-cache": true, "onepagerv2-sg-preview": true, "onepagerv2-th-cache": true, "onepagerv2-th-preview": true, "onepagerv2-tr-cache": true, "onepagerv2-tr-preview": true, "onepagerv2-tw-cache": true, "onepagerv2-tw-preview": true, "onepagerv2-ua-cache": true, "onepagerv2-ua-preview": true, "onepagerv2-uy-cache": true, "onepagerv2-uy-preview": true, "onepagerv2-vn-cache": true, "onepagerv2-vn-preview": true, "onepagerv2-xx-cache": true, "onepagerv2-xx-preview": true, "onepagerv2-za-cache": true, "onepagerv2-za-preview": true, "$flagsState": { "onepagerv2-ar-cache": { "variation": 0, "version": 10 }, "onepagerv2-ar-preview": { "variation": 0, "version": 4 }, "onepagerv2-at-cache": { "variation": 0, "version": 5 }, "onepagerv2-at-preview": { "variation": 0, "version": 5 }, "onepagerv2-au-cache": { "variation": 0, "version": 5 }, "onepagerv2-au-preview": { "variation": 0, "version": 5 }, "onepagerv2-be-cache": { "variation": 0, "version": 5 }, "onepagerv2-be-preview": { "variation": 0, "version": 7 }, "onepagerv2-ca-cache": { "variation": 0, "version": 5 }, "onepagerv2-ca-preview": { "variation": 0, "version": 5 }, "onepagerv2-ch-cache": { "variation": 0, "version": 5 }, "onepagerv2-ch-preview": { "variation": 0, "version": 5 }, "onepagerv2-ci-cache": { "variation": 0, "version": 5 }, "onepagerv2-ci-preview": { "variation": 0, "version": 11 }, "onepagerv2-cl-cache": { "variation": 0, "version": 5 }, "onepagerv2-cl-preview": { "variation": 0, "version": 5 }, "onepagerv2-co-cache": { "variation": 0, "version": 5 }, "onepagerv2-co-preview": { "variation": 0, "version": 5 }, "onepagerv2-cz-cache": { "variation": 0, "version": 5 }, "onepagerv2-cz-preview": { "variation": 0, "version": 5 }, "onepagerv2-dk-cache": { "variation": 0, "version": 4 }, "onepagerv2-dk-preview": { "variation": 0, "version": 4 }, "onepagerv2-dz-cache": { "variation": 0, "version": 4 }, "onepagerv2-dz-preview": { "variation": 0, "version": 4 }, "onepagerv2-eg-cache": { "variation": 0, "version": 4 }, "onepagerv2-eg-preview": { "variation": 0, "version": 4 }, "onepagerv2-es-cache": { "variation": 0, "version": 4 }, "onepagerv2-es-preview": { "variation": 0, "version": 4 }, "onepagerv2-fi-cache": { "variation": 0, "version": 4 }, "onepagerv2-fi-preview": { "variation": 0, "version": 4 }, "onepagerv2-gr-cache": { "variation": 0, "version": 4 }, "onepagerv2-gr-preview": { "variation": 0, "version": 4 }, "onepagerv2-hk-cache": { "variation": 0, "version": 4 }, "onepagerv2-hk-preview": { "variation": 0, "version": 4 }, "onepagerv2-hu-cache": { "variation": 0, "version": 4 }, "onepagerv2-hu-preview": { "variation": 0, "version": 4 }, "onepagerv2-ie-cache": { "variation": 0, "version": 4 }, "onepagerv2-ie-preview": { "variation": 0, "version": 4 }, "onepagerv2-il-cache": { "variation": 0, "version": 4 }, "onepagerv2-il-preview": { "variation": 0, "version": 4 }, "onepagerv2-in-cache": { "variation": 0, "version": 4 }, "onepagerv2-in-preview": { "variation": 0, "version": 4 }, "onepagerv2-it-cache": { "variation": 0, "version": 4 }, "onepagerv2-it-preview": { "variation": 0, "version": 4 }, "onepagerv2-kr-cache": { "variation": 0, "version": 4 }, "onepagerv2-kr-preview": { "variation": 0, "version": 4 }, "onepagerv2-lb-cache": { "variation": 0, "version": 4 }, "onepagerv2-lb-preview": { "variation": 0, "version": 4 }, "onepagerv2-ma-cache": { "variation": 0, "version": 4 }, "onepagerv2-ma-preview": { "variation": 0, "version": 4 }, "onepagerv2-mx-cache": { "variation": 0, "version": 4 }, "onepagerv2-mx-preview": { "variation": 0, "version": 4 }, "onepagerv2-my-cache": { "variation": 0, "version": 4 }, "onepagerv2-my-preview": { "variation": 0, "version": 4 }, "onepagerv2-nl-cache": { "variation": 0, "version": 4 }, "onepagerv2-nl-preview": { "variation": 0, "version": 4 }, "onepagerv2-no-cache": { "variation": 0, "version": 4 }, "onepagerv2-no-preview": { "variation": 0, "version": 4 }, "onepagerv2-pa-cache": { "variation": 0, "version": 4 }, "onepagerv2-pa-preview": { "variation": 0, "version": 4 }, "onepagerv2-pe-cache": { "variation": 0, "version": 4 }, "onepagerv2-pe-preview": { "variation": 0, "version": 4 }, "onepagerv2-pl-cache": { "variation": 0, "version": 4 }, "onepagerv2-pl-preview": { "variation": 0, "version": 4 }, "onepagerv2-pt-cache": { "variation": 0, "version": 4 }, "onepagerv2-pt-preview": { "variation": 0, "version": 4 }, "onepagerv2-py-cache": { "variation": 0, "version": 4 }, "onepagerv2-py-preview": { "variation": 0, "version": 4 }, "onepagerv2-ro-cache": { "variation": 0, "version": 4 }, "onepagerv2-ro-preview": { "variation": 0, "version": 4 }, "onepagerv2-ru-cache": { "variation": 0, "version": 4 }, "onepagerv2-ru-preview": { "variation": 0, "version": 4 }, "onepagerv2-sa-cache": { "variation": 0, "version": 4 }, "onepagerv2-sa-preview": { "variation": 0, "version": 4 }, "onepagerv2-se-cache": { "variation": 0, "version": 4 }, "onepagerv2-se-preview": { "variation": 0, "version": 4 }, "onepagerv2-sg-cache": { "variation": 0, "version": 4 }, "onepagerv2-sg-preview": { "variation": 0, "version": 4 }, "onepagerv2-th-cache": { "variation": 0, "version": 4 }, "onepagerv2-th-preview": { "variation": 0, "version": 4 }, "onepagerv2-tr-cache": { "variation": 0, "version": 4 }, "onepagerv2-tr-preview": { "variation": 0, "version": 4 }, "onepagerv2-tw-cache": { "variation": 0, "version": 4 }, "onepagerv2-tw-preview": { "variation": 0, "version": 4 }, "onepagerv2-ua-cache": { "variation": 0, "version": 4 }, "onepagerv2-ua-preview": { "variation": 0, "version": 4 }, "onepagerv2-uy-cache": { "variation": 0, "version": 4 }, "onepagerv2-uy-preview": { "variation": 0, "version": 4 }, "onepagerv2-vn-cache": { "variation": 0, "version": 4 }, "onepagerv2-vn-preview": { "variation": 0, "version": 4 }, "onepagerv2-xx-cache": { "variation": 0, "version": 4 }, "onepagerv2-xx-preview": { "variation": 0, "version": 5 }, "onepagerv2-za-cache": { "variation": 0, "version": 4 }, "onepagerv2-za-preview": { "variation": 0, "version": 4 } }, "$valid": true };window.ldUser={ "key": "test", "anonymous": true };</script><title>Latest Sanofi Press Releases and News | Sanofi</title><meta name="description" content="Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi."/><meta name="keywords" content="press release, sanofi press release, sanofi news"/><meta property="og:title" content="Press Releases, review Sanofi healthcare news stories, including media releases and featured information"/><meta property="og:type" value="landing page"/><meta property="og:description" content="View the latest press releases from Sanofi global pharmaceutical and healthcare company. "/><meta property="og:url" content="https://www.sanofi.com/en/media-room/press-releases"/><meta property="og:image" content="https://www.sanofi.com/assets/dotcom/pages/images/media-room/hero-media-room02_20230707101239.jpg"/><meta property="og:locale" content="en"/><meta property="og:locale:alternate" content="fr"/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Press Releases, review Sanofi healthcare news stories, including media releases and featured information"/><meta name="twitter:description" content="View the latest press releases from Sanofi global pharmaceutical and healthcare company. "/><meta name="twitter:url" content="https://www.sanofi.com/en/media-room/press-releases"/><meta name="twitter:image" content="https://www.sanofi.com/assets/dotcom/pages/images/media-room/hero-media-room02_20230707101239.jpg"/><link rel="canonical" href="https://www.sanofi.com/en/media-room/press-releases"/><link rel="preload" href="/static/_assets/Sanofi_Sans-Regular-XSMTS7PK.woff2" as="font" type="font/woff2" crossorigin="anonymous"/><link rel="preload" href="/static/_assets/Sanofi_Sans-Bold-C4ON3UHE.woff2" as="font" type="font/woff2" crossorigin="anonymous"/><link rel="icon" sizes="any" type="image/png" href="/favicon.ico"/><link rel="icon" type="image/svg+xml" href="/icons/favicon.svg"/><link rel="apple-touch-icon" sizes="180x180" type="image/png" href="/icons/favicon-180x180.png"/><link rel="manifest" href="/icons/manifest.webmanifest"/><meta name="emotion"/><style data-emotion="css-global 1rlx0w">body,html{scroll-padding-top:75px;}@font-face{font-family:Sanofi Sans;font-style:normal;font-weight:400;src:url(/static/_assets/Sanofi_Sans-Regular-XSMTS7PK.woff2) format("woff2");font-display:swap;}@font-face{font-family:Sanofi Sans;font-style:normal;font-weight:700;src:url(/static/_assets/Sanofi_Sans-Bold-C4ON3UHE.woff2) format("woff2");font-display:swap;}.svg-inline--fa{height:1em;}a{color:currentColor;-webkit-text-decoration:none;text-decoration:none;}@media screen and (max-width: 1024px){.lockBodyScroll{overflow:hidden;}}div[aria-label^="carousel"][role~="region"] div[aria-label^="Item"][class|="elements"]{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}.dotcom-hero-cta{-webkit-text-decoration:none;text-decoration:none;border:0 none transparent;position:relative;cursor:pointer;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;vertical-align:middle;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;border-radius:calc(8px / 2);height:44px;padding:0 24px;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Normal;line-height:100%;font-size:1rem;letter-spacing:0px;color:#fff;background-color:#7a00e6;}.dotcom-header-search button{background-color:transparent;border:none 0;}.dotcom-header-languageswitch div#languages_select{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-webkit-justify-content:space-between;justify-content:space-between;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;height:48px;padding:0 16px 0 12px;border-radius:calc(8px / 2);}.dotcom-header-languageswitch svg{width:1em;height:1em;color:#5d5d5d;margin-left:16px;}</style><style data-emotion="css-global 8mbdgj">html{-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;box-sizing:border-box;-webkit-text-size-adjust:100%;}*,*::before,*::after{box-sizing:inherit;}strong,b{font-weight:Bold;}body{margin:0;color:#0d0d0d;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Normal;line-height:150%;font-size:1rem;letter-spacing:0px;background-color:#fff;}@media print{body{background-color:#fff;}}body::backdrop{background-color:#fff;}</style><style data-emotion="css 1sb87pj jbxqua 1s4q8eq jbvua0 11feumg 1a8ug3n-MuiSvgIcon-root 12t0typ coveql-MuiSvgIcon-root 15mda6m-MuiButtonBase-root-MuiIconButton-root 1cqj9cj-MuiSvgIcon-root 1f94a5v 1pmzs1y 1iyrj07-MuiList-root 7v3ck0 wen7gr 1v9d7j7 ezq9xk ymxx1b 8893o5-MuiTypography-root 1w57mgj 1hj1fp6 1777e4e 1d9vbqz-MuiSvgIcon-root tpvpkp 1yvnwr8 lpkobr dyli1u oq95y2 1lyzz7t xesgy4-MuiSvgIcon-root 1otjjom y1im4h-MuiTypography-root-MuiBreadcrumbs-root 4pdmu4-MuiBreadcrumbs-ol 14aisoc 1wuw8dw-MuiBreadcrumbs-separator ead8px-MuiSvgIcon-root 1boheuq-MuiTypography-root j9j92j-MuiStack-root 7vsjpe 10rfme0-MuiContainer-root 1qgmfta-MuiGrid2-root 689yzq-MuiGrid2-root 1hnspsh-MuiTypography-root 1f4kha5-MuiContainer-root u69w57-MuiStack-root gei8j6 19xm1y8-MuiGrid2-root 1wodyvb-MuiGrid2-root 17ts118-MuiGrid2-root 1b1hect-MuiGrid2-root epopls-MuiGrid2-root 1pytp3s-MuiDivider-root y36fim 14o2ao6-MuiGrid2-root 1q768l5-MuiGrid2-root 1ufdk6m-MuiTypography-root 1fchgxt-MuiTypography-root 1i53qr6-MuiGrid2-root c7yewm-MuiGrid2-root 1cc1yhr-MuiGrid2-root 4q3mua jqikz1 cr2kt9-MuiGrid2-root c8gmj9-MuiGrid2-root 1te8woh-MuiTypography-root 146zs5-MuiGrid2-root qiso3p-MuiStack-root 1n0w9uy 1elqj97 46kbhf-MuiSvgIcon-root 1juh738 amrgmt-MuiTypography-root 1oc5ep0-MuiList-root 16yom0i-MuiListItem-root 1l93wsm 3759vn 17gnk4t-MuiButtonBase-root-MuiIconButton-root 1boijxs 1l2zhvo-MuiList-root 73fo95-MuiListItem-root 1u4cuma hwnj0i-MuiStack-root 1ubkcfk-MuiTypography-root">@media (max-width:1279.95px){.css-1sb87pj{overflow:initial;}}.css-jbxqua{min-height:100%;display:grid;grid-template-rows:auto 1fr auto;grid-template-columns:100%;}.css-1s4q8eq{display:grid;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;height:auto;position:-webkit-sticky;position:sticky;top:0px;padding-left:16px;padding-right:16px;background-color:#fff;z-index:1100;border-bottom:1px solid #f5f5f5;}@media (min-width:0px){.css-1s4q8eq{grid-template-rows:62px auto;grid-template-columns:max-content auto max-content;grid-template-areas:" toggle brand search " " panel panel panel ";}}@media (min-width:1280px){.css-1s4q8eq{grid-template-rows:72px;grid-template-columns:max-content auto max-content max-content max-content;grid-template-areas:"brand main utility search directory";}}.css-1s4q8eq.panelIsOpen{grid-template-areas:"backButton title toggle" "panel panel panel";}@media (min-width:0px){.css-1s4q8eq.panelIsOpen{height:calc(100vh - 62px);}}@media (min-width:1280px){.css-1s4q8eq.panelIsOpen{height:auto;}}.css-1s4q8eq:not(.panelIsOpen){-webkit-column-gap:12px;column-gap:12px;}@media (min-width:1280px){.css-1s4q8eq:not(.panelIsOpen),.css-1s4q8eq.panelIsOpen{height:auto;-webkit-column-gap:32px;column-gap:32px;padding-left:32px;padding-right:32px;}}.css-jbvua0{display:contents;}.css-11feumg{justify-self:center;color:#000;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;margin-left:-4px;margin-right:-4px;}@media (min-width:1280px){.css-11feumg{justify-self:auto;}}.css-11feumg:focus-visible{outline:#b3a8e6;outline-style:solid;outline-width:4px;border-radius:calc(8px / 2);}.css-1a8ug3n-MuiSvgIcon-root{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;display:inline-block;fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:1.7142857142857142rem;font-size:1.2rem;margin-left:4px;margin-top:4px;margin-right:4px;margin-bottom:8px;height:auto;font-size:5rem;grid-area:brand;}.panelIsOpen .css-1a8ug3n-MuiSvgIcon-root{display:none;}@media (min-width:1280px){.panelIsOpen .css-1a8ug3n-MuiSvgIcon-root{display:block;}}.css-12t0typ{grid-area:search;}@media (min-width:0px){.css-12t0typ{margin-left:0px;margin-right:-12px;}}@media (min-width:768px){.css-12t0typ{margin-left:0px;margin-right:-12px;}}@media (min-width:1280px){.css-12t0typ{margin-left:-22px;margin-right:-22px;}}@media (min-width:0px){.panelIsOpen .css-12t0typ{display:none;}}@media (min-width:1280px){.panelIsOpen .css-12t0typ{display:block;}}.css-coveql-MuiSvgIcon-root{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;display:inline-block;fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:1.7142857142857142rem;font-size:1.2rem;}.css-15mda6m-MuiButtonBase-root-MuiIconButton-root{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;position:relative;box-sizing:border-box;-webkit-tap-highlight-color:transparent;background-color:transparent;outline:0;border:0;margin:0;border-radius:0;padding:0;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;vertical-align:middle;-moz-appearance:none;-webkit-appearance:none;-webkit-text-decoration:none;text-decoration:none;color:inherit;text-align:center;-webkit-flex:0 0 auto;-ms-flex:0 0 auto;flex:0 0 auto;font-size:1.7142857142857142rem;padding:8px;border-radius:50%;overflow:visible;color:rgba(0, 0, 0, 0.54);-webkit-transition:background-color 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:background-color 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:1rem;grid-area:toggle;padding:0px;border:none;background:transparent;cursor:pointer;color:#7a00e6;}.css-15mda6m-MuiButtonBase-root-MuiIconButton-root::-moz-focus-inner{border-style:none;}.css-15mda6m-MuiButtonBase-root-MuiIconButton-root.Mui-disabled{pointer-events:none;cursor:default;}@media print{.css-15mda6m-MuiButtonBase-root-MuiIconButton-root{-webkit-print-color-adjust:exact;color-adjust:exact;}}.css-15mda6m-MuiButtonBase-root-MuiIconButton-root.Mui-disabled{background-color:transparent;color:rgba(0, 0, 0, 0.26);}@media (min-width:1280px){.css-15mda6m-MuiButtonBase-root-MuiIconButton-root{display:none;}}.css-1cqj9cj-MuiSvgIcon-root{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;display:inline-block;fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:2.5rem;font-size:1.5rem;}.css-1f94a5v{display:none;grid-area:panel;position:absolute;top:1;left:-16px;overflow-x:hidden;overflow-y:scroll;height:100%;width:calc(100% + (16px) * 2);background-color:#fff;}.panelIsOpen .css-1f94a5v{display:grid;grid-template-columns:auto;grid-template-rows:max-content max-content auto max-content;grid-template-areas:"main" "utility" "." "directory";}@media (min-width:1280px){.css-1f94a5v{display:contents;}.panelIsOpen .css-1f94a5v{display:contents;}}.css-1pmzs1y{grid-area:main;}@media (max-width:1279.95px){.css-1pmzs1y{width:100vw;}}.css-1iyrj07-MuiList-root{list-style:none;margin:0;padding:0;position:relative;position:initial;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-column-gap:8px;column-gap:8px;}@media (min-width:0px){.panelIsOpen .css-1iyrj07-MuiList-root{-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;}}@media (min-width:768px){.panelIsOpen .css-1iyrj07-MuiList-root{-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;}}@media (min-width:1280px){.panelIsOpen .css-1iyrj07-MuiList-root{-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;}}.css-7v3ck0{list-style:none;}@media (max-width:1279.95px){.css-7v3ck0{padding:8px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;min-height:62px;border-top:0.5px solid #c9c9c9;font-weight:Bold;}}@media (min-width:1280px){.css-7v3ck0{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;font-weight:Bold;}}@media (min-width:1280px){.css-7v3ck0{cursor:pointer;}}@media (max-width:1279.95px){.css-wen7gr{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;width:100%;padding:8px;-webkit-box-pack:justify;-webkit-justify-content:space-between;justify-content:space-between;}.css-wen7gr:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);}}@media (min-width:1280px){.css-wen7gr{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;line-height:20px;-webkit-flex:0 1 auto;-ms-flex:0 1 auto;flex:0 1 auto;padding:8px;}.css-wen7gr:hover{color:#7a00e6;-webkit-text-decoration:underline;text-decoration:underline;}.css-wen7gr:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);}}.css-1v9d7j7{display:none;position:absolute;top:0;padding:0;width:100%;background-color:#fff;z-index:3;}@media (max-width:1279.95px){.css-1v9d7j7{min-height:100vh;left:0;}}@media (min-width:1280px){.css-1v9d7j7{list-style:none;height:auto;max-height:calc(100vh - 72px);overflow-y:auto;-webkit-flex:none;-ms-flex:none;flex:none;left:0px;-webkit-order:unset;-ms-flex-order:unset;order:unset;width:100%;padding-left:calc((100vw - 1184px) / 2);padding-right:calc((100vw - 1184px) / 2);top:calc(72px + 1px - 0px);padding-top:calc(0px + 32px);padding-bottom:32px;}}.css-ezq9xk{list-style:none;}@media (max-width:1279.95px){.css-ezq9xk{padding:8px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;min-height:62px;border-top:0.5px solid #c9c9c9;}}@media (min-width:1280px){.css-ezq9xk{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;font-weight:500;margin-left:-8px;padding:8px;width:320px;min-height:48px;}}@media (max-width:1279.95px){.css-ymxx1b{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;width:100%;padding:8px;}.css-ymxx1b:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);}}@media (min-width:1280px){.css-ymxx1b{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;padding:8px;line-height:20px;}.css-ymxx1b:hover{color:#7a00e6;-webkit-text-decoration:underline;text-decoration:underline;}.css-ymxx1b:active{color:#7a00e6;}.css-ymxx1b:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);}}.css-8893o5-MuiTypography-root{margin:0;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:125%;font-size:1.125rem;letter-spacing:0px;color:#000000;color:inherit;}@media (min-width:768px){.css-8893o5-MuiTypography-root{font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:125%;font-size:1.125rem;letter-spacing:0px;}}@media (min-width:1280px){.css-8893o5-MuiTypography-root{font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:125%;font-size:1.125rem;letter-spacing:0px;}}.css-1w57mgj{list-style:none;}@media (max-width:1279.95px){.css-1w57mgj{padding:8px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;min-height:62px;border-top:0.5px solid #c9c9c9;font-weight:500;}}@media (min-width:1280px){.css-1w57mgj{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;font-weight:500;margin-left:-8px;padding:8px;width:320px;min-height:48px;}}@media (max-width:1279.95px){.css-1hj1fp6{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;width:100%;padding:8px;}.css-1hj1fp6:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);}}@media (min-width:1280px){.css-1hj1fp6{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;padding:8px;line-height:20px;}.css-1hj1fp6:hover{color:#7a00e6;-webkit-text-decoration:underline;text-decoration:underline;}.css-1hj1fp6:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);}}@media (max-width:1279.95px){.css-1777e4e{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;width:100%;padding:8px;-webkit-box-pack:justify;-webkit-justify-content:space-between;justify-content:space-between;}.css-1777e4e:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);}}@media (min-width:1280px){.css-1777e4e{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;padding:8px;line-height:20px;}.css-1777e4e:hover{color:#7a00e6;-webkit-text-decoration:underline;text-decoration:underline;}.css-1777e4e:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);}}.css-1d9vbqz-MuiSvgIcon-root{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;display:inline-block;fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:2.5rem;font-size:1.5rem;padding:0px;padding-left:6px;}.css-tpvpkp{display:none;position:absolute;top:0;padding:0;width:100%;background-color:#fff;z-index:4;}@media (max-width:1279.95px){.css-tpvpkp{height:100vh;left:0;}}@media (min-width:1280px){.css-tpvpkp{list-style:none;height:auto;max-height:calc(100vh - 72px);overflow-y:auto;-webkit-flex:none;-ms-flex:none;flex:none;-webkit-order:unset;-ms-flex-order:unset;order:unset;border-left:1px solid #e4e4e4;top:0;margin-top:calc(0px + 32px + 48px + 8px );left:calc(((100vw - 1184px) / 2) + 320px);right:calc((100vw - 1184px) / 2);width:auto;padding-left:32px;}}.css-1yvnwr8{list-style:none;}@media (max-width:1279.95px){.css-1yvnwr8{padding:8px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;min-height:62px;border-top:0.5px solid #c9c9c9;}}@media (min-width:1280px){.css-1yvnwr8{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;font-weight:500;margin-left:0;padding:8px;width:100%;min-height:48px;}}.css-lpkobr{list-style:none;}@media (max-width:1279.95px){.css-lpkobr{padding:8px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;min-height:62px;border-top:0.5px solid #c9c9c9;font-weight:500;}}@media (min-width:1280px){.css-lpkobr{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;font-weight:500;padding:8px;width:100%;min-height:48px;}}.css-dyli1u{grid-area:utility;}@media (max-width:1279.95px){.css-dyli1u{width:100vw;}}@media (max-width:1279.95px){.css-oq95y2{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;width:100%;padding:8px;}.css-oq95y2:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);}}@media (min-width:1280px){.css-oq95y2{line-height:20px;-webkit-flex:0 1 auto;-ms-flex:0 1 auto;flex:0 1 auto;padding:8px;}.css-oq95y2:hover{color:#7a00e6;-webkit-text-decoration:underline;text-decoration:underline;}.css-oq95y2:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);}}.css-1lyzz7t{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-column-gap:8px;column-gap:8px;grid-area:directory;padding:0px;border:none;background:transparent;font-size:inherit;font-family:inherit;font-weight:Bold;cursor:pointer;}@media (max-width:1279.95px){.css-1lyzz7t{-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;padding:0px 16px;height:62px;background:#f5f5f5;border-bottom:1px solid #c9c9c9;font-weight:500;position:fixed;z-index:1100;width:100%;bottom:0;}}.css-1lyzz7t:focus-visible{outline:#b3a8e6 solid 4px;outline-offset:4px;border-radius:calc(8px / 2);}.css-xesgy4-MuiSvgIcon-root{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;display:inline-block;fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:1.7142857142857142rem;font-size:1.2rem;}.css-1otjjom{display:none;}@media (min-width:768px){.css-1otjjom{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;padding-inline:16px;min-height:32px;}}@media (min-width:1280px){.css-1otjjom{padding-inline:32px;}}.css-y1im4h-MuiTypography-root-MuiBreadcrumbs-root{margin:0;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Normal;line-height:150%;font-size:1rem;letter-spacing:0px;color:#0d0d0d;color:rgba(0, 0, 0, 0.6);}.css-4pdmu4-MuiBreadcrumbs-ol{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex-wrap:wrap;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;padding:0;margin:0;list-style:none;}.css-14aisoc{font-size:0.875rem;}.css-1wuw8dw-MuiBreadcrumbs-separator{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;margin-left:8px;margin-right:8px;}.css-ead8px-MuiSvgIcon-root{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;display:inline-block;fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:1.4285714285714284rem;}.css-1boheuq-MuiTypography-root{margin:0;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Normal;line-height:150%;font-size:0.875rem;letter-spacing:0px;color:#0d0d0d;color:rgba(0, 0, 0, 0.87);}.css-j9j92j-MuiStack-root{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;background-color:#fff;}@media (min-width:0px){.css-7vsjpe{margin-top:0px;}}@media (min-width:768px){.css-7vsjpe{margin-top:0px;}}@media (min-width:1280px){.css-7vsjpe{margin-top:0px;}}.css-10rfme0-MuiContainer-root{width:100%;margin-left:auto;box-sizing:border-box;margin-right:auto;display:block;padding-left:4px;padding-right:4px;}@media (min-width:smpx){.css-10rfme0-MuiContainer-root{padding-left:6px;padding-right:6px;}}@media (min-width:1280px){.css-10rfme0-MuiContainer-root{max-width:1280px;}}@media (min-width:0px){.css-10rfme0-MuiContainer-root{padding-left:16px;padding-right:16px;padding-bottom:0px;}}@media (min-width:768px){.css-10rfme0-MuiContainer-root{padding-bottom:32px;}}@media (min-width:1280px){.css-10rfme0-MuiContainer-root{padding-left:48px;padding-right:48px;padding-bottom:32px;}}.css-1qgmfta-MuiGrid2-root{--Grid-columns:4;--Grid-columnSpacing:0px;--Grid-rowSpacing:0px;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;min-width:0;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex-wrap:wrap;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;margin:calc(var(--Grid-rowSpacing) / -2) calc(var(--Grid-columnSpacing) / -2);}@media (min-width:768px){.css-1qgmfta-MuiGrid2-root{--Grid-columns:8;}}@media (min-width:1280px){.css-1qgmfta-MuiGrid2-root{--Grid-columns:12;}}@media (min-width:0px){.css-1qgmfta-MuiGrid2-root{min-height:136px;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:start;justify-content:start;}}@media (min-width:768px){.css-1qgmfta-MuiGrid2-root{min-height:136px;-webkit-box-pack:end;-ms-flex-pack:end;-webkit-justify-content:end;justify-content:end;}}@media (min-width:1280px){.css-1qgmfta-MuiGrid2-root{min-height:136px;-webkit-box-pack:end;-ms-flex-pack:end;-webkit-justify-content:end;justify-content:end;}}.css-689yzq-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 4 / var(--Grid-columns));min-width:0;box-sizing:border-box;padding:calc(var(--Grid-rowSpacing) / 2) calc(var(--Grid-columnSpacing) / 2);}@media (min-width:768px){.css-689yzq-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 8 / var(--Grid-columns));}}@media (min-width:1280px){.css-689yzq-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 12 / var(--Grid-columns));}}@media (min-width:0px){.css-689yzq-MuiGrid2-root{color:inherit;padding-bottom:16px;}}@media (min-width:768px){.css-689yzq-MuiGrid2-root{color:inherit;padding-bottom:0px;}}@media (min-width:1280px){.css-689yzq-MuiGrid2-root{color:inherit;padding-bottom:0px;}}.css-1hnspsh-MuiTypography-root{margin:0;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:150%;font-size:2.25rem;letter-spacing:0px;color:#000000;color:inherit;}@media (min-width:768px){.css-1hnspsh-MuiTypography-root{font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:150%;font-size:2.5rem;letter-spacing:0px;}}@media (min-width:1280px){.css-1hnspsh-MuiTypography-root{font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:150%;font-size:3rem;letter-spacing:0px;}}@media (min-width:0px){.css-1hnspsh-MuiTypography-root{margin-top:16px;}}@media (min-width:768px){.css-1hnspsh-MuiTypography-root{margin-top:32px;}}@media (min-width:1280px){.css-1hnspsh-MuiTypography-root{margin-top:32px;}}.css-1f4kha5-MuiContainer-root{width:100%;margin-left:auto;box-sizing:border-box;margin-right:auto;display:block;padding-left:4px;padding-right:4px;}@media (min-width:smpx){.css-1f4kha5-MuiContainer-root{padding-left:6px;padding-right:6px;}}@media (min-width:1280px){.css-1f4kha5-MuiContainer-root{max-width:1280px;}}@media (min-width:0px){.css-1f4kha5-MuiContainer-root{padding-left:16px;padding-right:16px;}}@media (min-width:1280px){.css-1f4kha5-MuiContainer-root{padding-left:48px;padding-right:48px;}}.css-u69w57-MuiStack-root{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;background-color:#fff;}@media (min-width:0px){.css-u69w57-MuiStack-root{margin-top:32px;}}@media (min-width:768px){.css-u69w57-MuiStack-root{margin-top:48px;}}@media (min-width:1280px){.css-u69w57-MuiStack-root{margin-top:48px;}}@media (min-width:0px){.css-gei8j6{margin-top:0px;}}@media (min-width:768px){.css-gei8j6{margin-top:0px;}}@media (min-width:1280px){.css-gei8j6{margin-top:48px;}}.css-19xm1y8-MuiGrid2-root{--Grid-columns:4;--Grid-columnSpacing:0px;--Grid-rowSpacing:0px;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;min-width:0;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex-wrap:wrap;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;margin:calc(var(--Grid-rowSpacing) / -2) calc(var(--Grid-columnSpacing) / -2);padding:0px;}@media (min-width:768px){.css-19xm1y8-MuiGrid2-root{--Grid-columns:8;}}@media (min-width:1280px){.css-19xm1y8-MuiGrid2-root{--Grid-columns:12;}}.css-1wodyvb-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 4 / var(--Grid-columns));min-width:0;box-sizing:border-box;padding:calc(var(--Grid-rowSpacing) / 2) calc(var(--Grid-columnSpacing) / 2);}@media (min-width:768px){.css-1wodyvb-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 8 / var(--Grid-columns));}}@media (min-width:1280px){.css-1wodyvb-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 12 / var(--Grid-columns));}}@media (min-width:0px){.css-1wodyvb-MuiGrid2-root{margin-bottom:24px;}}@media (min-width:768px){.css-1wodyvb-MuiGrid2-root{margin-bottom:24px;}}@media (min-width:1280px){.css-1wodyvb-MuiGrid2-root{margin-bottom:32px;}}.css-17ts118-MuiGrid2-root{--Grid-columnsLevel1:4;--Grid-columnSpacingLevel1:6px;--Grid-rowSpacingLevel1:6px;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;min-width:0;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex-wrap:wrap;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;margin:calc(var(--Grid-rowSpacingLevel1) / -2) calc(var(--Grid-columnSpacingLevel1) / -2);padding:calc(var(--Grid-rowSpacing) / 2) calc(var(--Grid-columnSpacing) / 2);padding:0px;}@media (min-width:768px){.css-17ts118-MuiGrid2-root{--Grid-columnsLevel1:8;}}@media (min-width:1280px){.css-17ts118-MuiGrid2-root{--Grid-columnsLevel1:12;}}.css-1b1hect-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 2 / var(--Grid-columnsLevel1));min-width:0;box-sizing:border-box;padding:calc(var(--Grid-rowSpacingLevel1) / 2) calc(var(--Grid-columnSpacingLevel1) / 2);}@media (min-width:768px){.css-1b1hect-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 3 / var(--Grid-columnsLevel1));}}@media (min-width:1280px){.css-1b1hect-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 3 / var(--Grid-columnsLevel1));}}.css-epopls-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 4 / var(--Grid-columns));min-width:0;box-sizing:border-box;padding:calc(var(--Grid-rowSpacing) / 2) calc(var(--Grid-columnSpacing) / 2);}@media (min-width:768px){.css-epopls-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 8 / var(--Grid-columns));}}@media (min-width:1280px){.css-epopls-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 12 / var(--Grid-columns));}}.css-1pytp3s-MuiDivider-root{margin:0;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;border-width:0;border-style:solid;border-color:#e4e4e4;border-bottom-width:thin;border-color:#c9c9c9;}.css-y36fim{width:100%;}@media (min-width:0px){.css-y36fim{padding-left:16px;padding-right:16px;padding-top:32px;padding-bottom:32px;}}@media (min-width:768px){.css-y36fim{padding-left:32px;padding-right:32px;padding-top:48px;padding-bottom:48px;}}@media (min-width:1280px){.css-y36fim{padding-left:32px;padding-right:32px;padding-top:48px;padding-bottom:48px;}}.css-14o2ao6-MuiGrid2-root{--Grid-columns:4;--Grid-columnSpacing:0px;--Grid-rowSpacing:16px;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;min-width:0;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex-wrap:wrap;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;margin:calc(var(--Grid-rowSpacing) / -2) calc(var(--Grid-columnSpacing) / -2);padding:0px;}@media (min-width:768px){.css-14o2ao6-MuiGrid2-root{--Grid-columns:8;}}@media (min-width:1280px){.css-14o2ao6-MuiGrid2-root{--Grid-columns:12;}}@media (min-width:768px){.css-14o2ao6-MuiGrid2-root{--Grid-columnSpacing:16px;}}@media (min-width:1280px){.css-14o2ao6-MuiGrid2-root{--Grid-columnSpacing:16px;}}@media (min-width:768px){.css-14o2ao6-MuiGrid2-root{--Grid-rowSpacing:0px;}}@media (min-width:1280px){.css-14o2ao6-MuiGrid2-root{--Grid-rowSpacing:0px;}}.css-1q768l5-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 4 / var(--Grid-columns));min-width:0;box-sizing:border-box;padding:calc(var(--Grid-rowSpacing) / 2) calc(var(--Grid-columnSpacing) / 2);}@media (min-width:768px){.css-1q768l5-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 7 / var(--Grid-columns));}}@media (min-width:1280px){.css-1q768l5-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 10 / var(--Grid-columns));}}.css-1ufdk6m-MuiTypography-root{margin:0;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Normal;line-height:150%;font-size:0.875rem;letter-spacing:0px;color:#0d0d0d;font-weight:Bold;}.css-1fchgxt-MuiTypography-root{margin:0;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:150%;font-size:1.25rem;letter-spacing:0px;color:#000000;margin-top:12px;}@media (min-width:768px){.css-1fchgxt-MuiTypography-root{font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:150%;font-size:1.5rem;letter-spacing:0px;}}@media (min-width:1280px){.css-1fchgxt-MuiTypography-root{font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:150%;font-size:1.5rem;letter-spacing:0px;}}.css-1i53qr6-MuiGrid2-root{--Grid-columnsLevel2:4;--Grid-columnSpacingLevel2:0px;--Grid-rowSpacingLevel2:0px;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;min-width:0;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex-wrap:wrap;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;margin:calc(var(--Grid-rowSpacingLevel2) / -2) calc(var(--Grid-columnSpacingLevel2) / -2);padding:calc(var(--Grid-rowSpacingLevel1) / 2) calc(var(--Grid-columnSpacingLevel1) / 2);padding:0px;}@media (min-width:0px){.css-1i53qr6-MuiGrid2-root{margin-top:12px;}}@media (min-width:768px){.css-1i53qr6-MuiGrid2-root{margin-top:12px;}}@media (min-width:1280px){.css-1i53qr6-MuiGrid2-root{margin-top:16px;}}.css-c7yewm-MuiGrid2-root{-webkit-flex-basis:0;-ms-flex-preferred-size:0;flex-basis:0;-webkit-box-flex:1;-webkit-flex-grow:1;-ms-flex-positive:1;flex-grow:1;max-width:100%;min-width:0;box-sizing:border-box;padding:calc(var(--Grid-rowSpacingLevel2) / 2) calc(var(--Grid-columnSpacingLevel2) / 2);-webkit-align-self:flex-end;-ms-flex-item-align:flex-end;align-self:flex-end;}.css-1cc1yhr-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 4 / var(--Grid-columns));min-width:0;box-sizing:border-box;padding:calc(var(--Grid-rowSpacing) / 2) calc(var(--Grid-columnSpacing) / 2);display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:end;-ms-flex-pack:end;-webkit-justify-content:end;justify-content:end;}@media (min-width:768px){.css-1cc1yhr-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 1 / var(--Grid-columns));}}@media (min-width:1280px){.css-1cc1yhr-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 2 / var(--Grid-columns));}}.css-4q3mua{width:100%;text-align:center;margin-top:32px;}@media (min-width:0px){.css-jqikz1{margin-top:64px;}}@media (min-width:768px){.css-jqikz1{margin-top:128px;}}@media (min-width:1280px){.css-jqikz1{margin-top:128px;}}.css-cr2kt9-MuiGrid2-root{--Grid-columns:4;--Grid-columnSpacing:12px;--Grid-rowSpacing:12px;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;min-width:0;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex-wrap:wrap;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;margin:calc(var(--Grid-rowSpacing) / -2) calc(var(--Grid-columnSpacing) / -2);padding:0px;}@media (min-width:768px){.css-cr2kt9-MuiGrid2-root{--Grid-columns:8;}}@media (min-width:1280px){.css-cr2kt9-MuiGrid2-root{--Grid-columns:12;}}@media (min-width:768px){.css-cr2kt9-MuiGrid2-root{--Grid-columnSpacing:16px;}}@media (min-width:1280px){.css-cr2kt9-MuiGrid2-root{--Grid-columnSpacing:16px;}}@media (min-width:768px){.css-cr2kt9-MuiGrid2-root{--Grid-rowSpacing:24px;}}@media (min-width:1280px){.css-cr2kt9-MuiGrid2-root{--Grid-rowSpacing:24px;}}.css-c8gmj9-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 4 / var(--Grid-columns));min-width:0;box-sizing:border-box;padding:calc(var(--Grid-rowSpacing) / 2) calc(var(--Grid-columnSpacing) / 2);}@media (min-width:768px){.css-c8gmj9-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 8 / var(--Grid-columns));}}@media (min-width:1280px){.css-c8gmj9-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 8 / var(--Grid-columns));}}.css-1te8woh-MuiTypography-root{margin:0;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:150%;font-size:1.75rem;letter-spacing:0px;color:#000000;}@media (min-width:768px){.css-1te8woh-MuiTypography-root{font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:150%;font-size:2rem;letter-spacing:0px;}}@media (min-width:1280px){.css-1te8woh-MuiTypography-root{font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Bold;line-height:150%;font-size:2.25rem;letter-spacing:0px;}}.css-146zs5-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 4 / var(--Grid-columns));min-width:0;box-sizing:border-box;padding:calc(var(--Grid-rowSpacing) / 2) calc(var(--Grid-columnSpacing) / 2);}@media (min-width:768px){.css-146zs5-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 8 / var(--Grid-columns));}}@media (min-width:1280px){.css-146zs5-MuiGrid2-root{-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;width:calc(100% * 8 / var(--Grid-columns));}}.css-qiso3p-MuiStack-root{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;background-color:#fff;}@media (min-width:0px){.css-qiso3p-MuiStack-root{margin-bottom:48px;}}@media (min-width:768px){.css-qiso3p-MuiStack-root{margin-bottom:64px;}}@media (min-width:1280px){.css-qiso3p-MuiStack-root{margin-bottom:128px;}}.css-1n0w9uy{display:grid;grid-template-rows:auto auto auto;grid-row-gap:16px;place-items:center;padding:16px 32px;color:#fff;background-color:#000;}@media (min-width:1280px){.css-1n0w9uy{grid-template-columns:max-content auto max-content;grid-template-rows:auto;grid-column-gap:64px;place-items:initial;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;}}.css-1elqj97{margin-left:-4px;margin-right:-4px;}.css-46kbhf-MuiSvgIcon-root{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;display:inline-block;fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:fill 200ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;font-size:1.7142857142857142rem;font-size:1.2rem;margin-left:4px;margin-top:4px;margin-right:4px;margin-bottom:8px;height:auto;font-size:5rem;display:block;}.css-1juh738{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;}@media (min-width:1280px){.css-1juh738{-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;-webkit-box-pack:end;-ms-flex-pack:end;-webkit-justify-content:end;justify-content:end;}}.css-amrgmt-MuiTypography-root{margin:0;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Normal;line-height:150%;font-size:1rem;letter-spacing:0px;color:#0d0d0d;font-weight:Bold;color:inherit;}@media (min-width:0px){.css-amrgmt-MuiTypography-root{margin-right:0px;}}@media (min-width:768px){.css-amrgmt-MuiTypography-root{margin-right:0px;}}@media (min-width:1280px){.css-amrgmt-MuiTypography-root{margin-right:16px;}}.css-1oc5ep0-MuiList-root{list-style:none;margin:0;padding:0;position:relative;padding-top:8px;padding-bottom:8px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;gap:16px;-webkit-box-flex-wrap:wrap;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}.css-16yom0i-MuiListItem-root{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:flex-start;justify-content:flex-start;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;-webkit-text-decoration:none;text-decoration:none;width:100%;box-sizing:border-box;text-align:left;width:auto;}.css-16yom0i-MuiListItem-root.Mui-focusVisible{background-color:rgba(0, 0, 0, 0.12);}.css-16yom0i-MuiListItem-root.Mui-selected{background-color:rgba(122, 0, 230, 0.08);}.css-16yom0i-MuiListItem-root.Mui-selected.Mui-focusVisible{background-color:rgba(122, 0, 230, 0.2);}.css-16yom0i-MuiListItem-root.Mui-disabled{opacity:0.38;}.css-1l93wsm{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;width:2.5rem;height:2.5rem;border:1px solid #fff;border-radius:50%;color:#fff;}.css-1l93wsm:focus-visible{outline:#b3a8e6 solid 4px;}.css-3759vn{display:grid;grid-template-columns:auto auto;grid-column-gap:8px;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;color:#fff;}.css-17gnk4t-MuiButtonBase-root-MuiIconButton-root{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;position:relative;box-sizing:border-box;-webkit-tap-highlight-color:transparent;background-color:transparent;outline:0;border:0;margin:0;border-radius:0;padding:0;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;vertical-align:middle;-moz-appearance:none;-webkit-appearance:none;-webkit-text-decoration:none;text-decoration:none;color:inherit;text-align:center;-webkit-flex:0 0 auto;-ms-flex:0 0 auto;flex:0 0 auto;font-size:1.7142857142857142rem;padding:8px;border-radius:50%;overflow:visible;color:rgba(0, 0, 0, 0.54);-webkit-transition:background-color 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;transition:background-color 150ms cubic-bezier(0.4, 0, 0.2, 1) 0ms;padding:5px;font-size:1.2857142857142856rem;font-size:1rem;display:grid;grid-template-columns:auto auto;grid-column-gap:8px;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;color:#fff;}.css-17gnk4t-MuiButtonBase-root-MuiIconButton-root::-moz-focus-inner{border-style:none;}.css-17gnk4t-MuiButtonBase-root-MuiIconButton-root.Mui-disabled{pointer-events:none;cursor:default;}@media print{.css-17gnk4t-MuiButtonBase-root-MuiIconButton-root{-webkit-print-color-adjust:exact;color-adjust:exact;}}.css-17gnk4t-MuiButtonBase-root-MuiIconButton-root.Mui-disabled{background-color:transparent;color:rgba(0, 0, 0, 0.26);}.css-17gnk4t-MuiButtonBase-root-MuiIconButton-root:focus-visible{outline:#b3a8e6;outline-style:solid;outline-width:4px;border-radius:calc(8px / 2);}.css-1boijxs{display:grid;grid-template-rows:auto auto;grid-row-gap:16px;padding:16px;background-color:#fff;}.css-1boijxs .MuiList-root{-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-align-self:flex-start;-ms-flex-item-align:flex-start;align-self:flex-start;}.css-1boijxs #navigation{-webkit-align-self:flex-start;-ms-flex-item-align:flex-start;align-self:flex-start;}@media (min-width:1280px){.css-1boijxs{grid-row-gap:32px;padding:32px;}.css-1boijxs .MuiList-root{-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:flex-start;justify-content:flex-start;}}.css-1l2zhvo-MuiList-root{list-style:none;margin:0;padding:0;position:relative;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex-wrap:wrap;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:flex-start;justify-content:flex-start;-webkit-column-gap:24px;column-gap:24px;row-gap:8px;margin-left:-8px;margin-right:-8px;}@media (min-width:0px){.css-1l2zhvo-MuiList-root{-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;}}@media (min-width:768px){.css-1l2zhvo-MuiList-root{-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;}}@media (min-width:1280px){.css-1l2zhvo-MuiList-root{-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;}}.css-73fo95-MuiListItem-root{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:flex-start;justify-content:flex-start;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;-webkit-text-decoration:none;text-decoration:none;width:100%;box-sizing:border-box;text-align:left;display:block;width:auto;-webkit-box-flex:0;-webkit-flex-grow:0;-ms-flex-positive:0;flex-grow:0;-webkit-flex-shrink:1;-ms-flex-negative:1;flex-shrink:1;-webkit-flex-basis:auto;-ms-flex-preferred-size:auto;flex-basis:auto;}.css-73fo95-MuiListItem-root.Mui-focusVisible{background-color:rgba(0, 0, 0, 0.12);}.css-73fo95-MuiListItem-root.Mui-selected{background-color:rgba(122, 0, 230, 0.08);}.css-73fo95-MuiListItem-root.Mui-selected.Mui-focusVisible{background-color:rgba(122, 0, 230, 0.2);}.css-73fo95-MuiListItem-root.Mui-disabled{opacity:0.38;}.css-1u4cuma{font-size:16;display:block;padding:8px;}.css-1u4cuma:hover{color:#7a00e6;}.css-1u4cuma:focus{outline:#b3a8e6 solid 4px;border-radius:calc(8px / 2);z-index:3;}.css-hwnj0i-MuiStack-root{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;gap:8px;}.css-1ubkcfk-MuiTypography-root{margin:0;font-family:Sanofi Sans,Work Sans,Raleway,Roboto,sans-serif;font-weight:Normal;line-height:150%;font-size:1rem;letter-spacing:0px;color:#0d0d0d;}</style></head><body class="css-1sb87pj"><noscript><iframe height="0" src="https://www.googletagmanager.com/ns.html?id=GTM-N67QVH3" style="display:none;visibility:hidden" title="GTM" width="0"></iframe></noscript><div class="css-jbxqua"><header class="undefined MuiBox-root css-1s4q8eq" dir="ltr"><div class="css-jbvua0"><a title="Back to the sanofi.com homepage" aria-label="Back to the sanofi.com homepage" class="css-11feumg" data-discover="true" href="/en"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-1a8ug3n-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 80 22" xmlns="http://www.w3.org/2000/svg" width="80" height="22" fill="none" data-testid="logo" aria-label="Sanofi"><path d="M28.4057 7.29145C26.5895 6.58049 24.6556 6.21743 22.7051 6.22122C18.3338 6.22122 15.2656 9.14389 15.2656 13.7488C15.2656 18.4061 17.9277 21.2764 22.6461 21.2764C24.6249 21.2899 26.5854 20.8967 28.4057 20.1211C28.6384 20.0363 28.836 19.8762 28.9671 19.6663C29.0982 19.4563 29.1553 19.2086 29.1294 18.9625V8.45004C29.1294 7.78238 28.8707 7.46492 28.4057 7.29145ZM25.3671 16.75C25.3671 17.1853 25.1346 17.3882 24.6435 17.5322C24.0047 17.7139 23.3429 17.8021 22.6788 17.7941C20.8255 17.7941 19.077 16.6944 19.077 13.7423C19.077 10.7901 20.8124 9.69373 22.6788 9.69373C23.3428 9.68465 24.0045 9.77175 24.6435 9.95229C25.1346 10.0963 25.3671 10.2992 25.3671 10.7345V16.75Z" fill="#000"></path><path d="M4.03447 11.053C4.03447 10.1693 4.93163 9.60638 6.46732 9.60638C7.94407 9.60638 9.36187 10.0973 10.8386 10.9155C10.9694 10.9927 11.119 11.0324 11.2709 11.0301C11.4062 11.0283 11.5386 10.9899 11.6539 10.9191C11.7692 10.8482 11.8631 10.7474 11.9257 10.6275L12.8229 8.71615C12.8961 8.56268 12.9352 8.39521 12.9375 8.22522C12.9378 8.10625 12.9056 7.98945 12.8445 7.88738C12.7833 7.78532 12.6955 7.70183 12.5904 7.64591C10.76 6.62407 8.69484 6.09619 6.5983 6.11422C2.72143 6.11422 0.23291 8.19577 0.23291 11.3214C0.23291 17.4547 9.55181 15.0786 9.55181 19.3333C9.55488 19.6973 9.49619 20.0592 9.37825 20.4036C9.36067 20.4598 9.35076 20.5181 9.34879 20.577C9.34601 20.6336 9.35561 20.6901 9.37693 20.7426C9.39826 20.7951 9.4308 20.8424 9.47226 20.881C9.51373 20.9196 9.56315 20.9488 9.61704 20.9664C9.67093 20.9839 9.72798 20.9896 9.78427 20.9828H12.3874C12.8229 20.9828 12.9964 20.8388 13.1405 20.4036C13.3015 19.8732 13.38 19.3213 13.373 18.7671C13.3567 12.1821 4.03447 13.7629 4.03447 11.053Z" fill="#000"></path><path d="M39.2007 6.22119C37.2161 6.23484 35.2483 6.58681 33.3821 7.26196C33.1495 7.34674 32.9519 7.50684 32.8208 7.71677C32.6897 7.92671 32.6325 8.17442 32.6585 8.42055V20.396C32.6537 20.4733 32.6654 20.5507 32.6928 20.6232C32.7203 20.6956 32.7628 20.7614 32.8176 20.8162C32.8724 20.871 32.9382 20.9135 33.0107 20.9409C33.0832 20.9684 33.1607 20.9801 33.238 20.9753H35.8575C35.9349 20.9801 36.0124 20.9684 36.0849 20.9409C36.1574 20.9135 36.2232 20.871 36.278 20.8162C36.3328 20.7614 36.3753 20.6956 36.4028 20.6232C36.4302 20.5507 36.4419 20.4733 36.4371 20.396V10.6756C36.4371 10.2435 36.6663 10.0406 37.1313 9.9228C37.832 9.75321 38.552 9.67619 39.2727 9.6937C40.8346 9.6937 42.0789 10.417 42.0789 12.1516V20.396C42.0741 20.4733 42.0858 20.5507 42.1132 20.6232C42.1407 20.6956 42.1832 20.7614 42.238 20.8162C42.2928 20.871 42.3586 20.9135 42.4311 20.9409C42.5036 20.9684 42.5811 20.9801 42.6584 20.9753H45.278C45.355 20.9796 45.4322 20.9675 45.5043 20.9399C45.5764 20.9122 45.6418 20.8696 45.6962 20.8149C45.7507 20.7602 45.7929 20.6946 45.8201 20.6224C45.8474 20.5502 45.859 20.473 45.8543 20.396V11.6607C45.8281 8.12927 43.6572 6.22119 39.2007 6.22119Z" fill="#000"></path><path d="M55.7858 6.22119C51.444 6.22119 48.6084 9.37296 48.6084 13.7488C48.6084 18.1246 51.444 21.2764 55.9888 21.2764C60.3307 21.2764 63.1663 18.1246 63.1663 13.7488C63.1663 9.37296 60.3307 6.22119 55.7858 6.22119ZM55.9888 17.794C53.8474 17.794 52.4296 16.4031 52.4296 13.7422C52.4296 11.0814 53.8474 9.6937 55.7858 9.6937C57.9273 9.6937 59.3451 11.0814 59.3451 13.7422C59.3451 16.4031 57.9273 17.794 55.9888 17.794Z" fill="#000"></path><path d="M79.2862 6.5083H76.6831C76.363 6.5083 76.1035 6.76766 76.1035 7.0876V20.3951C76.1035 20.715 76.363 20.9744 76.6831 20.9744H79.2862C79.6063 20.9744 79.8658 20.715 79.8658 20.3951V7.0876C79.8658 6.76766 79.6063 6.5083 79.2862 6.5083Z" fill="#000"></path><path d="M73.7294 0.926411C73.1329 0.785744 72.5216 0.717613 71.9088 0.723495C68.307 0.723495 65.9756 2.63485 65.9756 6.80121V20.3967C65.9709 20.4737 65.9825 20.5509 66.0098 20.6231C66.037 20.6953 66.0792 20.7609 66.1337 20.8156C66.1881 20.8704 66.2535 20.913 66.3256 20.9406C66.3977 20.9682 66.4748 20.9803 66.5519 20.976H69.1289C69.2062 20.9808 69.2837 20.9691 69.3562 20.9416C69.4287 20.9142 69.4945 20.8717 69.5493 20.8169C69.6041 20.7622 69.6467 20.6964 69.6741 20.6239C69.7015 20.5515 69.7132 20.474 69.7084 20.3967V9.69441H73.3823C73.4602 9.70144 73.5387 9.69129 73.6122 9.66467C73.6857 9.63804 73.7524 9.59558 73.8077 9.54032C73.863 9.48505 73.9054 9.41833 73.9321 9.34485C73.9587 9.27137 73.9689 9.19296 73.9619 9.11513V7.11867C73.9718 7.03889 73.9639 6.95791 73.9387 6.88157C73.9135 6.80523 73.8717 6.73543 73.8162 6.6772C73.7608 6.61897 73.6931 6.57376 73.6181 6.54484C73.543 6.51591 73.4625 6.50398 73.3823 6.50992H69.7084V6.18263C69.7084 4.59202 70.4026 3.78034 72.0005 3.78034C72.5801 3.78034 73.2022 3.92762 73.4183 3.92762C73.7654 3.92762 73.9095 3.72471 73.9684 3.37778L74.2598 1.87227C74.2888 1.74857 74.3074 1.62267 74.3155 1.49589C74.309 1.18496 74.1354 1.01478 73.7294 0.926411Z" fill="#000"></path><path d="M1.96463 17.2759C0.779304 17.2759 0 18.0254 0 19.269C0 20.5127 0.782588 21.2655 2.05632 21.2655C3.24165 21.2655 4.02096 20.4865 4.02096 19.269C4.02096 18.0515 3.23837 17.2759 1.96463 17.2759Z" fill="#7a00e6"></path><path d="M77.9436 0.729004C76.755 0.729004 75.979 1.48177 75.979 2.72546C75.979 3.96915 76.7616 4.7219 78.0353 4.7219C79.2207 4.7219 80 3.9397 80 2.72546C80 1.51123 79.2141 0.729004 77.9436 0.729004Z" fill="#7a00e6"></path></svg></a><div class="dotcom-header-search MuiBox-root css-12t0typ"><a class="elements-ds-1cki4g0" style="border-radius:100%;height:44px;width:44px;padding:0px" title="Search" aria-label="Search"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-coveql-MuiSvgIcon-root" focusable="false" aria-hidden="true" role="img" viewBox="0 0 512 512" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill="#7a00e6" d="M416 208c0 45.9-14.9 88.3-40 122.7L502.6 457.4c12.5 12.5 12.5 32.8 0 45.3s-32.8 12.5-45.3 0L330.7 376c-34.4 25.2-76.8 40-122.7 40C93.1 416 0 322.9 0 208S93.1 0 208 0S416 93.1 416 208zM208 352c79.5 0 144-64.5 144-144s-64.5-144-144-144S64 128.5 64 208s64.5 144 144 144z"></path></svg></a></div><button class="MuiButtonBase-root MuiIconButton-root MuiIconButton-sizeMedium css-15mda6m-MuiButtonBase-root-MuiIconButton-root" tabindex="0" type="button" aria-label="Open the menu"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1cqj9cj-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="MenuRoundedIcon"><path d="M4 18h16c.55 0 1-.45 1-1s-.45-1-1-1H4c-.55 0-1 .45-1 1s.45 1 1 1m0-5h16c.55 0 1-.45 1-1s-.45-1-1-1H4c-.55 0-1 .45-1 1s.45 1 1 1M3 7c0 .55.45 1 1 1h16c.55 0 1-.45 1-1s-.45-1-1-1H4c-.55 0-1 .45-1 1"></path></svg></button></div><div class="css-1f94a5v"><nav class="css-1pmzs1y" id="navigation_main"><ul class="MuiList-root css-1iyrj07-MuiList-root"><li class="css-7v3ck0"><a href="" class="css-wen7gr">Our Company</a><ul class="css-1v9d7j7"><li class="css-ezq9xk"><a class="css-ymxx1b" data-discover="true" href="/en/our-company" target="_self"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Our Company</div></a></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/our-company/our-strategy" target="_self">Our Strategy</a></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Governance<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/our-company/governance"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Governance</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-company/governance/board-of-directors" target="_self">Board of Directors</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-company/governance/executive-committee" target="_self">Executive Committee</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-company/governance/specialist-committees" target="_self">Specialist Committees</a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Social Impact<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/our-company/social-impact"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Social Impact</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-company/social-impact/access-to-healthcare">Access to Healthcare</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-company/social-impact/innovation-for-vulnerable-communities" target="_self">Innovation for Vulnerable Communities</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-company/social-impact/environmental-sustainability-and-resilience" target="_self">Environmental Sustainability and Resilience</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace">Diversity, Equity, and Inclusion In and Beyond the Workplace</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-company/social-impact/responsible-business-values">Code of Conduct and Responsible Business</a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/our-company/our-legacy" target="_self">Our Legacy</a></li></ul></li><li class="css-7v3ck0"><a href="" class="css-wen7gr">Our Science</a><ul class="css-1v9d7j7"><li class="css-ezq9xk"><a class="css-ymxx1b" data-discover="true" href="/en/our-science" target="_self"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Our Science</div></a></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/our-pipeline" target="_self">Our Pipeline</a></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Our R&D Focus<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/our-science/rd-focus-areas"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Our R&D Focus</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/rd-focus-areas/immunology-rd" target="_self">Immunology R&D</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/rd-focus-areas/neurology-rd" target="_self">Neurology R&D</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/rd-focus-areas/oncology-rd" target="_self">Oncology R&D</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/rd-focus-areas/rare-blood-disorders-rd" target="_self">Rare Blood Disorders R&D</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/rd-focus-areas/rare-diseases-rd" target="_self">Rare Diseases R&D</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/rd-focus-areas/vaccines-rd" target="_self">Vaccines R&D</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/rd-focus-areas/artificial-intelligence-rd" target="_self">Artificial Intelligence in R&D </a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/technology-platforms" target="_self">Technology Platforms </a></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Clinical Trials & Results<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/our-science/clinical-trials-and-results"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Clinical Trials & Results</div></a></li><li class="css-lpkobr"><a class="css-1hj1fp6" href="https://www.sanofistudies.com/global/en/ " target="_blank">Find a Clinical Trial</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/clinical-trials-and-results/clinical-study-results">Clinical Study Results</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/clinical-trials-and-results/investigator-sponsored-studies" target="_self">Investigator Sponsored Studies</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/clinical-trials-and-results/diversity-in-clinical-trials" target="_self">Diversity in Clinical Trials</a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Scientific Collaboration<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/our-science/scientific-collaboration"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Scientific Collaboration</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/scientific-collaboration/north-america" target="_self">Scientific Collaboration in North America</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/scientific-collaboration/europe" target="_self">Scientific Collaboration in Europe</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/scientific-collaboration/china" target="_self">Scientific Collaboration in China</a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/digital" target="_self">Digital</a></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/our-science/manufacturing-and-supply" target="_self">Manufacturing and Supply</a></li></ul></li><li class="css-7v3ck0"><a href="" class="css-wen7gr">Your Health</a><ul class="css-1v9d7j7"><li class="css-ezq9xk"><a class="css-ymxx1b" data-discover="true" href="/en/your-health" target="_self"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Your Health</div></a></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Vaccines & Infectious Diseases<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/your-health/vaccines"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Vaccines & Infectious Diseases</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/vaccines/influenza" target="_self">Influenza</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/vaccines/meningococcal-meningitis" target="_self">Meningococcal Meningitis</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/vaccines/pertussis" target="_self">Pertussis</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/vaccines/respiratory-syncytial-virus" target="_self">Respiratory Syncytial Virus (RSV)</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/vaccines/production" target="_self">Production</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/vaccines/why-vaccines-matter" target="_self">Why Vaccines Matter</a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Medicines<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/your-health/medicines"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Medicines</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/medicines/immunology" target="_self">Immunology</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/medicines/neurology" target="_self">Neurology</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/medicines/oncology" target="_self">Oncology</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/medicines/rare-blood-disorders" target="_self">Rare Blood Disorders</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/medicines/rare-diseases" target="_self">Rare Diseases</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/medicines/cardiovascular-diseases" target="_self">Cardiovascular Diseases</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/medicines/diabetes" target="_self">Diabetes</a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Consumer Healthcare<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/your-health/consumer-healthcare"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Consumer Healthcare</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/consumer-healthcare/sustainability-at-sanofi-consumer-healthcare" target="_self">Sustainability at Sanofi Consumer Healthcare</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/consumer-healthcare/allergy" target="_self">Allergy</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/consumer-healthcare/cough-cold-and-flu" target="_self">Cough, Cold & Flu</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/consumer-healthcare/digestive-wellness" target="_self">Digestive Wellness</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/consumer-healthcare/pain-care" target="_self">Pain Care</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/consumer-healthcare/physical-and-mental-wellness" target="_self">Physical & Mental Wellness</a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/patient-engagement" target="_self">Integrated Patient Engagement</a></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Healthcare Professionals Support<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/your-health/healthcare-professional-support"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Healthcare Professionals Support</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/healthcare-professional-support/sanofi-manage-access-program" target="_self">Managed Access Programs (MAPs)</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/healthcare-professional-support/sanofi-preregistration-import-license" target="_self">Pre-Registration Import Licenses</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/your-health/healthcare-professional-support/post-trial-access" target="_self">Post Trial Access (PTA)</a></li></ul></li></ul></li><li class="css-7v3ck0"><a href="" class="css-wen7gr">Partnering</a><ul class="css-1v9d7j7"><li class="css-ezq9xk"><a class="css-ymxx1b" data-discover="true" href="/en/partnering" target="_self"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Partnering</div></a></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Partnering Focus Areas<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/partnering/partnering-focus-areas"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Partnering Focus Areas</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/partnering-focus-areas/china" target="_self">China</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/partnering-focus-areas/digital" target="_self">Digital</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/partnering-focus-areas/general-medicines" target="_self">General Medicines</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/partnering-focus-areas/immunology" target="_self">Immunology</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/partnering-focus-areas/neuroscience" target="_self">Neuroscience</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/partnering-focus-areas/oncology" target="_self">Oncology</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/partnering-focus-areas/out-licensing" target="_self">Out-Licensing</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/partnering-focus-areas/rare-disease" target="_self">Rare Disease</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/partnering-focus-areas/technology-platforms" target="_self">Technology Platforms</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/partnering-focus-areas/vaccines" target="_self">Vaccines</a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/meet-the-partnering-team" target="_self">Meet the Partnering Team</a></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/partnering/contact-business-development-team" target="_self">Contact Business Development Team</a></li></ul></li></ul></nav><nav class="css-dyli1u" id="navigation_utility"><ul class="MuiList-root css-1iyrj07-MuiList-root"><li class="css-7v3ck0"><a href="" class="css-wen7gr">Media</a><ul class="css-1v9d7j7"><li class="css-ezq9xk"><a class="css-ymxx1b" data-discover="true" href="/en/media-room" target="_self"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Media</div></a></li><li tabindex="1" class="css-1w57mgj"><a class="css-1hj1fp6" href="https://www.sanofi.com/en/magazine" target="_self">Stories</a></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" aria-current="page" class="css-1hj1fp6 active" href="/en/media-room/press-releases" target="_self">Press Releases</a></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/media-room/contact" target="_self">Contacts</a></li></ul></li><li class="css-7v3ck0"><a href="" class="css-wen7gr">Investors</a><ul class="css-1v9d7j7"><li class="css-ezq9xk"><a class="css-ymxx1b" data-discover="true" href="/en/investors" target="_self"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Investors</div></a></li><li tabindex="1" class="css-1w57mgj"><a class="css-1hj1fp6" href="https://www.sanofi.com/en/media-room/press-releases" target="_self">News</a></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Results and Presentations<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/investors/financial-results-and-events"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Results and Presentations</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/financial-results-and-events/financial-results" target="_self">Results</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/financial-results-and-events/investor-presentations" target="_self">Presentations</a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/broker-conferences" target="_self">Conferences</a></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/environment-social-governance" target="_self">Environment, Social, Governance</a></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/individual-shareholders" target="_self">Private Shareholders</a></li><li tabindex="1" class="css-1w57mgj"><a href="" class="css-1777e4e">Shares and ADRs<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeLarge css-1d9vbqz-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></a><ul class="css-tpvpkp"><li class="css-1yvnwr8"><a class="css-ymxx1b" data-discover="true" href="/en/investors/sanofi-share-and-adrs"><div class="MuiTypography-root MuiTypography-h4 css-8893o5-MuiTypography-root">Shares and ADRs</div></a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/sanofi-share-and-adrs/stock-chart" target="_self">Sanofi stock chart</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/sanofi-share-and-adrs/dividend" target="_self">Dividend</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/sanofi-share-and-adrs/adrs" target="_self">ADRs</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/sanofi-share-and-adrs/shares-structure-vote" target="_self">Shares, Structure & Vote</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/sanofi-share-and-adrs/analyst-coverage" target="_self">Analyst Coverage</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/sanofi-share-and-adrs/vara-consensus" target="_self">Vara consensus</a></li><li class="css-lpkobr"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/sanofi-share-and-adrs/share-repurchases" target="_self">Share Repurchases</a></li></ul></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/bonds" target="_self">Bonds</a></li><li tabindex="1" class="css-1w57mgj"><a data-discover="true" class="css-1hj1fp6" href="/en/investors/contacts" target="_self">Contacts</a></li></ul></li><li class="css-7v3ck0"><a class="css-oq95y2" href="https://jobs.sanofi.com" target="_self">Careers</a></li></ul></nav><button aria-label="global-panel-toggle" aria-controls="global-panel" aria-expanded="false" class="css-1lyzz7t"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-xesgy4-MuiSvgIcon-root" focusable="false" aria-hidden="true" role="img" viewBox="0 0 512 512" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill="#7a00e6" d="M352 256c0 22.2-1.2 43.6-3.3 64H163.3c-2.2-20.4-3.3-41.8-3.3-64s1.2-43.6 3.3-64H348.7c2.2 20.4 3.3 41.8 3.3 64zm28.8-64H503.9c5.3 20.5 8.1 41.9 8.1 64s-2.8 43.5-8.1 64H380.8c2.1-20.6 3.2-42 3.2-64s-1.1-43.4-3.2-64zm112.6-32H376.7c-10-63.9-29.8-117.4-55.3-151.6c78.3 20.7 142 77.5 171.9 151.6zm-149.1 0H167.7c6.1-36.4 15.5-68.6 27-94.7c10.5-23.6 22.2-40.7 33.5-51.5C239.4 3.2 248.7 0 256 0s16.6 3.2 27.8 13.8c11.3 10.8 23 27.9 33.5 51.5c11.6 26 21 58.2 27 94.7zm-209 0H18.6C48.6 85.9 112.2 29.1 190.6 8.4C165.1 42.6 145.3 96.1 135.3 160zM8.1 192H131.2c-2.1 20.6-3.2 42-3.2 64s1.1 43.4 3.2 64H8.1C2.8 299.5 0 278.1 0 256s2.8-43.5 8.1-64zM194.7 446.6c-11.6-26-20.9-58.2-27-94.6H344.3c-6.1 36.4-15.5 68.6-27 94.6c-10.5 23.6-22.2 40.7-33.5 51.5C272.6 508.8 263.3 512 256 512s-16.6-3.2-27.8-13.8c-11.3-10.8-23-27.9-33.5-51.5zM135.3 352c10 63.9 29.8 117.4 55.3 151.6C112.2 482.9 48.6 426.1 18.6 352H135.3zm358.1 0c-30 74.1-93.6 130.9-171.9 151.6c25.5-34.2 45.2-87.7 55.3-151.6H493.4z"></path></svg><span>Global</span></button></div></header><main dir="ltr"><div class="css-1otjjom"><nav class="MuiTypography-root MuiTypography-body1 MuiBreadcrumbs-root css-y1im4h-MuiTypography-root-MuiBreadcrumbs-root" aria-label="breadcrumb"><ol class="MuiBreadcrumbs-ol css-4pdmu4-MuiBreadcrumbs-ol"><li class="MuiBreadcrumbs-li"><a color="inherit" class="css-14aisoc" data-discover="true" href="/en" target="_self">Homepage</a></li><li aria-hidden="true" class="MuiBreadcrumbs-separator css-1wuw8dw-MuiBreadcrumbs-separator"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeSmall css-ead8px-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></li><li class="MuiBreadcrumbs-li"><a color="inherit" class="css-14aisoc" data-discover="true" href="/en/media-room" target="_self">Media</a></li><li aria-hidden="true" class="MuiBreadcrumbs-separator css-1wuw8dw-MuiBreadcrumbs-separator"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeSmall css-ead8px-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 24 24" data-testid="NavigateNextIcon"><path d="M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"></path></svg></li><li class="MuiBreadcrumbs-li"><span class="MuiTypography-root MuiTypography-body2 css-1boheuq-MuiTypography-root">Press Releases</span></li></ol></nav></div><div class="MuiStack-root css-j9j92j-MuiStack-root" id="top"><div class="dotcom-hero-banner MuiBox-root css-7vsjpe"><div class="MuiBox-root css-0"><div class="MuiBox-root css-0"><div class="MuiContainer-root MuiContainer-maxWidthDesktop css-10rfme0-MuiContainer-root"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-column css-1qgmfta-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-desktop-12 MuiGrid2-grid-tablet-8 MuiGrid2-grid-mobile-4 css-689yzq-MuiGrid2-root"><h1 class="MuiTypography-root MuiTypography-h1 css-1hnspsh-MuiTypography-root">Press Releases</h1></div></div></div></div></div></div></div><div class="MuiContainer-root MuiContainer-maxWidthDesktop css-1f4kha5-MuiContainer-root"><div class="MuiStack-root css-u69w57-MuiStack-root" id="main"><div class="dotcom-press-releases-list MuiBox-root css-gei8j6"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-19xm1y8-MuiGrid2-root" id="prlist"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-8 MuiGrid2-grid-desktop-12 css-1wodyvb-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row MuiGrid2-spacing-mobile-3 css-17ts118-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-2 MuiGrid2-grid-tablet-3 MuiGrid2-grid-desktop-3 css-1b1hect-MuiGrid2-root"><div class="elements-ds-1242ofb"><div tabindex="0" role="button" aria-label="Filter per year" id="year_select" class="elements-ds-ginb5w"><div class="elements-ds-1h2ruwl">Filter per year</div><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="chevron-down" class="svg-inline--fa fa-chevron-down elements-ds-5bb3vk" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M201.4 406.6c12.5 12.5 32.8 12.5 45.3 0l192-192c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 338.7 54.6 169.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l192 192z"></path></svg></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-2 MuiGrid2-grid-tablet-3 MuiGrid2-grid-desktop-3 css-1b1hect-MuiGrid2-root"><div class="elements-ds-1242ofb"><div tabindex="0" role="button" aria-label="Filter per category" id="category_select" class="elements-ds-ginb5w"><div class="elements-ds-1h2ruwl">Filter per category</div><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="chevron-down" class="svg-inline--fa fa-chevron-down elements-ds-5bb3vk" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M201.4 406.6c12.5 12.5 32.8 12.5 45.3 0l192-192c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L224 338.7 54.6 169.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l192 192z"></path></svg></div></div></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-8 MuiGrid2-grid-desktop-12 css-epopls-MuiGrid2-root"><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">March 8, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD" href="/en/media-room/press-releases/2025/2025-03-08-18-00-00-3039375" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-03-08-18-00-00-3039375-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">March 5, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press release: Sanofi successfully prices EUR 1.5 billion of bond issue</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press release: Sanofi successfully prices EUR 1.5 billion of bond issue" href="/en/media-room/press-releases/2025/2025-03-05-17-10-00-3037644" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-03-05-17-10-00-3037644-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">February 28, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Media Update: AAD: new data advance Sanofi’s scientific leadership across innovative treatments for inflammatory skin diseases</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Media Update: AAD: new data advance Sanofi’s scientific leadership across innovative treatments for inflammatory skin diseases" href="/en/media-room/press-releases/2025/2025-02-28-14-00-00-3034759" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Media Update</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-02-28-14-00-00-3034759-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">February 25, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma" href="/en/media-room/press-releases/2025/2025-02-25-06-00-00-3031655" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-02-25-06-00-00-3031655-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">February 22, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease" href="/en/media-room/press-releases/2025/2025-02-22-07-30-00-3030764" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-02-22-07-30-00-3030764-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">February 19, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Sanofi and CD&R sign Opella share purchase agreement</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Sanofi and CD&R sign Opella share purchase agreement" href="/en/media-room/press-releases/2025/2025-02-19-06-30-00-3028464" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-02-19-06-30-00-3028464-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">February 18, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid" href="/en/media-room/press-releases/2025/2025-02-18-06-00-00-3027482" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-02-18-06-00-00-3027482-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">February 13, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report" href="/en/media-room/press-releases/2025/2025-02-13-19-09-00-3026227" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-02-13-19-09-00-3026227-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">February 13, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study" href="/en/media-room/press-releases/2025/2025-02-13-06-00-00-3025576" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-02-13-06-00-00-3025576-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">February 7, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Execution of a share buyback agreement for up to €2 billion</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Execution of a share buyback agreement for up to €2 billion" href="/en/media-room/press-releases/2025/2025-02-07-06-00-00-3022540" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-02-07-06-00-00-3022540-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">February 6, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Media Update: AAAAI: new data reinforce Sanofi’s leadership in immunology and scientific innovation for patients </div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Media Update: AAAAI: new data reinforce Sanofi’s leadership in immunology and scientific innovation for patients " href="/en/media-room/press-releases/2025/2025-02-06-06-00-00-3021697" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Media Update</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-02-06-06-00-00-3021697-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">February 3, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Sanofi announces buy back of shares from L’Oréal</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Sanofi announces buy back of shares from L’Oréal" href="/en/media-room/press-releases/2025/2025-02-03-06-30-00-3019186" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-02-03-06-30-00-3019186-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">January 31, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant" href="/en/media-room/press-releases/2025/2025-01-31-06-00-00-3018540" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-01-31-06-00-00-3018540-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">January 30, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025" href="/en/media-room/press-releases/2025/2025-01-30-06-30-00-3017713" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-01-30-06-30-00-3017713-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">January 22, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma" href="/en/media-room/press-releases/2025/2025-01-22-06-00-00-3013183" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-01-22-06-00-00-3013183-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">January 21, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Opella reaches study milestone for Cialis</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Opella reaches study milestone for Cialis" href="/en/media-room/press-releases/2025/2025-01-21-06-00-00-3012315" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-01-21-06-00-00-3012315-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">January 13, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma" href="/en/media-room/press-releases/2025/2025-01-13-06-00-00-3008102" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-01-13-06-00-00-3008102-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">January 9, 2025</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma" href="/en/media-room/press-releases/2025/2025-01-09-06-00-00-3006798" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2025/2025-01-09-06-00-00-3006798-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">December 23, 2024</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines" href="/en/media-room/press-releases/2024/2024-12-23-06-00-00-3001006" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2024/2024-12-23-06-00-00-3001006-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/><div class="MuiBox-root css-y36fim"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-14o2ao6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-7 MuiGrid2-grid-desktop-10 css-1q768l5-MuiGrid2-root"><div class="MuiTypography-root MuiTypography-body2 css-1ufdk6m-MuiTypography-root">December 19, 2024</div><div class="MuiTypography-root MuiTypography-h3 css-1fchgxt-MuiTypography-root">Press Release: Jean-Paul Kress to join Sanofi's Board of Directors</div><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-1i53qr6-MuiGrid2-root"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-true css-c7yewm-MuiGrid2-root"><a class="elements-ds-dgpxh5" target="_self" title="Press Release: Jean-Paul Kress to join Sanofi's Board of Directors" href="/en/media-room/press-releases/2024/2024-12-19-17-00-00-3000094" icon="fasArrowRight"><span style="margin-inline-end:0">Read the Press Release</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-1 MuiGrid2-grid-desktop-2 css-1cc1yhr-MuiGrid2-root"><a class="elements-ds-1861jrd" href="/assets/dotcom/pressreleases/2024/2024-12-19-17-00-00-3000094-en.pdf" aria-label="link" target="_blank"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="download" class="svg-inline--fa fa-download elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M288 32c0-17.7-14.3-32-32-32s-32 14.3-32 32V274.7l-73.4-73.4c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3l128 128c12.5 12.5 32.8 12.5 45.3 0l128-128c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0L288 274.7V32zM64 352c-35.3 0-64 28.7-64 64v32c0 35.3 28.7 64 64 64H448c35.3 0 64-28.7 64-64V416c0-35.3-28.7-64-64-64H346.5l-45.3 45.3c-25 25-65.5 25-90.5 0L165.5 352H64zm368 56a24 24 0 1 1 0 48 24 24 0 1 1 0-48z"></path></svg></a></div></div></div><hr class="MuiDivider-root MuiDivider-fullWidth css-1pytp3s-MuiDivider-root"/></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-8 MuiGrid2-grid-desktop-12 css-epopls-MuiGrid2-root"><div class="MuiBox-root css-4q3mua"><nav role="navigation"><ul aria-label="List of 25 items" class="elements-ds-iciknd"><li class="elements-ds-155za0w"><button icon="[object Object]" disabled="" aria-label="Go to first page" tabindex="-1" class="elements-ds-1oa67mk"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angles-left" class="svg-inline--fa fa-angles-left elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M9.4 233.4c-12.5 12.5-12.5 32.8 0 45.3l160 160c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3L77.3 256 214.6 118.6c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0l-160 160zm352-160l-160 160c-12.5 12.5-12.5 32.8 0 45.3l160 160c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3L269.3 256 406.6 118.6c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0z"></path></svg></button></li><li class="elements-ds-155za0w"><button icon="[object Object]" disabled="" tabindex="-1" aria-label="Go to previous page, page 0" class="elements-ds-1oa67mk"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="chevron-left" class="svg-inline--fa fa-chevron-left elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512"><path fill="currentColor" d="M9.4 233.4c-12.5 12.5-12.5 32.8 0 45.3l192 192c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3L77.3 256 246.6 86.6c12.5-12.5 12.5-32.8 0-45.3s-32.8-12.5-45.3 0l-192 192z"></path></svg></button></li><li class="elements-ds-155za0w"><button label="1" selected="" tabindex="0" aria-current="page" aria-label="Current page, Page 1" class="elements-ds-6pdsw">1</button></li><li class="elements-ds-155za0w"><button label="2" tabindex="-1" aria-label="Go to page 2" class="elements-ds-118xrnj">2</button></li><li class="elements-ds-155za0w"><button label="3" tabindex="-1" aria-label="Go to page 3" class="elements-ds-118xrnj">3</button></li><li class="elements-ds-155za0w"><button label="4" tabindex="-1" aria-label="Go to page 4" class="elements-ds-118xrnj">4</button></li><li class="elements-ds-155za0w"><button label="5" tabindex="-1" aria-label="Go to page 5" class="elements-ds-118xrnj">5</button></li><li class="elements-ds-155za0w"><button label="6" tabindex="-1" aria-label="Go to page 6" class="elements-ds-118xrnj">6</button></li><li class="elements-ds-155za0w"><button label="7" tabindex="-1" aria-label="Go to page 7" class="elements-ds-118xrnj">7</button></li><li class="elements-ds-155za0w"><button icon="[object Object]" aria-label="Go to next page, page 2" tabindex="-1" class="elements-ds-1oa67mk"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="chevron-right" class="svg-inline--fa fa-chevron-right elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512"><path fill="currentColor" d="M310.6 233.4c12.5 12.5 12.5 32.8 0 45.3l-192 192c-12.5 12.5-32.8 12.5-45.3 0s-12.5-32.8 0-45.3L242.7 256 73.4 86.6c-12.5-12.5-12.5-32.8 0-45.3s32.8-12.5 45.3 0l192 192z"></path></svg></button></li><li class="elements-ds-155za0w"><button icon="[object Object]" aria-label="Go to last page" tabindex="-1" class="elements-ds-1oa67mk"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angles-right" class="svg-inline--fa fa-angles-right elements-ds-8xk1se" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L370.7 256 233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160zm-352 160l160-160c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L178.7 256 41.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0z"></path></svg></button></li></ul></nav></div></div></div></div><div class="dotcom-content-block MuiBox-root css-jqikz1"><div class="MuiGrid2-root MuiGrid2-container MuiGrid2-direction-xs-row css-cr2kt9-MuiGrid2-root" id="85615052-acfb-46db-9d35-52bb11d44bfe"><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-8 MuiGrid2-grid-desktop-8 css-c8gmj9-MuiGrid2-root"><h2 class="MuiTypography-root MuiTypography-h2 css-1te8woh-MuiTypography-root">Press Statements </h2></div><div class="MuiGrid2-root MuiGrid2-direction-xs-row MuiGrid2-grid-mobile-4 MuiGrid2-grid-tablet-8 MuiGrid2-grid-desktop-8 css-146zs5-MuiGrid2-root"><a class="elements-ds-dgpxh5" title="Press Statements" icon="fasArrowRight" data-discover="true" href="/en/media-room/press-statements" target="_self"><span style="margin-inline-end:0">See more</span><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="arrow-right" class="svg-inline--fa fa-arrow-right elements-ds-1i9a2yw" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M438.6 278.6c12.5-12.5 12.5-32.8 0-45.3l-160-160c-12.5-12.5-32.8-12.5-45.3 0s-12.5 32.8 0 45.3L338.8 224 32 224c-17.7 0-32 14.3-32 32s14.3 32 32 32l306.7 0L233.4 393.4c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0l160-160z"></path></svg></a></div></div></div></div><div class="MuiStack-root css-qiso3p-MuiStack-root" id="bottom"></div></div></main><footer class="dotcom-footer"><div class="css-1n0w9uy"><div class="MuiBox-root css-1elqj97"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-46kbhf-MuiSvgIcon-root" focusable="false" aria-hidden="true" viewBox="0 0 80 22" xmlns="http://www.w3.org/2000/svg" width="80" height="22" fill="none" data-testid="logo" aria-label="Sanofi"><path d="M28.4057 7.29145C26.5895 6.58049 24.6556 6.21743 22.7051 6.22122C18.3338 6.22122 15.2656 9.14389 15.2656 13.7488C15.2656 18.4061 17.9277 21.2764 22.6461 21.2764C24.6249 21.2899 26.5854 20.8967 28.4057 20.1211C28.6384 20.0363 28.836 19.8762 28.9671 19.6663C29.0982 19.4563 29.1553 19.2086 29.1294 18.9625V8.45004C29.1294 7.78238 28.8707 7.46492 28.4057 7.29145ZM25.3671 16.75C25.3671 17.1853 25.1346 17.3882 24.6435 17.5322C24.0047 17.7139 23.3429 17.8021 22.6788 17.7941C20.8255 17.7941 19.077 16.6944 19.077 13.7423C19.077 10.7901 20.8124 9.69373 22.6788 9.69373C23.3428 9.68465 24.0045 9.77175 24.6435 9.95229C25.1346 10.0963 25.3671 10.2992 25.3671 10.7345V16.75Z" fill="#fff"></path><path d="M4.03447 11.053C4.03447 10.1693 4.93163 9.60638 6.46732 9.60638C7.94407 9.60638 9.36187 10.0973 10.8386 10.9155C10.9694 10.9927 11.119 11.0324 11.2709 11.0301C11.4062 11.0283 11.5386 10.9899 11.6539 10.9191C11.7692 10.8482 11.8631 10.7474 11.9257 10.6275L12.8229 8.71615C12.8961 8.56268 12.9352 8.39521 12.9375 8.22522C12.9378 8.10625 12.9056 7.98945 12.8445 7.88738C12.7833 7.78532 12.6955 7.70183 12.5904 7.64591C10.76 6.62407 8.69484 6.09619 6.5983 6.11422C2.72143 6.11422 0.23291 8.19577 0.23291 11.3214C0.23291 17.4547 9.55181 15.0786 9.55181 19.3333C9.55488 19.6973 9.49619 20.0592 9.37825 20.4036C9.36067 20.4598 9.35076 20.5181 9.34879 20.577C9.34601 20.6336 9.35561 20.6901 9.37693 20.7426C9.39826 20.7951 9.4308 20.8424 9.47226 20.881C9.51373 20.9196 9.56315 20.9488 9.61704 20.9664C9.67093 20.9839 9.72798 20.9896 9.78427 20.9828H12.3874C12.8229 20.9828 12.9964 20.8388 13.1405 20.4036C13.3015 19.8732 13.38 19.3213 13.373 18.7671C13.3567 12.1821 4.03447 13.7629 4.03447 11.053Z" fill="#fff"></path><path d="M39.2007 6.22119C37.2161 6.23484 35.2483 6.58681 33.3821 7.26196C33.1495 7.34674 32.9519 7.50684 32.8208 7.71677C32.6897 7.92671 32.6325 8.17442 32.6585 8.42055V20.396C32.6537 20.4733 32.6654 20.5507 32.6928 20.6232C32.7203 20.6956 32.7628 20.7614 32.8176 20.8162C32.8724 20.871 32.9382 20.9135 33.0107 20.9409C33.0832 20.9684 33.1607 20.9801 33.238 20.9753H35.8575C35.9349 20.9801 36.0124 20.9684 36.0849 20.9409C36.1574 20.9135 36.2232 20.871 36.278 20.8162C36.3328 20.7614 36.3753 20.6956 36.4028 20.6232C36.4302 20.5507 36.4419 20.4733 36.4371 20.396V10.6756C36.4371 10.2435 36.6663 10.0406 37.1313 9.9228C37.832 9.75321 38.552 9.67619 39.2727 9.6937C40.8346 9.6937 42.0789 10.417 42.0789 12.1516V20.396C42.0741 20.4733 42.0858 20.5507 42.1132 20.6232C42.1407 20.6956 42.1832 20.7614 42.238 20.8162C42.2928 20.871 42.3586 20.9135 42.4311 20.9409C42.5036 20.9684 42.5811 20.9801 42.6584 20.9753H45.278C45.355 20.9796 45.4322 20.9675 45.5043 20.9399C45.5764 20.9122 45.6418 20.8696 45.6962 20.8149C45.7507 20.7602 45.7929 20.6946 45.8201 20.6224C45.8474 20.5502 45.859 20.473 45.8543 20.396V11.6607C45.8281 8.12927 43.6572 6.22119 39.2007 6.22119Z" fill="#fff"></path><path d="M55.7858 6.22119C51.444 6.22119 48.6084 9.37296 48.6084 13.7488C48.6084 18.1246 51.444 21.2764 55.9888 21.2764C60.3307 21.2764 63.1663 18.1246 63.1663 13.7488C63.1663 9.37296 60.3307 6.22119 55.7858 6.22119ZM55.9888 17.794C53.8474 17.794 52.4296 16.4031 52.4296 13.7422C52.4296 11.0814 53.8474 9.6937 55.7858 9.6937C57.9273 9.6937 59.3451 11.0814 59.3451 13.7422C59.3451 16.4031 57.9273 17.794 55.9888 17.794Z" fill="#fff"></path><path d="M79.2862 6.5083H76.6831C76.363 6.5083 76.1035 6.76766 76.1035 7.0876V20.3951C76.1035 20.715 76.363 20.9744 76.6831 20.9744H79.2862C79.6063 20.9744 79.8658 20.715 79.8658 20.3951V7.0876C79.8658 6.76766 79.6063 6.5083 79.2862 6.5083Z" fill="#fff"></path><path d="M73.7294 0.926411C73.1329 0.785744 72.5216 0.717613 71.9088 0.723495C68.307 0.723495 65.9756 2.63485 65.9756 6.80121V20.3967C65.9709 20.4737 65.9825 20.5509 66.0098 20.6231C66.037 20.6953 66.0792 20.7609 66.1337 20.8156C66.1881 20.8704 66.2535 20.913 66.3256 20.9406C66.3977 20.9682 66.4748 20.9803 66.5519 20.976H69.1289C69.2062 20.9808 69.2837 20.9691 69.3562 20.9416C69.4287 20.9142 69.4945 20.8717 69.5493 20.8169C69.6041 20.7622 69.6467 20.6964 69.6741 20.6239C69.7015 20.5515 69.7132 20.474 69.7084 20.3967V9.69441H73.3823C73.4602 9.70144 73.5387 9.69129 73.6122 9.66467C73.6857 9.63804 73.7524 9.59558 73.8077 9.54032C73.863 9.48505 73.9054 9.41833 73.9321 9.34485C73.9587 9.27137 73.9689 9.19296 73.9619 9.11513V7.11867C73.9718 7.03889 73.9639 6.95791 73.9387 6.88157C73.9135 6.80523 73.8717 6.73543 73.8162 6.6772C73.7608 6.61897 73.6931 6.57376 73.6181 6.54484C73.543 6.51591 73.4625 6.50398 73.3823 6.50992H69.7084V6.18263C69.7084 4.59202 70.4026 3.78034 72.0005 3.78034C72.5801 3.78034 73.2022 3.92762 73.4183 3.92762C73.7654 3.92762 73.9095 3.72471 73.9684 3.37778L74.2598 1.87227C74.2888 1.74857 74.3074 1.62267 74.3155 1.49589C74.309 1.18496 74.1354 1.01478 73.7294 0.926411Z" fill="#fff"></path><path d="M1.96463 17.2759C0.779304 17.2759 0 18.0254 0 19.269C0 20.5127 0.782588 21.2655 2.05632 21.2655C3.24165 21.2655 4.02096 20.4865 4.02096 19.269C4.02096 18.0515 3.23837 17.2759 1.96463 17.2759Z" fill="#fff"></path><path d="M77.9436 0.729004C76.755 0.729004 75.979 1.48177 75.979 2.72546C75.979 3.96915 76.7616 4.7219 78.0353 4.7219C79.2207 4.7219 80 3.9397 80 2.72546C80 1.51123 79.2141 0.729004 77.9436 0.729004Z" fill="#fff"></path></svg></div><div style="color:#fff" class="css-1juh738"><div class="MuiTypography-root MuiTypography-body1 css-amrgmt-MuiTypography-root">Follow us</div><ul class="MuiList-root MuiList-padding css-1oc5ep0-MuiList-root"><li class="MuiListItem-root MuiListItem-gutters css-16yom0i-MuiListItem-root"><a href="https://www.linkedin.com/company/sanofi" aria-label="Go to Sanofi on Linkedin" title="Sanofi on Linkedin" target="_blank" class="css-1l93wsm"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-xesgy4-MuiSvgIcon-root" focusable="false" aria-hidden="true" role="img" viewBox="0 0 448 512" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M100.28 448H7.4V148.9h92.88zM53.79 108.1C24.09 108.1 0 83.5 0 53.8a53.79 53.79 0 0 1 107.58 0c0 29.7-24.1 54.3-53.79 54.3zM447.9 448h-92.68V302.4c0-34.7-.7-79.2-48.29-79.2-48.29 0-55.69 37.7-55.69 76.7V448h-92.78V148.9h89.08v40.8h1.3c12.4-23.5 42.69-48.3 87.88-48.3 94 0 111.28 61.9 111.28 142.3V448z"></path></svg></a></li><li class="MuiListItem-root MuiListItem-gutters css-16yom0i-MuiListItem-root"><a href="https://twitter.com/sanofi" aria-label="Go to Sanofi on Twitter" title="Sanofi on Twitter" target="_blank" class="css-1l93wsm"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-xesgy4-MuiSvgIcon-root" focusable="false" aria-hidden="true" role="img" viewBox="0 0 512 512" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z"></path></svg></a></li><li class="MuiListItem-root MuiListItem-gutters css-16yom0i-MuiListItem-root"><a href="https://www.instagram.com/sanofi/" aria-label="Go to Sanofi on Instagram" title="Sanofi on Instagram" target="_blank" class="css-1l93wsm"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-xesgy4-MuiSvgIcon-root" focusable="false" aria-hidden="true" role="img" viewBox="0 0 448 512" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M224.1 141c-63.6 0-114.9 51.3-114.9 114.9s51.3 114.9 114.9 114.9S339 319.5 339 255.9 287.7 141 224.1 141zm0 189.6c-41.1 0-74.7-33.5-74.7-74.7s33.5-74.7 74.7-74.7 74.7 33.5 74.7 74.7-33.6 74.7-74.7 74.7zm146.4-194.3c0 14.9-12 26.8-26.8 26.8-14.9 0-26.8-12-26.8-26.8s12-26.8 26.8-26.8 26.8 12 26.8 26.8zm76.1 27.2c-1.7-35.9-9.9-67.7-36.2-93.9-26.2-26.2-58-34.4-93.9-36.2-37-2.1-147.9-2.1-184.9 0-35.8 1.7-67.6 9.9-93.9 36.1s-34.4 58-36.2 93.9c-2.1 37-2.1 147.9 0 184.9 1.7 35.9 9.9 67.7 36.2 93.9s58 34.4 93.9 36.2c37 2.1 147.9 2.1 184.9 0 35.9-1.7 67.7-9.9 93.9-36.2 26.2-26.2 34.4-58 36.2-93.9 2.1-37 2.1-147.8 0-184.8zM398.8 388c-7.8 19.6-22.9 34.7-42.6 42.6-29.5 11.7-99.5 9-132.1 9s-102.7 2.6-132.1-9c-19.6-7.8-34.7-22.9-42.6-42.6-11.7-29.5-9-99.5-9-132.1s-2.6-102.7 9-132.1c7.8-19.6 22.9-34.7 42.6-42.6 29.5-11.7 99.5-9 132.1-9s102.7-2.6 132.1 9c19.6 7.8 34.7 22.9 42.6 42.6 11.7 29.5 9 99.5 9 132.1s2.7 102.7-9 132.1z"></path></svg></a></li><li class="MuiListItem-root MuiListItem-gutters css-16yom0i-MuiListItem-root"><a href="https://www.facebook.com/Sanofi" aria-label="Go to Sanofi on Facebook" title="Sanofi on Facebook" target="_blank" class="css-1l93wsm"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-xesgy4-MuiSvgIcon-root" focusable="false" aria-hidden="true" role="img" viewBox="0 0 320 512" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M279.14 288l14.22-92.66h-88.91v-60.13c0-25.35 12.42-50.06 52.24-50.06h40.42V6.26S260.43 0 225.36 0c-73.22 0-121.08 44.38-121.08 124.72v70.62H22.89V288h81.39v224h100.17V288z"></path></svg></a></li><li class="MuiListItem-root MuiListItem-gutters css-16yom0i-MuiListItem-root"><a href="https://www.tiktok.com/@sanofi" aria-label="Go to Sanofi on TikTok" title="Sanofi on TikTok" target="_blank" class="css-1l93wsm"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-xesgy4-MuiSvgIcon-root" focusable="false" aria-hidden="true" role="img" viewBox="0 0 448 512" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M448,209.91a210.06,210.06,0,0,1-122.77-39.25V349.38A162.55,162.55,0,1,1,185,188.31V278.2a74.62,74.62,0,1,0,52.23,71.18V0l88,0a121.18,121.18,0,0,0,1.86,22.17h0A122.18,122.18,0,0,0,381,102.39a121.43,121.43,0,0,0,67,20.14Z"></path></svg></a></li><li class="MuiListItem-root MuiListItem-gutters css-16yom0i-MuiListItem-root"><a href="https://www.youtube.com/@sanofi" aria-label="Go to Sanofi on Youtube" title="Sanofi on Youtube" target="_blank" class="css-1l93wsm"><svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-xesgy4-MuiSvgIcon-root" focusable="false" aria-hidden="true" role="img" viewBox="0 0 576 512" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M549.655 124.083c-6.281-23.65-24.787-42.276-48.284-48.597C458.781 64 288 64 288 64S117.22 64 74.629 75.486c-23.497 6.322-42.003 24.947-48.284 48.597-11.412 42.867-11.412 132.305-11.412 132.305s0 89.438 11.412 132.305c6.281 23.65 24.787 41.5 48.284 47.821C117.22 448 288 448 288 448s170.78 0 213.371-11.486c23.497-6.321 42.003-24.171 48.284-47.821 11.412-42.867 11.412-132.305 11.412-132.305s0-89.438-11.412-132.305zm-317.51 213.508V175.185l142.739 81.205-142.739 81.201z"></path></svg></a></li></ul></div><div class="css-3759vn"><button class="MuiButtonBase-root MuiIconButton-root MuiIconButton-sizeSmall css-17gnk4t-MuiButtonBase-root-MuiIconButton-root" tabindex="0" type="button" aria-label="Back to top">Back to top<svg class="MuiSvgIcon-root MuiSvgIcon-fontSizeMedium css-xesgy4-MuiSvgIcon-root" focusable="false" aria-hidden="true" role="img" viewBox="0 0 384 512" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M214.6 41.4c-12.5-12.5-32.8-12.5-45.3 0l-160 160c-12.5 12.5-12.5 32.8 0 45.3s32.8 12.5 45.3 0L160 141.2V448c0 17.7 14.3 32 32 32s32-14.3 32-32V141.2L329.4 246.6c12.5 12.5 32.8 12.5 45.3 0s12.5-32.8 0-45.3l-160-160z"></path></svg></button></div></div><div class="css-1boijxs"><nav class="css-0" id="navigation_information"><ul class="MuiList-root css-1l2zhvo-MuiList-root"><li class="MuiListItem-root MuiListItem-gutters css-73fo95-MuiListItem-root"><a data-discover="true" class="css-1u4cuma" href="/en/magazine" target="_self">Stories</a></li><li class="MuiListItem-root MuiListItem-gutters css-73fo95-MuiListItem-root"><a data-discover="true" class="css-1u4cuma" href="/en/contact" target="_self">Contact</a></li><li class="MuiListItem-root MuiListItem-gutters css-73fo95-MuiListItem-root"><a data-discover="true" class="css-1u4cuma" href="/en/legal-notice" target="_self">Legal notice</a></li><li class="MuiListItem-root MuiListItem-gutters css-73fo95-MuiListItem-root"><a data-discover="true" class="css-1u4cuma" href="/en/privacy-and-data-protection" target="_self">Privacy & data protection</a></li><li class="MuiListItem-root MuiListItem-gutters css-73fo95-MuiListItem-root"><a data-discover="true" class="css-1u4cuma" href="/en/data-privacy" target="_self">Cookies Policy</a></li><li class="MuiListItem-root MuiListItem-gutters css-73fo95-MuiListItem-root"><a data-discover="true" class="css-1u4cuma" href="/en/publications" target="_self">Our publications</a></li><li class="MuiListItem-root MuiListItem-gutters css-73fo95-MuiListItem-root"><a data-discover="true" class="css-1u4cuma" href="/en/directory" target="_self">Directory</a></li><li class="MuiListItem-root MuiListItem-gutters css-73fo95-MuiListItem-root"><a data-discover="true" class="css-1u4cuma" href="/en/sitemap" target="_self">Sitemap</a></li><li class="MuiListItem-root MuiListItem-gutters css-73fo95-MuiListItem-root"><a data-discover="true" class="css-1u4cuma" href="/en/accessibility-partial-compliance" target="_self">Accessibility: partial compliance</a></li><li class="MuiListItem-root MuiListItem-gutters css-73fo95-MuiListItem-root"><a class="css-1u4cuma" href="https://www.codeofconduct.sanofi/" target="_blank">Code of Conduct</a></li></ul></nav><div class="MuiStack-root css-hwnj0i-MuiStack-root"><span class="MuiTypography-root MuiTypography-body1 css-1ubkcfk-MuiTypography-root">© Sanofi 2004-2025 - All rights reserved</span></div></div></footer></div><script>((v,p)=>{if(!window.history.state||!window.history.state.key){let h=Math.random().toString(32).slice(2);window.history.replaceState({key:h},"")}try{let g=JSON.parse(sessionStorage.getItem(v)||"{}")[p||window.history.state.key];typeof g=="number"&&window.scrollTo(0,g)}catch(h){console.error(h),sessionStorage.removeItem(v)}})("positions", null)</script><link rel="modulepreload" href="/static/manifest-A69F9EC4.js"/><link rel="modulepreload" href="/static/entry.client-G3JUSURV.js"/><link rel="modulepreload" href="/static/_shared/chunk-IDZZSJV2.js"/><link rel="modulepreload" href="/static/_shared/chunk-SQ6ZANJC.js"/><link rel="modulepreload" href="/static/_shared/chunk-FJNYTLRL.js"/><link rel="modulepreload" href="/static/_shared/chunk-B2T57KYA.js"/><link rel="modulepreload" href="/static/_shared/chunk-LIRFA2LM.js"/><link rel="modulepreload" href="/static/_shared/chunk-QANMD64B.js"/><link rel="modulepreload" href="/static/_shared/chunk-ORD77M2J.js"/><link rel="modulepreload" href="/static/_shared/chunk-RWAGXVDE.js"/><link rel="modulepreload" href="/static/_shared/chunk-Z2AVRDCR.js"/><link rel="modulepreload" href="/static/root-PCUIZQI5.js"/><link rel="modulepreload" href="/static/routes/$-KESNOA4U.js"/><script>window.__remixContext = {"future":{"v3_fetcherPersist":false,"v3_relativeSplatPath":false,"v3_throwAbortReason":false,"v3_routeConfig":false,"v3_singleFetch":false,"v3_lazyRouteDiscovery":false,"unstable_optimizeDeps":false},"state":{"loaderData":{"root":{"locale":"en","gtm":"GTM-N67QVH3","oneTrustId":"5ba9840f-2af3-4f28-b54d-b9d55e0175d5","ldClientSideId":"63779209b9abad1176b1c8de","siteKey":"COM","clientEnvVars":{"SITE_KEY":"COM","GTM":"GTM-N67QVH3","LD_CLIENT_SIDE":"63779209b9abad1176b1c8de","ONETRUST":"5ba9840f-2af3-4f28-b54d-b9d55e0175d5","SCRIPTS_HEAD":"","IMG_OPTIM":true}},"routes/$":{"data":{"localization":[{"type":"nav-item-link","label":"English","code":"en","href":"/en/media-room/press-releases"},{"type":"nav-item-link","label":"Français","code":"fr","href":"/fr/media-room/communiques-de-presse"}],"type":"pageFound","locale":"en","defaultLocale":"en","localesLabels":{"en":"English","fr":"Français"},"navigation":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company","label":"Our Company"},"items":[{"type":"nav-item-link","href":"/en/our-company/our-strategy","label":"Our Strategy"},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/governance","label":"Governance"},"items":[{"type":"nav-item-link","href":"/en/our-company/governance/board-of-directors","label":"Board of Directors"},{"type":"nav-item-link","href":"/en/our-company/governance/executive-committee","label":"Executive Committee"},{"type":"nav-item-link","href":"/en/our-company/governance/specialist-committees","label":"Specialist Committees"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/social-impact","label":"Social Impact"},"items":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/social-impact/access-to-healthcare","label":"Access to Healthcare"},"items":[{"type":"nav-item-link","href":"/en/our-company/social-impact/access-to-healthcare/global-health-unit","label":"Global Health Unit"},{"type":"nav-item-link","href":"/en/our-company/social-impact/access-to-healthcare/foundation-s","label":"Foundation S"}]},{"type":"nav-item-link","href":"/en/our-company/social-impact/innovation-for-vulnerable-communities","label":"Innovation for Vulnerable Communities"},{"type":"nav-item-link","href":"/en/our-company/social-impact/environmental-sustainability-and-resilience","label":"Environmental Sustainability and Resilience"},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace","label":"Diversity, Equity, and Inclusion In and Beyond the Workplace"},"items":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/a-million-conversations","label":"A Million Conversations"},"items":[{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/a-million-conversations/sanofi-nextgen-scholars","label":"Sanofi NextGen Scholars"},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/a-million-conversations/advisory-group-hub","label":"Advisory Group Hub"}]},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/allyship","label":"Allyship"},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/employee-resource-groups","label":"Employee Resource Groups"},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/board","label":"Diversity, Equity and Inclusion Board"},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/gender-balance","label":"Gender Balance"},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/lgbtqplus","label":"LGBTQ+"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/social-impact/responsible-business-values","label":"Code of Conduct and Responsible Business"},"items":[{"type":"nav-item-link","href":"/en/our-company/social-impact/responsible-business-values/information-on-dengvaxia","label":"Information on Dengvaxia®"},{"type":"nav-item-link","href":"/en/our-company/social-impact/responsible-business-values/sodium-valproate","label":"Information on Sodium Valproate"}]}]},{"type":"nav-item-link","href":"/en/our-company/our-legacy","label":"Our Legacy"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-science","label":"Our Science"},"items":[{"type":"nav-item-link","href":"/en/our-science/our-pipeline","label":"Our Pipeline"},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas","label":"Our R\u0026D Focus"},"items":[{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/immunology-rd","label":"Immunology R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/neurology-rd","label":"Neurology R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/oncology-rd","label":"Oncology R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/rare-blood-disorders-rd","label":"Rare Blood Disorders R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/rare-diseases-rd","label":"Rare Diseases R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/vaccines-rd","label":"Vaccines R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/artificial-intelligence-rd","label":"Artificial Intelligence in R\u0026D "}]},{"type":"nav-item-link","href":"/en/our-science/technology-platforms","label":"Technology Platforms "},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results","label":"Clinical Trials \u0026 Results"},"items":[{"type":"nav-item-link","target":"_blank","href":"https://www.sanofistudies.com/global/en/ ","label":"Find a Clinical Trial","showOutgoingModal":false},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results/clinical-study-results","label":"Clinical Study Results"},"items":[{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results/clinical-study-results/medicines","label":"Medicines"},{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results/clinical-study-results/vaccines","label":"Vaccines"}]},{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results/investigator-sponsored-studies","label":"Investigator Sponsored Studies"},{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results/diversity-in-clinical-trials","label":"Diversity in Clinical Trials"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-science/scientific-collaboration","label":"Scientific Collaboration"},"items":[{"type":"nav-item-link","href":"/en/our-science/scientific-collaboration/north-america","label":"Scientific Collaboration in North America"},{"type":"nav-item-link","href":"/en/our-science/scientific-collaboration/europe","label":"Scientific Collaboration in Europe"},{"type":"nav-item-link","href":"/en/our-science/scientific-collaboration/china","label":"Scientific Collaboration in China"}]},{"type":"nav-item-link","href":"/en/our-science/digital","label":"Digital"},{"type":"nav-item-link","href":"/en/our-science/manufacturing-and-supply","label":"Manufacturing and Supply"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/your-health","label":"Your Health"},"items":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/your-health/vaccines","label":"Vaccines \u0026 Infectious Diseases"},"items":[{"type":"nav-item-link","href":"/en/your-health/vaccines/influenza","label":"Influenza"},{"type":"nav-item-link","href":"/en/your-health/vaccines/meningococcal-meningitis","label":"Meningococcal Meningitis"},{"type":"nav-item-link","href":"/en/your-health/vaccines/pertussis","label":"Pertussis"},{"type":"nav-item-link","href":"/en/your-health/vaccines/respiratory-syncytial-virus","label":"Respiratory Syncytial Virus (RSV)"},{"type":"nav-item-link","href":"/en/your-health/vaccines/production","label":"Production"},{"type":"nav-item-link","href":"/en/your-health/vaccines/why-vaccines-matter","label":"Why Vaccines Matter"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/your-health/medicines","label":"Medicines"},"items":[{"type":"nav-item-link","href":"/en/your-health/medicines/immunology","label":"Immunology"},{"type":"nav-item-link","href":"/en/your-health/medicines/neurology","label":"Neurology"},{"type":"nav-item-link","href":"/en/your-health/medicines/oncology","label":"Oncology"},{"type":"nav-item-link","href":"/en/your-health/medicines/rare-blood-disorders","label":"Rare Blood Disorders"},{"type":"nav-item-link","href":"/en/your-health/medicines/rare-diseases","label":"Rare Diseases"},{"type":"nav-item-link","href":"/en/your-health/medicines/cardiovascular-diseases","label":"Cardiovascular Diseases"},{"type":"nav-item-link","href":"/en/your-health/medicines/diabetes","label":"Diabetes"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare","label":"Consumer Healthcare"},"items":[{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/sustainability-at-sanofi-consumer-healthcare","label":"Sustainability at Sanofi Consumer Healthcare"},{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/allergy","label":"Allergy"},{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/cough-cold-and-flu","label":"Cough, Cold \u0026 Flu"},{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/digestive-wellness","label":"Digestive Wellness"},{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/pain-care","label":"Pain Care"},{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/physical-and-mental-wellness","label":"Physical \u0026 Mental Wellness"}]},{"type":"nav-item-link","href":"/en/your-health/patient-engagement","label":"Integrated Patient Engagement"},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/your-health/healthcare-professional-support","label":"Healthcare Professionals Support"},"items":[{"type":"nav-item-link","href":"/en/your-health/healthcare-professional-support/sanofi-manage-access-program","label":"Managed Access Programs (MAPs)"},{"type":"nav-item-link","href":"/en/your-health/healthcare-professional-support/sanofi-preregistration-import-license","label":"Pre-Registration Import Licenses"},{"type":"nav-item-link","href":"/en/your-health/healthcare-professional-support/post-trial-access","label":"Post Trial Access (PTA)"}]}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/partnering","label":"Partnering"},"items":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas","label":"Partnering Focus Areas"},"items":[{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/china","label":"China"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/digital","label":"Digital"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/general-medicines","label":"General Medicines"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/immunology","label":"Immunology"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/neuroscience","label":"Neuroscience"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/oncology","label":"Oncology"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/out-licensing","label":"Out-Licensing"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/rare-disease","label":"Rare Disease"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/technology-platforms","label":"Technology Platforms"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/vaccines","label":"Vaccines"}]},{"type":"nav-item-link","href":"/en/partnering/meet-the-partnering-team","label":"Meet the Partnering Team"},{"type":"nav-item-link","href":"/en/partnering/contact-business-development-team","label":"Contact Business Development Team"}]}],"actions":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/media-room","label":"Media"},"items":[{"type":"nav-item-link","target":"_self","href":"https://www.sanofi.com/en/magazine","label":"Stories","showOutgoingModal":false},{"type":"nav-item-link","href":"/en/media-room/press-releases","label":"Press Releases"},{"type":"nav-item-link","href":"/en/media-room/contact","label":"Contacts"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/investors","label":"Investors"},"items":[{"type":"nav-item-link","target":"_self","href":"https://www.sanofi.com/en/media-room/press-releases","label":"News","showOutgoingModal":false},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/investors/financial-results-and-events","label":"Results and Presentations"},"items":[{"type":"nav-item-link","href":"/en/investors/financial-results-and-events/financial-results","label":"Results"},{"type":"nav-item-link","href":"/en/investors/financial-results-and-events/investor-presentations","label":"Presentations"}]},{"type":"nav-item-link","href":"/en/investors/broker-conferences","label":"Conferences"},{"type":"nav-item-link","href":"/en/investors/environment-social-governance","label":"Environment, Social, Governance"},{"type":"nav-item-link","href":"/en/investors/individual-shareholders","label":"Private Shareholders"},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs","label":"Shares and ADRs"},"items":[{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/stock-chart","label":"Sanofi stock chart"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/dividend","label":"Dividend"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/adrs","label":"ADRs"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/shares-structure-vote","label":"Shares, Structure \u0026 Vote"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/analyst-coverage","label":"Analyst Coverage"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/vara-consensus","label":"Vara consensus"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/share-repurchases","label":"Share Repurchases"}]},{"type":"nav-item-link","href":"/en/investors/bonds","label":"Bonds"},{"type":"nav-item-link","href":"/en/investors/contacts","label":"Contacts"}]},{"type":"nav-item-link","target":"_self","href":"https://jobs.sanofi.com","label":"Careers","showOutgoingModal":true}],"social":[{"type":"nav-item-link","href":"https://www.linkedin.com/company/sanofi","label":"Go to Sanofi on Linkedin","title":"Sanofi on Linkedin","icon":"linkedin","domain":"external"},{"type":"nav-item-link","href":"https://twitter.com/sanofi","label":"Go to Sanofi on Twitter","title":"Sanofi on Twitter","icon":"twitter","domain":"external"},{"type":"nav-item-link","href":"https://www.instagram.com/sanofi/","label":"Go to Sanofi on Instagram","title":"Sanofi on Instagram","icon":"instagram","domain":"external"},{"type":"nav-item-link","href":"https://www.facebook.com/Sanofi","label":"Go to Sanofi on Facebook","title":"Sanofi on Facebook","icon":"facebook","domain":"external"},{"type":"nav-item-link","href":"https://www.tiktok.com/@sanofi","label":"Go to Sanofi on TikTok","title":"Sanofi on TikTok","icon":"tiktok","domain":"external"},{"type":"nav-item-link","href":"https://www.youtube.com/@sanofi","label":"Go to Sanofi on Youtube","title":"Sanofi on Youtube","icon":"youtube","domain":"external"}],"informations":[{"type":"nav-item-link","href":"/en/magazine","label":"Stories"},{"type":"nav-item-link","href":"/en/contact","label":"Contact"},{"type":"nav-item-link","href":"/en/legal-notice","label":"Legal notice"},{"type":"nav-item-link","href":"/en/privacy-and-data-protection","label":"Privacy \u0026 data protection"},{"type":"nav-item-link","href":"/en/data-privacy","label":"Cookies Policy"},{"type":"nav-item-link","href":"/en/publications","label":"Our publications"},{"type":"nav-item-link","href":"/en/directory","label":"Directory"},{"type":"nav-item-link","href":"/en/sitemap","label":"Sitemap"},{"type":"nav-item-link","href":"/en/accessibility-partial-compliance","label":"Accessibility: partial compliance"},{"type":"nav-item-link","target":"_blank","href":"https://www.codeofconduct.sanofi/","label":"Code of Conduct","showOutgoingModal":true}],"intl":{"en":{"general.htmlTitleSuffix":"","general.close":"Close","general.ctaPage":"See more","general.ctaExternal":"Explore site","general.ctaFile":"Download","general.videoPlay":"Play the video","general.menuIconOpen":"Open the menu","general.menuIconClose":"Close the menu","general.backToHome":"Back to the sanofi.com homepage","general.backToTop":"Back to top","general.localePickerTitle":"My language","general.socialCTATitle":"Follow us","general.updateLanguage":"Update language","general.globalPanelTitle":"Global","general.copyright":"© Sanofi 2004-2025 - All rights reserved","general.outgoingModalTitle":"You are about to leave www.sanofi.com","general.outgoingModalText":"If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.","general.outgoingModalAction":"Proceed","general.shareTitle":"Share","countryWebsites.description":"We operate in 135 countries and regions, visit your regional site for more relevant information.","countryWebsites.searchPlaceholder":"Search a country or region","search.searchLinkTitle":"Search","search.searchLinkLabel":"Search","search.searchPlaceholder":"Search...","biographies.bioHeading":"Education and Business Experience","biographies.bioIdentity":"At a Glance","biographies.bioBirthdate":"Date of birth","biographies.bioNationality":"Nationality","biographies.bioFirstAppointment":"First elected or appointed","biographies.bioLastReappointment":"Last reappointment","biographies.bioTermExpiration":"Term expires","biographies.bioContact":"Contact information","biographies.bioPositions":"Directorships \u0026 Appointments","biographies.bioPositionsCompany":"Inside the Sanofi Group","biographies.bioPositionsOtherCompanies":"Outside the Sanofi Group","biographies.bioOtherExecutives":"Meet the Sanofi Executive Committee","biographies.bioOtherDirectors":"Meet the Sanofi Board of Directors","biographies.bioCTA":"See more","biographies.directorsSummaryTitle":"Summary table","biographies.directorsSummaryLegend":"\u003cp\u003eAC: Audit Committee\u003cbr /\u003e\nAGC: Appointments, Governance and CSR Committee\u003cbr /\u003e\nCC: Compensation Committee\u003cbr /\u003e\nSC: Strategy Committee\u003cbr /\u003e\nSciC: Scientific Committee\u003cbr /\u003e\nC: Chairman/Chairwoman\u003c/p\u003e\n","biographies.directorsSummaryColName":"Director","biographies.directorsSummaryColAge":"Age","biographies.directorsSummaryColNationality":"Nationality","biographies.directorsSummaryColFirstAppoinment":"First Appointed","biographies.directorsSummaryColTermExpiration":"Term expires","biographies.directorsSummaryColSeniority":"Seniority","biographies.committeePrefix":"Member of the","biographies.chairPrefixMan":"Chairman of the","biographies.chairPrefixWoman":"Chairwoman of the","biographies.listedCompaniesLegend":"Listed company","pressReleases.prDownload":"Download PDF","pressReleases.prCTA":"Read the Press Release","pressReleases.muCTA":"Read the Media Update","pressReleases.filterPerYear":"Filter per year","pressReleases.allYears":"All years","pressReleases.filterPerCategory":"Filter per category","pressReleases.allCategories":"All categories","pressReleases.prCategory":"Press Release","pressReleases.muCategory":"Media Update","publicationsdocs.ctaFileLabel":"Download PDF","publicationsdocs.ctaSiteLabel":"Explore site","documentsCenter.documentFileLink":"Download","documentsCenter.documentUrlLink":"Explore site","documentsCenter.searchPlaceholder":"Search title","documentsCenter.searchAction":"Search","events.featuringTitle":"Featuring","events.contactTitle":"Contact","events.downloadLink":"Downloads","events.highlightsTitle":"Highlights","events.streamingTitle":"Streaming","events.streamingRegister":"Register","events.streamingLive":"Live","events.streamingReplay":"Replay available","events.ctaUpComing":"Upcoming","events.ctaOnGoing":"Discover more","events.ctaOnPast":"Discover more","events.filterPerYear":"Filter per year","events.allYears":"All years","events.filterResult":"{{nbResult}} event(s) found","articles.articleCTA":"Read the article","articles.datePrefix":"Published on: ","articles.authorPrefix":"By: ","articles.exploreMoreTitle":"Explore more","articles.referencesTitle":"References","articles.yearFilter":"Year","articles.typeFilter":"Topic","clinicalStudies.tradeName":"Not Marketed","clinicalStudies.studyName":"NA"},"fr":{"general.htmlTitleSuffix":" - Sanofi","general.close":"Fermer","general.ctaPage":"En savoir plus","general.ctaExternal":"Visitez le site","general.ctaFile":"Télécharger","general.videoPlay":"Jouer la vidéo","general.menuIconOpen":"Ouvir le menu","general.menuIconClose":"Fermer le menu","general.backToHome":"Retour à la page d’accueil du site sanofi.com","general.backToTop":"Haut de la page","general.localePickerTitle":"Ma langue","general.socialCTATitle":"Suivez nous","general.updateLanguage":"Mettre à jour la langue","general.globalPanelTitle":"Global","general.copyright":"© Sanofi 2004-2025 - Tous droits réservés","general.outgoingModalTitle":"Vous allez quitter sanofi.com","general.outgoingModalText":"Si vous souhaitez poursuivre votre navigation sur ce site internet externe, cliquez sur Continuer. Il vous est proposé à titre d’information. Sanofi n’est pas responsable des contenus présents sur ce site internet.","general.outgoingModalAction":"Continuer","general.shareTitle":"Partagez","countryWebsites.description":"Nous opérons dans 135 pays et régions, visitez votre site régional pour plus d'informations pertinentes","countryWebsites.searchPlaceholder":"Rechercher un pays ou une région","search.searchLinkTitle":"Recherche","search.searchLinkLabel":"Recherche","search.searchPlaceholder":"Chercher...","biographies.bioHeading":"Education et expériences professionnelles","biographies.bioIdentity":"En bref","biographies.bioBirthdate":"Date de naissance","biographies.bioNationality":"Nationalité","biographies.bioFirstAppointment":"Première nomination/élection","biographies.bioLastReappointment":"Dernier renouvellement ","biographies.bioTermExpiration":"Fin du mandat en cours","biographies.bioContact":"Informations et contact","biographies.bioPositions":"Mandats et fonctions exercés","biographies.bioPositionsCompany":"Au sein du groupe Sanofi","biographies.bioPositionsOtherCompanies":"En dehors du groupe Sanofi","biographies.bioOtherExecutives":"Découvrez le Comité Exécutif de Sanofi","biographies.bioOtherDirectors":"Découvrez le Conseil d'Administration de Sanofi","biographies.bioCTA":"En savoir plus","biographies.directorsSummaryTitle":"Tableau récapitulatif","biographies.directorsSummaryLegend":"\u003cp\u003eCA : Comit\u0026eacute; d\u0026rsquo;audit\u003cbr /\u003e\nCNG : Comit\u0026eacute; des nominations, de la gouvernance et de la RSE\u003cbr /\u003e\nCR : Comit\u0026eacute; des r\u0026eacute;mun\u0026eacute;rations\u003cbr /\u003e\nCS : Comit\u0026eacute; de r\u0026eacute;flexion strat\u0026eacute;gique\u003cbr /\u003e\nCSci : Comit\u0026eacute; scientifique\u003cbr /\u003e\nP : Pr\u0026eacute;sident(e)\u003c/p\u003e\n","biographies.directorsSummaryColName":"Administrateur","biographies.directorsSummaryColAge":"Age","biographies.directorsSummaryColNationality":"Nationalité","biographies.directorsSummaryColFirstAppoinment":"1ère Nomination","biographies.directorsSummaryColTermExpiration":"Echéance du mandat","biographies.directorsSummaryColSeniority":"Ancienneté","biographies.committeePrefix":"Membre du","biographies.chairPrefixMan":"Président du","biographies.chairPrefixWoman":"Présidente du","biographies.listedCompaniesLegend":"Société cotée en Bourse","pressReleases.prDownload":"Télécharger le PDF","pressReleases.prCTA":"Lire le communiqué","pressReleases.muCTA":"Lire la mise à jour média","pressReleases.filterPerYear":"Filtrer par année","pressReleases.allYears":"Toutes les années","pressReleases.filterPerCategory":"Filtrer par catégorie","pressReleases.allCategories":"Toutes les catégories","pressReleases.prCategory":"Communiqués de presse","pressReleases.muCategory":"Mise à jour média","publicationsdocs.ctaFileLabel":"Télécharger le PDF","publicationsdocs.ctaSiteLabel":"Visiter le site","documentsCenter.documentFileLink":"Télécharger","documentsCenter.documentUrlLink":"Explorer le site","documentsCenter.searchPlaceholder":"Rechercher un titre","documentsCenter.searchAction":"Rechercher","events.featuringTitle":"Avec","events.contactTitle":"Contacts","events.downloadLink":"Documents à télécharger","events.highlightsTitle":"Faits marquants","events.streamingTitle":"Webinaire","events.streamingRegister":"S'enregistrer","events.streamingLive":"Direct","events.streamingReplay":"Différé","events.ctaUpComing":"A venir","events.ctaOnGoing":"Découvrir plus","events.ctaOnPast":"Découvrir plus","events.filterPerYear":"Filtrer par année","events.allYears":"Toutes les années","events.filterResult":"{{nbResult}} évènement(s) trouvé(s)","articles.articleCTA":"Lire l'article","articles.datePrefix":"Publié le: ","articles.authorPrefix":"Par: ","articles.exploreMoreTitle":"Découvrir plus","articles.referencesTitle":"Références","articles.yearFilter":"Année","articles.typeFilter":"Sujet","clinicalStudies.tradeName":"Non Commercialisé","clinicalStudies.studyName":"NA"}},"countryWebsites":[{"code":"dz","name":"Algeria","url":"https://www.sanofi.com/fr/algerie"},{"code":"ar","name":"Argentina","url":"https://www.sanofi.com/es/argentina"},{"code":"au","name":"Australia","url":"https://www.sanofi.com/en/australia"},{"code":"at","name":"Austria","url":"http://www.sanofi.at"},{"code":"br","name":"Brazil","url":"https://www.sanofi.com.br"},{"code":"be","name":"Belgium","url":"https://www.sanofi.com/fr/belgique"},{"code":"ca","name":"Canada","url":"https://www.sanofi.com/en/canada"},{"code":"cl","name":"Chile","url":"https://www.sanofi.com/es/chile"},{"code":"co","name":"Colombia","url":"https://www.sanofi.com/es/colombia"},{"code":"cn","name":"China","url":"http://www.sanofi.cn"},{"code":"cz","name":" Czech Republic","url":"https://www.sanofi.com/cs/ceska-republika"},{"code":"dk","name":" Denmark","url":"https://www.sanofi.com/da/danmark"},{"code":"eg","name":"Egypt","url":"https://www.sanofi.com/en/egypt"},{"code":"fi","name":"Finland","url":"https://www.sanofi.com/fi/suomi"},{"code":"fr","name":"France","url":"https://www.sanofi.fr"},{"code":"de","name":"Germany","url":"https://www.sanofi.de"},{"code":"gr","name":" Greece","url":"https://www.sanofi.com/el/greece"},{"code":"hk","name":"Hong Kong, SAR, China","url":"https://www.sanofi.com/en/hong-kong"},{"code":"hu","name":"Hungary","url":"https://www.sanofi.com/hu/magyarorszag"},{"code":"in","name":" India","url":"https://www.sanofi.in"},{"code":"ie","name":"Ireland","url":"https://www.sanofi.com/en/ireland"},{"code":"il","name":" Israel","url":"https://www.sanofi.com/he/israel"},{"code":"it","name":"Italy","url":"https://www.sanofi.com/it/italia"},{"code":"jp","name":"Japan","url":"http://www.sanofi.co.jp"},{"code":"lb","name":"Lebanon","url":"https://www.sanofi.com/en/levant"},{"code":"my","name":"Malaysia","url":"https://www.sanofi.com/en/malaysia"},{"code":"mx","name":"Mexico","url":"https://www.sanofi.com/es/mexico"},{"code":"ma","name":"Morocco","url":"https://www.sanofi.com/fr/maroc"},{"code":"nl","name":"Netherlands","url":"https://www.sanofi.nl"},{"code":"nz","name":"New Zealand","url":"https://www.sanofi.com/en/australia"},{"code":"no","name":"Norway","url":"https://www.sanofi.com/no/norge"},{"code":"py","name":"Paraguay","url":"https://www.sanofi.com.py"},{"code":"pe","name":"Peru","url":"https://www.sanofi.com/es/peru"},{"code":"ph","name":"Philippines","url":"https://www.sanofi.com/en/philippines"},{"code":"pl","name":"Poland","url":"https://www.sanofi.com/pl/polska"},{"code":"pt","name":"Portugal","url":"https://www.sanofi.com/pt/portugal"},{"code":"ro","name":"Romania","url":"https://www.sanofi.com/ro/romania"},{"code":"ru","name":"Russia","url":"https://www.sanofi.com/ru/russia"},{"code":"pa","name":"Sanofi Pacifico","url":"https://www.sanofi.com/es/pacifico"},{"code":"sa","name":"Saudi Arabia","url":"https://www.sanofi.com/ar/saudi-arabia"},{"code":"sg","name":"Singapore","url":"https://www.sanofi.com/en/singapore"},{"code":"za","name":"South Africa","url":"https://www.sanofi.com/en/south-africa"},{"code":"kr","name":"South Korea","url":"http://www.sanofi.co.kr"},{"code":"es","name":"Spain","url":"https://www.sanofi.com/es/espana"},{"code":"ci","name":"Subsaharan Francophone Africa","url":"https://www.sanofi.com/fr/subsaharan-francophone-africa"},{"code":"se","name":"Sweden","url":"https://www.sanofi.com/sv/sverige"},{"code":"ch","name":"Switzerland","url":"https://www.sanofi.com/de/schweiz"},{"code":"tw0","name":"Taiwan, China","url":"https://www.sanofi.com/zh/taiwan"},{"code":"th","name":"Thailand","url":"https://www.sanofi.com/th/thailand"},{"code":"tr","name":"Turkey","url":"http://www.sanofi.com.tr"},{"code":"ua","name":"Ukraine","url":"https://www.sanofi.com/uk/ukraine"},{"code":"uk","name":"United Kingdom","url":"http://www.sanofi.co.uk"},{"code":"us","name":"United States","url":"https://www.sanofi.us"},{"code":"uy","name":"Uruguay","url":"https://www.sanofi.com/es/uruguay"},{"code":"vn","name":"Vietnam","url":"https://www.sanofi.com/vi/vietnam"}],"showGlobal":true,"id":"dbe32240-e4fe-4795-b3cf-d9396d2e823a","provider":"magnolia","status":200,"url":"/en/media-room/press-releases","title":"Press Releases","template":{"type":"landingPage","data":{"direction":"ltr","header":{"type":"default","searchPageUrl":"/en/search-result","actions":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/media-room","label":"Media"},"items":[{"type":"nav-item-link","target":"_self","href":"https://www.sanofi.com/en/magazine","label":"Stories","showOutgoingModal":false},{"type":"nav-item-link","href":"/en/media-room/press-releases","label":"Press Releases"},{"type":"nav-item-link","href":"/en/media-room/contact","label":"Contacts"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/investors","label":"Investors"},"items":[{"type":"nav-item-link","target":"_self","href":"https://www.sanofi.com/en/media-room/press-releases","label":"News","showOutgoingModal":false},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/investors/financial-results-and-events","label":"Results and Presentations"},"items":[{"type":"nav-item-link","href":"/en/investors/financial-results-and-events/financial-results","label":"Results"},{"type":"nav-item-link","href":"/en/investors/financial-results-and-events/investor-presentations","label":"Presentations"}]},{"type":"nav-item-link","href":"/en/investors/broker-conferences","label":"Conferences"},{"type":"nav-item-link","href":"/en/investors/environment-social-governance","label":"Environment, Social, Governance"},{"type":"nav-item-link","href":"/en/investors/individual-shareholders","label":"Private Shareholders"},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs","label":"Shares and ADRs"},"items":[{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/stock-chart","label":"Sanofi stock chart"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/dividend","label":"Dividend"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/adrs","label":"ADRs"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/shares-structure-vote","label":"Shares, Structure \u0026 Vote"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/analyst-coverage","label":"Analyst Coverage"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/vara-consensus","label":"Vara consensus"},{"type":"nav-item-link","href":"/en/investors/sanofi-share-and-adrs/share-repurchases","label":"Share Repurchases"}]},{"type":"nav-item-link","href":"/en/investors/bonds","label":"Bonds"},{"type":"nav-item-link","href":"/en/investors/contacts","label":"Contacts"}]},{"type":"nav-item-link","target":"_self","href":"https://jobs.sanofi.com","label":"Careers","showOutgoingModal":true}],"navigation":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company","label":"Our Company"},"items":[{"type":"nav-item-link","href":"/en/our-company/our-strategy","label":"Our Strategy"},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/governance","label":"Governance"},"items":[{"type":"nav-item-link","href":"/en/our-company/governance/board-of-directors","label":"Board of Directors"},{"type":"nav-item-link","href":"/en/our-company/governance/executive-committee","label":"Executive Committee"},{"type":"nav-item-link","href":"/en/our-company/governance/specialist-committees","label":"Specialist Committees"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/social-impact","label":"Social Impact"},"items":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/social-impact/access-to-healthcare","label":"Access to Healthcare"},"items":[{"type":"nav-item-link","href":"/en/our-company/social-impact/access-to-healthcare/global-health-unit","label":"Global Health Unit"},{"type":"nav-item-link","href":"/en/our-company/social-impact/access-to-healthcare/foundation-s","label":"Foundation S"}]},{"type":"nav-item-link","href":"/en/our-company/social-impact/innovation-for-vulnerable-communities","label":"Innovation for Vulnerable Communities"},{"type":"nav-item-link","href":"/en/our-company/social-impact/environmental-sustainability-and-resilience","label":"Environmental Sustainability and Resilience"},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace","label":"Diversity, Equity, and Inclusion In and Beyond the Workplace"},"items":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/a-million-conversations","label":"A Million Conversations"},"items":[{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/a-million-conversations/sanofi-nextgen-scholars","label":"Sanofi NextGen Scholars"},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/a-million-conversations/advisory-group-hub","label":"Advisory Group Hub"}]},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/allyship","label":"Allyship"},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/employee-resource-groups","label":"Employee Resource Groups"},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/board","label":"Diversity, Equity and Inclusion Board"},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/gender-balance","label":"Gender Balance"},{"type":"nav-item-link","href":"/en/our-company/social-impact/diversity-equity-and-inclusion-in-and-beyond-the-workplace/lgbtqplus","label":"LGBTQ+"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-company/social-impact/responsible-business-values","label":"Code of Conduct and Responsible Business"},"items":[{"type":"nav-item-link","href":"/en/our-company/social-impact/responsible-business-values/information-on-dengvaxia","label":"Information on Dengvaxia®"},{"type":"nav-item-link","href":"/en/our-company/social-impact/responsible-business-values/sodium-valproate","label":"Information on Sodium Valproate"}]}]},{"type":"nav-item-link","href":"/en/our-company/our-legacy","label":"Our Legacy"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-science","label":"Our Science"},"items":[{"type":"nav-item-link","href":"/en/our-science/our-pipeline","label":"Our Pipeline"},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas","label":"Our R\u0026D Focus"},"items":[{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/immunology-rd","label":"Immunology R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/neurology-rd","label":"Neurology R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/oncology-rd","label":"Oncology R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/rare-blood-disorders-rd","label":"Rare Blood Disorders R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/rare-diseases-rd","label":"Rare Diseases R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/vaccines-rd","label":"Vaccines R\u0026D"},{"type":"nav-item-link","href":"/en/our-science/rd-focus-areas/artificial-intelligence-rd","label":"Artificial Intelligence in R\u0026D "}]},{"type":"nav-item-link","href":"/en/our-science/technology-platforms","label":"Technology Platforms "},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results","label":"Clinical Trials \u0026 Results"},"items":[{"type":"nav-item-link","target":"_blank","href":"https://www.sanofistudies.com/global/en/ ","label":"Find a Clinical Trial","showOutgoingModal":false},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results/clinical-study-results","label":"Clinical Study Results"},"items":[{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results/clinical-study-results/medicines","label":"Medicines"},{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results/clinical-study-results/vaccines","label":"Vaccines"}]},{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results/investigator-sponsored-studies","label":"Investigator Sponsored Studies"},{"type":"nav-item-link","href":"/en/our-science/clinical-trials-and-results/diversity-in-clinical-trials","label":"Diversity in Clinical Trials"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/our-science/scientific-collaboration","label":"Scientific Collaboration"},"items":[{"type":"nav-item-link","href":"/en/our-science/scientific-collaboration/north-america","label":"Scientific Collaboration in North America"},{"type":"nav-item-link","href":"/en/our-science/scientific-collaboration/europe","label":"Scientific Collaboration in Europe"},{"type":"nav-item-link","href":"/en/our-science/scientific-collaboration/china","label":"Scientific Collaboration in China"}]},{"type":"nav-item-link","href":"/en/our-science/digital","label":"Digital"},{"type":"nav-item-link","href":"/en/our-science/manufacturing-and-supply","label":"Manufacturing and Supply"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/your-health","label":"Your Health"},"items":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/your-health/vaccines","label":"Vaccines \u0026 Infectious Diseases"},"items":[{"type":"nav-item-link","href":"/en/your-health/vaccines/influenza","label":"Influenza"},{"type":"nav-item-link","href":"/en/your-health/vaccines/meningococcal-meningitis","label":"Meningococcal Meningitis"},{"type":"nav-item-link","href":"/en/your-health/vaccines/pertussis","label":"Pertussis"},{"type":"nav-item-link","href":"/en/your-health/vaccines/respiratory-syncytial-virus","label":"Respiratory Syncytial Virus (RSV)"},{"type":"nav-item-link","href":"/en/your-health/vaccines/production","label":"Production"},{"type":"nav-item-link","href":"/en/your-health/vaccines/why-vaccines-matter","label":"Why Vaccines Matter"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/your-health/medicines","label":"Medicines"},"items":[{"type":"nav-item-link","href":"/en/your-health/medicines/immunology","label":"Immunology"},{"type":"nav-item-link","href":"/en/your-health/medicines/neurology","label":"Neurology"},{"type":"nav-item-link","href":"/en/your-health/medicines/oncology","label":"Oncology"},{"type":"nav-item-link","href":"/en/your-health/medicines/rare-blood-disorders","label":"Rare Blood Disorders"},{"type":"nav-item-link","href":"/en/your-health/medicines/rare-diseases","label":"Rare Diseases"},{"type":"nav-item-link","href":"/en/your-health/medicines/cardiovascular-diseases","label":"Cardiovascular Diseases"},{"type":"nav-item-link","href":"/en/your-health/medicines/diabetes","label":"Diabetes"}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare","label":"Consumer Healthcare"},"items":[{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/sustainability-at-sanofi-consumer-healthcare","label":"Sustainability at Sanofi Consumer Healthcare"},{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/allergy","label":"Allergy"},{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/cough-cold-and-flu","label":"Cough, Cold \u0026 Flu"},{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/digestive-wellness","label":"Digestive Wellness"},{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/pain-care","label":"Pain Care"},{"type":"nav-item-link","href":"/en/your-health/consumer-healthcare/physical-and-mental-wellness","label":"Physical \u0026 Mental Wellness"}]},{"type":"nav-item-link","href":"/en/your-health/patient-engagement","label":"Integrated Patient Engagement"},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/your-health/healthcare-professional-support","label":"Healthcare Professionals Support"},"items":[{"type":"nav-item-link","href":"/en/your-health/healthcare-professional-support/sanofi-manage-access-program","label":"Managed Access Programs (MAPs)"},{"type":"nav-item-link","href":"/en/your-health/healthcare-professional-support/sanofi-preregistration-import-license","label":"Pre-Registration Import Licenses"},{"type":"nav-item-link","href":"/en/your-health/healthcare-professional-support/post-trial-access","label":"Post Trial Access (PTA)"}]}]},{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/partnering","label":"Partnering"},"items":[{"type":"nav-item-node","self":{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas","label":"Partnering Focus Areas"},"items":[{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/china","label":"China"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/digital","label":"Digital"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/general-medicines","label":"General Medicines"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/immunology","label":"Immunology"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/neuroscience","label":"Neuroscience"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/oncology","label":"Oncology"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/out-licensing","label":"Out-Licensing"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/rare-disease","label":"Rare Disease"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/technology-platforms","label":"Technology Platforms"},{"type":"nav-item-link","href":"/en/partnering/partnering-focus-areas/vaccines","label":"Vaccines"}]},{"type":"nav-item-link","href":"/en/partnering/meet-the-partnering-team","label":"Meet the Partnering Team"},{"type":"nav-item-link","href":"/en/partnering/contact-business-development-team","label":"Contact Business Development Team"}]}]},"footer":{"type":"default","copyright":["© Sanofi 2004-2025 - All rights reserved"],"informations":[{"type":"nav-item-link","href":"/en/magazine","label":"Stories"},{"type":"nav-item-link","href":"/en/contact","label":"Contact"},{"type":"nav-item-link","href":"/en/legal-notice","label":"Legal notice"},{"type":"nav-item-link","href":"/en/privacy-and-data-protection","label":"Privacy \u0026 data protection"},{"type":"nav-item-link","href":"/en/data-privacy","label":"Cookies Policy"},{"type":"nav-item-link","href":"/en/publications","label":"Our publications"},{"type":"nav-item-link","href":"/en/directory","label":"Directory"},{"type":"nav-item-link","href":"/en/sitemap","label":"Sitemap"},{"type":"nav-item-link","href":"/en/accessibility-partial-compliance","label":"Accessibility: partial compliance"},{"type":"nav-item-link","target":"_blank","href":"https://www.codeofconduct.sanofi/","label":"Code of Conduct","showOutgoingModal":true}],"social":[{"type":"nav-item-link","href":"https://www.linkedin.com/company/sanofi","label":"Go to Sanofi on Linkedin","title":"Sanofi on Linkedin","icon":"linkedin","domain":"external"},{"type":"nav-item-link","href":"https://twitter.com/sanofi","label":"Go to Sanofi on Twitter","title":"Sanofi on Twitter","icon":"twitter","domain":"external"},{"type":"nav-item-link","href":"https://www.instagram.com/sanofi/","label":"Go to Sanofi on Instagram","title":"Sanofi on Instagram","icon":"instagram","domain":"external"},{"type":"nav-item-link","href":"https://www.facebook.com/Sanofi","label":"Go to Sanofi on Facebook","title":"Sanofi on Facebook","icon":"facebook","domain":"external"},{"type":"nav-item-link","href":"https://www.tiktok.com/@sanofi","label":"Go to Sanofi on TikTok","title":"Sanofi on TikTok","icon":"tiktok","domain":"external"},{"type":"nav-item-link","href":"https://www.youtube.com/@sanofi","label":"Go to Sanofi on Youtube","title":"Sanofi on Youtube","icon":"youtube","domain":"external"}]},"seo":{"sitemap":{"visible":true,"lastModified":"2025-03-17","changeFrequency":"weekly","priority":"0.5"},"meta":{"title":"Latest Sanofi Press Releases and News | Sanofi","description":"Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.","keywords":["press release"," sanofi press release"," sanofi news"],"canonicalUrl":"https://www.sanofi.com/en/media-room/press-releases"},"opengraph":{"type":"landing page","title":"Press Releases, review Sanofi healthcare news stories, including media releases and featured information","description":"View the latest press releases from Sanofi global pharmaceutical and healthcare company. ","url":"https://www.sanofi.com/en/media-room/press-releases","image":"https://www.sanofi.com/assets/dotcom/pages/images/media-room/hero-media-room02_20230707101239.jpg"},"twitter":{"card":"summary","title":"Press Releases, review Sanofi healthcare news stories, including media releases and featured information","description":"View the latest press releases from Sanofi global pharmaceutical and healthcare company. ","url":"https://www.sanofi.com/en/media-room/press-releases","image":"https://www.sanofi.com/assets/dotcom/pages/images/media-room/hero-media-room02_20230707101239.jpg"},"metaCustom":[]},"action":{"label":"Press Releases"},"breadcrumbs":[{"type":"nav-item-link","href":"/en","label":"Homepage","showOutgoingModal":false},{"type":"nav-item-link","href":"/en/media-room","label":"Media","showOutgoingModal":false},{"type":"nav-item-link","href":"/en/media-room/press-releases","label":"Press Releases","showOutgoingModal":false}],"title":"Press Releases","url":"/en/media-room/press-releases","top":[{"cmsComponentType":"hero-banner","title":"Press Releases","variant":"simple","noLazyLoading":false,"textToWhite":false,"borderRadius":1}],"main":[{"cmsComponentType":"press-releases-list","headingLevel":"h2","items":[{"date":"2025-03-08T18:00:00.000Z","title":"Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-03-08-18-00-00-3039375-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-03-08-18-00-00-3039375","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD","icon":"fasArrowRight"}},{"date":"2025-03-05T17:10:00.000Z","title":"Press release: Sanofi successfully prices EUR 1.5 billion of bond issue","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-03-05-17-10-00-3037644-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-03-05-17-10-00-3037644","label":"Read the Press Release","target":"_self","title":"Press release: Sanofi successfully prices EUR 1.5 billion of bond issue","icon":"fasArrowRight"}},{"date":"2025-02-28T14:00:00.000Z","title":"Media Update: AAD: new data advance Sanofi’s scientific leadership across innovative treatments for inflammatory skin diseases","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2025/2025-02-28-14-00-00-3034759-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-02-28-14-00-00-3034759","label":"Read the Media Update","target":"_self","title":"Media Update: AAD: new data advance Sanofi’s scientific leadership across innovative treatments for inflammatory skin diseases","icon":"fasArrowRight"}},{"date":"2025-02-25T06:00:00.000Z","title":"Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-02-25-06-00-00-3031655-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-02-25-06-00-00-3031655","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma","icon":"fasArrowRight"}},{"date":"2025-02-22T07:30:00.000Z","title":"Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-02-22-07-30-00-3030764-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-02-22-07-30-00-3030764","label":"Read the Press Release","target":"_self","title":"Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease","icon":"fasArrowRight"}},{"date":"2025-02-19T06:30:00.000Z","title":"Press Release: Sanofi and CD\u0026R sign Opella share purchase agreement","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-02-19-06-30-00-3028464-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-02-19-06-30-00-3028464","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and CD\u0026R sign Opella share purchase agreement","icon":"fasArrowRight"}},{"date":"2025-02-18T06:00:00.000Z","title":"Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-02-18-06-00-00-3027482-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-02-18-06-00-00-3027482","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid","icon":"fasArrowRight"}},{"date":"2025-02-13T19:09:00.000Z","title":"Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-02-13-19-09-00-3026227-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-02-13-19-09-00-3026227","label":"Read the Press Release","target":"_self","title":"Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report","icon":"fasArrowRight"}},{"date":"2025-02-13T06:00:00.000Z","title":"Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-02-13-06-00-00-3025576-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-02-13-06-00-00-3025576","label":"Read the Press Release","target":"_self","title":"Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study","icon":"fasArrowRight"}},{"date":"2025-02-07T06:00:00.000Z","title":"Press Release: Execution of a share buyback agreement for up to €2 billion","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-02-07-06-00-00-3022540-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-02-07-06-00-00-3022540","label":"Read the Press Release","target":"_self","title":"Press Release: Execution of a share buyback agreement for up to €2 billion","icon":"fasArrowRight"}},{"date":"2025-02-06T06:00:00.000Z","title":"Media Update: AAAAI: new data reinforce Sanofi’s leadership in immunology and scientific innovation for patients ","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2025/2025-02-06-06-00-00-3021697-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-02-06-06-00-00-3021697","label":"Read the Media Update","target":"_self","title":"Media Update: AAAAI: new data reinforce Sanofi’s leadership in immunology and scientific innovation for patients ","icon":"fasArrowRight"}},{"date":"2025-02-03T06:30:00.000Z","title":"Press Release: Sanofi announces buy back of shares from L’Oréal","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-02-03-06-30-00-3019186-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-02-03-06-30-00-3019186","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi announces buy back of shares from L’Oréal","icon":"fasArrowRight"}},{"date":"2025-01-31T06:00:00.000Z","title":"Press Release: Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-01-31-06-00-00-3018540-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-01-31-06-00-00-3018540","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant","icon":"fasArrowRight"}},{"date":"2025-01-30T06:30:00.000Z","title":"Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-01-30-06-30-00-3017713-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-01-30-06-30-00-3017713","label":"Read the Press Release","target":"_self","title":"Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025","icon":"fasArrowRight"}},{"date":"2025-01-22T06:00:00.000Z","title":"Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-01-22-06-00-00-3013183-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-01-22-06-00-00-3013183","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma","icon":"fasArrowRight"}},{"date":"2025-01-21T06:00:00.000Z","title":"Press Release: Opella reaches study milestone for Cialis","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-01-21-06-00-00-3012315-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-01-21-06-00-00-3012315","label":"Read the Press Release","target":"_self","title":"Press Release: Opella reaches study milestone for Cialis","icon":"fasArrowRight"}},{"date":"2025-01-13T06:00:00.000Z","title":"Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-01-13-06-00-00-3008102-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-01-13-06-00-00-3008102","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma","icon":"fasArrowRight"}},{"date":"2025-01-09T06:00:00.000Z","title":"Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2025/2025-01-09-06-00-00-3006798-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2025/2025-01-09-06-00-00-3006798","label":"Read the Press Release","target":"_self","title":"Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma","icon":"fasArrowRight"}},{"date":"2024-12-23T06:00:00.000Z","title":"Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2024/2024-12-23-06-00-00-3001006-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-12-23-06-00-00-3001006","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines","icon":"fasArrowRight"}},{"date":"2024-12-19T17:00:00.000Z","title":"Press Release: Jean-Paul Kress to join Sanofi's Board of Directors","category":"press-release","file":{"link":"/assets/dotcom/pressreleases/2024/2024-12-19-17-00-00-3000094-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-12-19-17-00-00-3000094","label":"Read the Press Release","target":"_self","title":"Press Release: Jean-Paul Kress to join Sanofi's Board of Directors","icon":"fasArrowRight"}},{"date":"2024-12-17T12:30:00.000Z","title":"Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease","file":{"link":"/assets/dotcom/pressreleases/2024/2024-12-17-12-30-00-2998154-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-12-17-12-30-00-2998154","label":"Read the Press Release","target":"_self","title":"Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease","icon":"fasArrowRight"}},{"date":"2024-12-17T06:30:00.000Z","title":"Press Release: Availability of the Q4 2024 Aide-mémoire","file":{"link":"/assets/dotcom/pressreleases/2024/2024-12-17-06-30-00-2997979-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-12-17-06-30-00-2997979","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q4 2024 Aide-mémoire","icon":"fasArrowRight"}},{"date":"2024-12-13T06:00:00.000Z","title":"Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis","file":{"link":"/assets/dotcom/pressreleases/2024/2024-12-13-06-00-00-2996609-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-12-13-06-00-00-2996609","label":"Read the Press Release","target":"_self","title":"Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis","icon":"fasArrowRight"}},{"date":"2024-12-11T06:00:00.000Z","title":"Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US","file":{"link":"/assets/dotcom/pressreleases/2024/2024-12-11-06-00-00-2995072-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-12-11-06-00-00-2995072","label":"Read the Press Release","target":"_self","title":"Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US","icon":"fasArrowRight"}},{"date":"2024-12-09T19:06:29.000Z","title":"Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients","file":{"link":"/assets/dotcom/pressreleases/2024/2024-12-09-19-06-29-2994044-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-12-09-19-06-29-2994044","label":"Read the Press Release","target":"_self","title":"Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients","icon":"fasArrowRight"}},{"date":"2024-12-07T16:30:00.000Z","title":"Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP","file":{"link":"/assets/dotcom/pressreleases/2024/2024-12-07-16-30-00-2993342-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-12-07-16-30-00-2993342","label":"Read the Press Release","target":"_self","title":"Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP","icon":"fasArrowRight"}},{"date":"2024-12-06T06:30:00.000Z","title":"Press Release: Availability of the profit and loss information of Sanofi excluding Opella","file":{"link":"/assets/dotcom/pressreleases/2024/2024-12-06-06-30-00-2992833-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-12-06-06-30-00-2992833","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the profit and loss information of Sanofi excluding Opella","icon":"fasArrowRight"}},{"date":"2024-11-15T11:00:00.000Z","title":"Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland","file":{"link":"/assets/dotcom/pressreleases/2024/2024-11-15-11-00-00-2981845-fr.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-11-15-11-00-00-2981845","label":"Read the Press Release","target":"_self","title":"Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland","icon":"fasArrowRight"}},{"date":"2024-11-15T06:00:00.000Z","title":"Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria","file":{"link":"/assets/dotcom/pressreleases/2024/2024-11-15-06-00-00-2981756-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-11-15-06-00-00-2981756","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria","icon":"fasArrowRight"}},{"date":"2024-11-14T16:42:42.000Z","title":"Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2024/2024-11-14-16-42-42-2981448-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-11-14-16-42-42-2981448","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma","icon":"fasArrowRight"}},{"date":"2024-11-06T06:00:00.000Z","title":"Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis","file":{"link":"/assets/dotcom/pressreleases/2024/2024-11-06-06-00-00-2975399-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-11-06-06-00-00-2975399","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis","icon":"fasArrowRight"}},{"date":"2024-10-25T05:30:00.000Z","title":"Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance","file":{"link":"/assets/dotcom/pressreleases/2024/2024-10-25-05-30-00-2969234-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-10-25-05-30-00-2969234","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance","icon":"fasArrowRight"}},{"date":"2024-10-24T12:00:00.000Z","title":"Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI","file":{"link":"/assets/dotcom/pressreleases/2024/2024-10-24-12-00-00-2968628-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-10-24-12-00-00-2968628","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI","icon":"fasArrowRight"}},{"date":"2024-10-21T05:30:00.000Z","title":"Press Release: Sanofi and CD\u0026R partner to fuel Opella’s ambitions in consumer healthcare","file":{"link":"/assets/dotcom/pressreleases/2024/2024-10-21-05-30-00-2965875-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-10-21-05-30-00-2965875","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and CD\u0026R partner to fuel Opella’s ambitions in consumer healthcare","icon":"fasArrowRight"}},{"date":"2024-10-17T05:30:00.000Z","title":"Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines","file":{"link":"/assets/dotcom/pressreleases/2024/2024-10-17-05-30-00-2964590-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-10-17-05-30-00-2964590","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines","icon":"fasArrowRight"}},{"date":"2024-10-11T06:30:00.000Z","title":"Press Release: Sanofi in discussions to sell a controlling stake in Opella","file":{"link":"/assets/dotcom/pressreleases/2024/2024-10-11-06-30-00-2961805-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-10-11-06-30-00-2961805","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi in discussions to sell a controlling stake in Opella","icon":"fasArrowRight"}},{"date":"2024-10-09T05:00:00.000Z","title":"Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants","file":{"link":"/assets/dotcom/pressreleases/2024/2024-10-09-05-00-00-2960218-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-10-09-05-00-00-2960218","label":"Read the Press Release","target":"_self","title":"Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants","icon":"fasArrowRight"}},{"date":"2024-09-27T13:35:00.000Z","title":"Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-27-13-35-00-2954551-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-27-13-35-00-2954551","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD","icon":"fasArrowRight"}},{"date":"2024-09-27T11:00:00.000Z","title":"Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-27-11-00-00-2954416-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-27-11-00-00-2954416","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD","icon":"fasArrowRight"}},{"date":"2024-09-26T05:30:00.000Z","title":"Press Release: Availability of the Q3 2024 Aide mémoire","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-26-05-30-00-2953499-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-26-05-30-00-2953499","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q3 2024 Aide mémoire","icon":"fasArrowRight"}},{"date":"2024-09-25T05:00:00.000Z","title":"Media Update: EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-25-05-00-00-2952680-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-25-05-00-00-2952680","label":"Read the Media Update","target":"_self","title":"Media Update: EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases","icon":"fasArrowRight"}},{"date":"2024-09-20T22:36:34.000Z","title":"Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-20-22-36-34-2949916-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-20-22-36-34-2949916","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant","icon":"fasArrowRight"}},{"date":"2024-09-20T11:45:00.000Z","title":"Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-20-11-45-00-2949619-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-20-11-45-00-2949619","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old","icon":"fasArrowRight"}},{"date":"2024-09-20T09:30:00.000Z","title":"Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-20-09-30-00-2949552-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-20-09-30-00-2949552","label":"Read the Press Release","target":"_self","title":"Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study","icon":"fasArrowRight"}},{"date":"2024-09-12T05:00:00.000Z","title":"Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-12-05-00-00-2944919-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-12-05-00-00-2944919","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers","icon":"fasArrowRight"}},{"date":"2024-09-11T05:05:00.000Z","title":"Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-11-05-05-00-2944239-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-11-05-05-00-2944239","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU","icon":"fasArrowRight"}},{"date":"2024-09-11T05:00:00.000Z","title":"Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-11-05-00-00-2944237-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-11-05-00-00-2944237","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study","icon":"fasArrowRight"}},{"date":"2024-09-10T15:00:00.000Z","title":"Communiqué de presse : Sanofi inaugure la première usine modulable de vaccins et biomédicaments au monde à Neuville-sur-Saône ","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-10-15-00-00-2943876-fr.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-10-15-00-00-2943876","label":"Read the Press Release","target":"_self","title":"Communiqué de presse : Sanofi inaugure la première usine modulable de vaccins et biomédicaments au monde à Neuville-sur-Saône ","icon":"fasArrowRight"}},{"date":"2024-09-10T10:30:00.000Z","title":"Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-10-10-30-00-2943464-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-10-10-30-00-2943464","label":"Read the Media Update","target":"_self","title":"Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies","icon":"fasArrowRight"}},{"date":"2024-09-02T05:00:00.000Z","title":"Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis","file":{"link":"/assets/dotcom/pressreleases/2024/2024-09-02-05-00-00-2938875-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-09-02-05-00-00-2938875","label":"Read the Press Release","target":"_self","title":"Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis","icon":"fasArrowRight"}},{"date":"2024-08-26T05:00:00.000Z","title":"Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-08-26-05-00-00-2935223-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-08-26-05-00-00-2935223","label":"Read the Media Update","target":"_self","title":"Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases","icon":"fasArrowRight"}},{"date":"2024-08-08T05:00:00.000Z","title":"Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant","file":{"link":"/assets/dotcom/pressreleases/2024/2024-08-08-05-00-00-2926566-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-08-08-05-00-00-2926566","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant","icon":"fasArrowRight"}},{"date":"2024-07-25T14:57:00.000Z","title":"Press Release: Online availability of Sanofi’s half-year financial report for 2024","file":{"link":"/assets/dotcom/pressreleases/2024/2024-07-25-14-57-00-2918977-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-07-25-14-57-00-2918977","label":"Read the Press Release","target":"_self","title":"Press Release: Online availability of Sanofi’s half-year financial report for 2024","icon":"fasArrowRight"}},{"date":"2024-07-25T05:30:00.000Z","title":"Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded","file":{"link":"/assets/dotcom/pressreleases/2024/2024-07-25-05-30-00-2918503-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-07-25-05-30-00-2918503","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded","icon":"fasArrowRight"}},{"date":"2024-07-17T21:27:40.000Z","title":"Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A","file":{"link":"/assets/dotcom/pressreleases/2024/2024-07-17-21-27-40-2914957-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-07-17-21-27-40-2914957","label":"Read the Press Release","target":"_self","title":"Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A","icon":"fasArrowRight"}},{"date":"2024-07-03T05:38:39.000Z","title":"Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD","file":{"link":"/assets/dotcom/pressreleases/2024/2024-07-03-05-38-39-2907918-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-07-03-05-38-39-2907918","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD","icon":"fasArrowRight"}},{"date":"2024-06-28T15:30:00.000Z","title":"Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-06-28-15-30-00-2906026-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-06-28-15-30-00-2906026","label":"Read the Media Update","target":"_self","title":"Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS","icon":"fasArrowRight"}},{"date":"2024-06-26T21:30:00.000Z","title":"Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM","file":{"link":"/assets/dotcom/pressreleases/2024/2024-06-26-21-30-00-2904847-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-06-26-21-30-00-2904847","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM","icon":"fasArrowRight"}},{"date":"2024-06-25T20:30:00.000Z","title":"Media Update: Riliprubart one-year results from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-06-25-20-30-00-2904145-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-06-25-20-30-00-2904145","label":"Read the Media Update","target":"_self","title":"Media Update: Riliprubart one-year results from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy","icon":"fasArrowRight"}},{"date":"2024-06-25T17:32:57.000Z","title":"Press Release: Availability of the Q2 2024 Aide-mémoire","file":{"link":"/assets/dotcom/pressreleases/2024/2024-06-25-17-32-57-2904090-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-06-25-17-32-57-2904090","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q2 2024 Aide-mémoire","icon":"fasArrowRight"}},{"date":"2024-06-21T07:30:00.000Z","title":"Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee","file":{"link":"/assets/dotcom/pressreleases/2024/2024-06-21-07-30-00-2902125-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-06-21-07-30-00-2902125","label":"Read the Press Release","target":"_self","title":"Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee","icon":"fasArrowRight"}},{"date":"2024-06-21T05:00:00.000Z","title":"Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran","file":{"link":"/assets/dotcom/pressreleases/2024/2024-06-21-05-00-00-2902104-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-06-21-05-00-00-2902104","label":"Read the Press Release","target":"_self","title":"Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran","icon":"fasArrowRight"}},{"date":"2024-06-20T12:00:00.000Z","title":"Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa","file":{"link":"/assets/dotcom/pressreleases/2024/2024-06-20-12-00-00-2901636-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-06-20-12-00-00-2901636","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa","icon":"fasArrowRight"}},{"date":"2024-06-03T20:15:00.000Z","title":"Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3","file":{"link":"/assets/dotcom/pressreleases/2024/2024-06-03-20-15-00-2892607-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-06-03-20-15-00-2892607","label":"Read the Press Release","target":"_self","title":"Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3","icon":"fasArrowRight"}},{"date":"2024-06-01T02:39:22.000Z","title":"Media Update: Sanofi update on Zantac litigation","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-06-01-02-39-22-2891788-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-06-01-02-39-22-2891788","label":"Read the Media Update","target":"_self","title":"Media Update: Sanofi update on Zantac litigation","icon":"fasArrowRight"}},{"date":"2024-05-31T10:00:00.000Z","title":"Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-31-10-00-00-2891408-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-31-10-00-00-2891408","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan","icon":"fasArrowRight"}},{"date":"2024-05-31T05:05:00.000Z","title":"Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-31-05-05-00-2891263-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-31-05-05-00-2891263","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD","icon":"fasArrowRight"}},{"date":"2024-05-31T05:00:00.000Z","title":"Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-31-05-00-00-2891259-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-31-05-00-00-2891259","label":"Read the Press Release","target":"_self","title":"Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation","icon":"fasArrowRight"}},{"date":"2024-05-30T13:01:38.000Z","title":"Press Release: Sanofi completes acquisition of Inhibrx, Inc.","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-30-13-01-38-2890833-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-30-13-01-38-2890833","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi completes acquisition of Inhibrx, Inc.","icon":"fasArrowRight"}},{"date":"2024-05-27T05:00:00.000Z","title":"Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-27-05-00-00-2888291-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-27-05-00-00-2888291","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma","icon":"fasArrowRight"}},{"date":"2024-05-22T17:15:00.000Z","title":"Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-22-17-15-00-2886776-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-22-17-15-00-2886776","label":"Read the Media Update","target":"_self","title":"Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma","icon":"fasArrowRight"}},{"date":"2024-05-21T05:30:00.000Z","title":"Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-21-05-30-00-2885244-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-21-05-30-00-2885244","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration","icon":"fasArrowRight"}},{"date":"2024-05-20T18:15:00.000Z","title":"Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-20-18-15-00-2885068-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-20-18-15-00-2885068","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM","icon":"fasArrowRight"}},{"date":"2024-05-13T05:00:00.000Z","title":"Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-13-05-00-00-2880074-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-13-05-00-00-2880074","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty","icon":"fasArrowRight"}},{"date":"2024-05-10T06:00:00.000Z","title":"Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-10-06-00-00-2879379-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-10-06-00-00-2879379","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines","icon":"fasArrowRight"}},{"date":"2024-05-02T05:00:00.000Z","title":"Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations","file":{"link":"/assets/dotcom/pressreleases/2024/2024-05-02-05-00-00-2873804-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-05-02-05-00-00-2873804","label":"Read the Press Release","target":"_self","title":"Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations","icon":"fasArrowRight"}},{"date":"2024-04-30T16:00:00.000Z","title":"Press Release: Annual General Meeting of April 30, 2024","file":{"link":"/assets/dotcom/pressreleases/2024/2024-04-30-16-00-00-2872582-EN.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-04-30-16-00-00-2872582","label":"Read the Press Release","target":"_self","title":"Press Release: Annual General Meeting of April 30, 2024","icon":"fasArrowRight"}},{"date":"2024-04-26T05:00:00.000Z","title":"Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-04-26-05-00-00-2870215-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-04-26-05-00-00-2870215","label":"Read the Media Update","target":"_self","title":"Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases","icon":"fasArrowRight"}},{"date":"2024-04-25T05:30:00.000Z","title":"Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance","file":{"link":"/assets/dotcom/pressreleases/2024/2024-04-25-05-30-00-2869276-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-04-25-05-30-00-2869276","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance","icon":"fasArrowRight"}},{"date":"2024-04-23T05:00:00.000Z","title":"Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia","file":{"link":"/assets/dotcom/pressreleases/2024/2024-04-23-05-00-00-2867327-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-04-23-05-00-00-2867327","label":"Read the Press Release","target":"_self","title":"Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia","icon":"fasArrowRight"}},{"date":"2024-04-17T05:00:00.000Z","title":"Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis","file":{"link":"/assets/dotcom/pressreleases/2024/2024-04-17-05-00-00-2864225-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-04-17-05-00-00-2864225","label":"Read the Press Release","target":"_self","title":"Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis","icon":"fasArrowRight"}},{"date":"2024-03-22T06:30:00.000Z","title":"Press Release: Availability of the Q1 2024 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2024/2024-03-22-06-30-00-2850748-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-03-22-06-30-00-2850748","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q1 2024 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2024-03-11T06:00:00.000Z","title":"Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2024/2024-03-11-06-00-00-2843456-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-03-11-06-00-00-2843456","label":"Read the Press Release","target":"_self","title":"Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis","icon":"fasArrowRight"}},{"date":"2024-02-24T14:51:48.000Z","title":"Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-24-14-51-48-2834723-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-24-14-51-48-2834723","label":"Read the Press Release","target":"_self","title":"Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria","icon":"fasArrowRight"}},{"date":"2024-02-24T13:00:00.000Z","title":"Media Update: Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma ","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-24-13-00-00-2834714-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-24-13-00-00-2834714","label":"Read the Media Update","target":"_self","title":"Media Update: Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma ","icon":"fasArrowRight"}},{"date":"2024-02-23T17:45:35.000Z","title":"Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-23-17-45-35-2834600-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-23-17-45-35-2834600","label":"Read the Press Release","target":"_self","title":"Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report","icon":"fasArrowRight"}},{"date":"2024-02-23T06:00:00.000Z","title":"Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-23-06-00-00-2834219-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-23-06-00-00-2834219","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation","icon":"fasArrowRight"}},{"date":"2024-02-22T18:02:50.000Z","title":"Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-22-18-02-50-2833994-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-22-18-02-50-2833994","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors","icon":"fasArrowRight"}},{"date":"2024-02-16T06:00:00.000Z","title":"Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-16-06-00-00-2830509-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-16-06-00-00-2830509","label":"Read the Press Release","target":"_self","title":"Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)","icon":"fasArrowRight"}},{"date":"2024-02-15T13:00:00.000Z","title":"Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-15-13-00-00-2829933-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-15-13-00-00-2829933","label":"Read the Press Release","target":"_self","title":"Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS","icon":"fasArrowRight"}},{"date":"2024-02-09T13:00:00.000Z","title":"Media Update: New data presented at AAAAI highlight Sanofi’s scientific leadership across inflammatory diseases","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-09-13-00-00-2826769-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-09-13-00-00-2826769","label":"Read the Media Update","target":"_self","title":"Media Update: New data presented at AAAAI highlight Sanofi’s scientific leadership across inflammatory diseases","icon":"fasArrowRight"}},{"date":"2024-02-05T23:00:00.000Z","title":"Media Update: New data demonstrate clinical safety, benefit and durability of Nexviazyme® across a wide-range of Pompe disease patient groups","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-05-23-00-00-2823915-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-05-23-00-00-2823915","label":"Read the Media Update","target":"_self","title":"Media Update: New data demonstrate clinical safety, benefit and durability of Nexviazyme® across a wide-range of Pompe disease patient groups","icon":"fasArrowRight"}},{"date":"2024-02-05T07:00:00.000Z","title":"Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-05-07-00-00-2823219-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-05-07-00-00-2823219","label":"Read the Press Release","target":"_self","title":"Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses","icon":"fasArrowRight"}},{"date":"2024-02-01T06:30:00.000Z","title":"Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-01-06-30-00-2821667-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-01-06-30-00-2821667","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline","icon":"fasArrowRight"}},{"date":"2024-02-01T06:30:00.000Z","title":"Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee","file":{"link":"/assets/dotcom/pressreleases/2024/2024-02-01-06-30-00-2821665-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-02-01-06-30-00-2821665","label":"Read the Press Release","target":"_self","title":"Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee","icon":"fasArrowRight"}},{"date":"2024-01-25T19:30:00.000Z","title":"Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)","file":{"link":"/assets/dotcom/pressreleases/2024/2024-01-25-19-30-00-2817342-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-01-25-19-30-00-2817342","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)","icon":"fasArrowRight"}},{"date":"2024-01-23T06:30:00.000Z","title":"Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in- class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline","file":{"link":"/assets/dotcom/pressreleases/2024/2024-01-23-06-30-00-2813696-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-01-23-06-30-00-2813696","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in- class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline","icon":"fasArrowRight"}},{"date":"2024-01-16T12:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) U.S. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement","file":{"link":"/assets/dotcom/pressreleases/2024/2024-01-16-12-00-00-2809681-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-01-16-12-00-00-2809681","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) U.S. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement","icon":"fasArrowRight"}},{"date":"2024-01-09T06:30:00.000Z","title":"Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee","file":{"link":"/assets/dotcom/pressreleases/2024/2024-01-09-06-30-00-2805967-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2024/2024-01-09-06-30-00-2805967","label":"Read the Press Release","target":"_self","title":"Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee","icon":"fasArrowRight"}},{"date":"2023-12-21T06:30:00.000Z","title":"Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint","file":{"link":"/assets/dotcom/pressreleases/2023/2023-12-21-06-30-00-2799759-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-12-21-06-30-00-2799759","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint","icon":"fasArrowRight"}},{"date":"2023-12-15T06:30:00.000Z","title":"Press Release: Availability of the Q4 2023 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2023/2023-12-15-06-30-00-2796822-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-12-15-06-30-00-2796822","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q4 2023 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2023-12-15T06:00:00.000Z","title":"Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa","file":{"link":"/assets/dotcom/pressreleases/2023/2023-12-15-06-00-00-2796815-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-12-15-06-00-00-2796815","label":"Read the Press Release","target":"_self","title":"Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa","icon":"fasArrowRight"}},{"date":"2023-12-11T21:08:20.000Z","title":"Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics","file":{"link":"/assets/dotcom/pressreleases/2023/2023-12-11-21-08-20-2794272-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-12-11-21-08-20-2794272","label":"Read the Press Release","target":"_self","title":"Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics","icon":"fasArrowRight"}},{"date":"2023-12-11T00:31:04.000Z","title":"Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone","file":{"link":"/assets/dotcom/pressreleases/2023/2023-12-11-00-31-04-2793482-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-12-11-00-31-04-2793482","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone","icon":"fasArrowRight"}},{"date":"2023-12-07T06:35:00.000Z","title":"Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant","file":{"link":"/assets/dotcom/pressreleases/2023/2023-12-07-06-35-00-2792221-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-12-07-06-35-00-2792221","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant","icon":"fasArrowRight"}},{"date":"2023-12-07T02:30:00.000Z","title":"Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology","file":{"link":"/assets/dotcom/pressreleases/2023/2023-12-07-02-30-00-2792186-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-12-07-02-30-00-2792186","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology","icon":"fasArrowRight"}},{"date":"2023-12-01T07:00:00.000Z","title":"Press Release: Sanofi’s Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainability","file":{"link":"/assets/dotcom/pressreleases/2023/2023-12-01-07-00-00-2789082-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-12-01-07-00-00-2789082","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi’s Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainability","icon":"fasArrowRight"}},{"date":"2023-11-27T06:30:00.000Z","title":"Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease","file":{"link":"/assets/dotcom/pressreleases/2023/2023-11-27-06-30-00-2785836-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-11-27-06-30-00-2785836","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease","icon":"fasArrowRight"}},{"date":"2023-11-09T07:00:00.000Z","title":"Press Release: Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E. coli (ExPEC)","file":{"link":"/assets/dotcom/pressreleases/2023/2023-11-09-07-00-00-2776970-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-11-09-07-00-00-2776970","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E. coli (ExPEC)","icon":"fasArrowRight"}},{"date":"2023-10-27T05:31:00.000Z","title":"Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-27-05-31-00-2768149-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-27-05-31-00-2768149","label":"Read the Press Release","target":"_self","title":"Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results","icon":"fasArrowRight"}},{"date":"2023-10-27T05:30:00.000Z","title":"Press Release: Sanofi Enters Next Chapter of Play to Win Strategy","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-27-05-30-00-2768148-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-27-05-30-00-2768148","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi Enters Next Chapter of Play to Win Strategy","icon":"fasArrowRight"}},{"date":"2023-10-22T19:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-22-19-00-00-2764338-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-22-19-00-00-2764338","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)","icon":"fasArrowRight"}},{"date":"2023-10-20T21:00:00.000Z","title":"Press Release: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-20-21-00-00-2764252-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-20-21-00-00-2764252","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria","icon":"fasArrowRight"}},{"date":"2023-10-19T10:00:00.000Z","title":"Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-19-10-00-00-2762972-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-19-10-00-00-2762972","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio","icon":"fasArrowRight"}},{"date":"2023-10-18T08:45:00.000Z","title":"Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The New England Journal of Medicine","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-18-08-45-00-2762096-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-18-08-45-00-2762096","label":"Read the Press Release","target":"_self","title":"Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The New England Journal of Medicine","icon":"fasArrowRight"}},{"date":"2023-10-13T14:00:00.000Z","title":"Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-13-14-00-00-2760021-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-13-14-00-00-2760021","label":"Read the Press Release","target":"_self","title":"Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis","icon":"fasArrowRight"}},{"date":"2023-10-06T06:00:00.000Z","title":"Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-06-06-00-00-2755893-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-06-06-00-00-2755893","label":"Read the Media Update","target":"_self","title":"Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease","icon":"fasArrowRight"}},{"date":"2023-10-04T05:00:00.000Z","title":"Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-04-05-00-00-2754288-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-04-05-00-00-2754288","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment","icon":"fasArrowRight"}},{"date":"2023-10-03T05:30:00.000Z","title":"Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-03-05-30-00-2753274-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-03-05-30-00-2753274","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli","icon":"fasArrowRight"}},{"date":"2023-10-02T06:00:00.000Z","title":"Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2023/2023-10-02-06-00-00-2752435-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-10-02-06-00-00-2752435","label":"Read the Media Update","target":"_self","title":"Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs","icon":"fasArrowRight"}},{"date":"2023-09-29T15:59:05.000Z","title":"Media Update: Sanofi completes acquisition of Qunol®","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2023/2023-09-29-15-59-05-2752155-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-09-29-15-59-05-2752155","label":"Read the Media Update","target":"_self","title":"Media Update: Sanofi completes acquisition of Qunol®","icon":"fasArrowRight"}},{"date":"2023-09-26T05:30:00.000Z","title":"Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review","file":{"link":"/assets/dotcom/pressreleases/2023/2023-09-26-05-30-00-2749151-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-09-26-05-30-00-2749151","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review","icon":"fasArrowRight"}},{"date":"2023-09-25T07:00:00.000Z","title":"Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A","file":{"link":"/assets/dotcom/pressreleases/2023/2023-09-25-07-00-00-2748334-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-09-25-07-00-00-2748334","label":"Read the Press Release","target":"_self","title":"Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A","icon":"fasArrowRight"}},{"date":"2023-09-22T05:30:00.000Z","title":"Press Release: Availability of the Q3 2023 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2023/2023-09-22-05-30-00-2747747-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-09-22-05-30-00-2747747","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q3 2023 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2023-09-19T06:30:00.000Z","title":"Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change","file":{"link":"/assets/dotcom/pressreleases/2023/2023-09-19-06-30-00-2745307-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-09-19-06-30-00-2745307","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change","icon":"fasArrowRight"}},{"date":"2023-09-14T06:00:00.000Z","title":"Media Update: New data at ERS showed Xenpozyme® (olipudase alfa) improved respiratory functions in adults with ASMD","file":{"link":"/assets/dotcom/pressreleases/2023/2023-09-14-06-00-00-2742967-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-09-14-06-00-00-2742967","label":"Read the Press Release","target":"_self","title":"Media Update: New data at ERS showed Xenpozyme® (olipudase alfa) improved respiratory functions in adults with ASMD","icon":"fasArrowRight"}},{"date":"2023-09-05T14:35:45.000Z","title":"Media Update: New data at ERS showcases Sanofi's scientific leadership in addressing unmet needs across a variety of respiratory conditions ","file":{"link":"/assets/dotcom/pressreleases/2023/2023-09-05-14-35-45-2737579-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-09-05-14-35-45-2737579","label":"Read the Press Release","target":"_self","title":"Media Update: New data at ERS showcases Sanofi's scientific leadership in addressing unmet needs across a variety of respiratory conditions ","icon":"fasArrowRight"}},{"date":"2023-08-31T05:30:00.000Z","title":"Press Release: Sanofi announces changes to its Executive Committee","file":{"link":"/assets/dotcom/pressreleases/2023/2023-08-31-05-30-00-2734891-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-08-31-05-30-00-2734891","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi announces changes to its Executive Committee","icon":"fasArrowRight"}},{"date":"2023-08-28T07:00:00.000Z","title":"Press Release: Sanofi, Meningitis Research Foundation, and the Confederation of Meningitis Organisations ignite a global awareness initiative against meningitis with launch of The Meningitis Flag","file":{"link":"/assets/dotcom/pressreleases/2023/2023-08-28-07-00-00-2732312-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-08-28-07-00-00-2732312","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi, Meningitis Research Foundation, and the Confederation of Meningitis Organisations ignite a global awareness initiative against meningitis with launch of The Meningitis Flag","icon":"fasArrowRight"}},{"date":"2023-08-03T19:21:36.000Z","title":"Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease","file":{"link":"/assets/dotcom/pressreleases/2023/2023-08-03-19-21-36-2718475-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-08-03-19-21-36-2718475","label":"Read the Press Release","target":"_self","title":"Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease","icon":"fasArrowRight"}},{"date":"2023-07-28T11:22:15.000Z","title":"Press release: Online availability of Sanofi’s half-year financial report for 2023","file":{"link":"/assets/dotcom/pressreleases/2023/2023-07-28-11-22-15-2713048-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-07-28-11-22-15-2713048","label":"Read the Press Release","target":"_self","title":"Press release: Online availability of Sanofi’s half-year financial report for 2023","icon":"fasArrowRight"}},{"date":"2023-07-28T05:32:00.000Z","title":"Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment","file":{"link":"/assets/dotcom/pressreleases/2023/2023-07-28-05-32-00-2712870-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-07-28-05-32-00-2712870","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment","icon":"fasArrowRight"}},{"date":"2023-07-28T05:30:00.000Z","title":"Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised","file":{"link":"/assets/dotcom/pressreleases/2023/2023-07-28-05-30-00-2712863-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-07-28-05-30-00-2712863","label":"Read the Press Release","target":"_self","title":"Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised","icon":"fasArrowRight"}},{"date":"2023-07-17T17:00:00.000Z","title":"FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease","file":{"link":"/assets/dotcom/pressreleases/2023/2023-07-17-17-00-00-2705911-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-07-17-17-00-00-2705911","label":"Read the Press Release","target":"_self","title":"FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease","icon":"fasArrowRight"}},{"date":"2023-06-29T05:30:00.000Z","title":"Press Release: Vaccines R\u0026D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease","file":{"link":"/assets/dotcom/pressreleases/2023/2023-06-29-05-30-00-2696706-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-06-29-05-30-00-2696706","label":"Read the Press Release","target":"_self","title":"Press Release: Vaccines R\u0026D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease","icon":"fasArrowRight"}},{"date":"2023-06-27T05:30:00.000Z","title":"Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody","file":{"link":"/assets/dotcom/pressreleases/2023/2023-06-27-05-30-00-2694938-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-06-27-05-30-00-2694938","label":"Read the Press Release","target":"_self","title":"Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody","icon":"fasArrowRight"}},{"date":"2023-06-25T14:30:00.000Z","title":"Press Release: ALTUVIIIO® late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing","file":{"link":"/assets/dotcom/pressreleases/2023/2023-06-25-14-30-00-2694016-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-06-25-14-30-00-2694016","label":"Read the Press Release","target":"_self","title":"Press Release: ALTUVIIIO® late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing","icon":"fasArrowRight"}},{"date":"2023-06-22T05:30:00.000Z","title":"Press Release: Availability of the Q2 2023 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2023/2023-06-22-05-30-00-2692600-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-06-22-05-30-00-2692600","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q2 2023 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2023-06-20T05:30:00.000Z","title":"Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim","file":{"link":"/assets/dotcom/pressreleases/2023/2023-06-20-05-30-00-2690713-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-06-20-05-30-00-2690713","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim","icon":"fasArrowRight"}},{"date":"2023-06-14T09:00:00.000Z","title":"Press Release: Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care","file":{"link":"/assets/dotcom/pressreleases/2023/2023-06-14-09-00-00-2687832-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-06-14-09-00-00-2687832","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care","icon":"fasArrowRight"}},{"date":"2023-06-13T12:00:00.000Z","title":"Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients","file":{"link":"/assets/dotcom/pressreleases/2023/2023-06-13-12-00-00-2687072-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-06-13-12-00-00-2687072","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients","icon":"fasArrowRight"}},{"date":"2023-06-08T21:19:00.000Z","title":"Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants","file":{"link":"/assets/dotcom/pressreleases/2023/2023-06-08-21-19-00-2685235-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-06-08-21-19-00-2685235","label":"Read the Press Release","target":"_self","title":"Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants","icon":"fasArrowRight"}},{"date":"2023-06-02T14:00:00.000Z","title":"Media Update: New data from Sanofi’s diverse, differentiated oncology pipeline and portfolio to be presented at ASCO 2023","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2023/2023-06-02-14-00-00-2681231-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-06-02-14-00-00-2681231","label":"Read the Media Update","target":"_self","title":"Media Update: New data from Sanofi’s diverse, differentiated oncology pipeline and portfolio to be presented at ASCO 2023","icon":"fasArrowRight"}},{"date":"2023-06-01T05:30:00.000Z","title":"Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan","file":{"link":"/assets/dotcom/pressreleases/2023/2023-06-01-05-30-00-2679947-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-06-01-05-30-00-2679947","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan","icon":"fasArrowRight"}},{"date":"2023-05-31T05:00:00.000Z","title":"Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis","file":{"link":"/assets/dotcom/pressreleases/2023/2023-05-31-05-00-00-2678991-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-05-31-05-00-00-2678991","label":"Read the Press Release","target":"_self","title":"Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis","icon":"fasArrowRight"}},{"date":"2023-05-25T16:10:27.000Z","title":"Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors","file":{"link":"/assets/dotcom/pressreleases/2023/2023-05-25-16-10-27-2676497-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-05-25-16-10-27-2676497","label":"Read the Press Release","target":"_self","title":"Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors","icon":"fasArrowRight"}},{"date":"2023-05-21T18:17:12.000Z","title":"Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine","file":{"link":"/assets/dotcom/pressreleases/2023/2023-05-21-18-17-12-2672904-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-05-21-18-17-12-2672904","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine","icon":"fasArrowRight"}},{"date":"2023-05-12T08:50:00.000Z","title":"Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting","file":{"link":"/assets/dotcom/pressreleases/2023/2023-05-12-08-50-00-2667568-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-05-12-08-50-00-2667568","label":"Read the Press Release","target":"_self","title":"Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting","icon":"fasArrowRight"}},{"date":"2023-05-08T12:30:00.000Z","title":"Media Update: Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2023/2023-05-08-12-30-00-2663289-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-05-08-12-30-00-2663289","label":"Read the Media Update","target":"_self","title":"Media Update: Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine","icon":"fasArrowRight"}},{"date":"2023-05-05T12:30:00.000Z","title":"Press Release: New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline","file":{"link":"/assets/dotcom/pressreleases/2023/2023-05-05-12-30-00-2662513-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-05-05-12-30-00-2662513","label":"Read the Press Release","target":"_self","title":"Press Release: New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline","icon":"fasArrowRight"}},{"date":"2023-04-27T12:40:19.000Z","title":"Press Release: Sanofi completes acquisition of Provention Bio, Inc.","file":{"link":"/assets/dotcom/pressreleases/2023/2023-04-27-12-40-19-2656379-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-04-27-12-40-19-2656379","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi completes acquisition of Provention Bio, Inc.","icon":"fasArrowRight"}},{"date":"2023-04-27T05:30:00.000Z","title":"Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC","file":{"link":"/assets/dotcom/pressreleases/2023/2023-04-27-05-30-00-2655840-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-04-27-05-30-00-2655840","label":"Read the Press Release","target":"_self","title":"Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC","icon":"fasArrowRight"}},{"date":"2023-04-26T06:00:00.000Z","title":"Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.","file":{"link":"/assets/dotcom/pressreleases/2023/2023-04-26-06-00-00-2654655-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-04-26-06-00-00-2654655","label":"Read the Press Release","target":"_self","title":"Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.","icon":"fasArrowRight"}},{"date":"2023-04-17T09:00:00.000Z","title":"Press Release: Elisabeth Moreno to join Sanofi's Diversity, Equity and Inclusion Board","file":{"link":"/assets/dotcom/pressreleases/2023/2023-04-17-09-00-00-2647634-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-04-17-09-00-00-2647634","label":"Read the Press Release","target":"_self","title":"Press Release: Elisabeth Moreno to join Sanofi's Diversity, Equity and Inclusion Board","icon":"fasArrowRight"}},{"date":"2023-04-11T06:00:00.000Z","title":"Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements","file":{"link":"/assets/dotcom/pressreleases/2023/2023-04-11-06-00-00-2644042-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-04-11-06-00-00-2644042","label":"Read the Press Release","target":"_self","title":"Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements","icon":"fasArrowRight"}},{"date":"2023-04-10T20:15:00.000Z","title":"Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.","file":{"link":"/assets/dotcom/pressreleases/2023/2023-04-10-20-15-00-2643960-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-04-10-20-15-00-2643960","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.","icon":"fasArrowRight"}},{"date":"2023-04-04T05:00:00.000Z","title":"Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia","file":{"link":"/assets/dotcom/pressreleases/2023/2023-04-04-05-00-00-2640246-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-04-04-05-00-00-2640246","label":"Read the Press Release","target":"_self","title":"Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia","icon":"fasArrowRight"}},{"date":"2023-03-30T05:30:00.000Z","title":"Press Release: Availability of the Q1 2023 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2023/2023-03-30-05-30-00-2637310-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-03-30-05-30-00-2637310","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q1 2023 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2023-03-23T06:00:00.000Z","title":"Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial","file":{"link":"/assets/dotcom/pressreleases/2023/2023-03-23-06-00-00-2632822-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-03-23-06-00-00-2632822","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial","icon":"fasArrowRight"}},{"date":"2023-03-21T06:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2023/2023-03-21-06-00-00-2630956-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-03-21-06-00-00-2630956","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2023-03-18T14:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis","file":{"link":"/assets/dotcom/pressreleases/2023/2023-03-18-14-00-00-2629819-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-03-18-14-00-00-2629819","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis","icon":"fasArrowRight"}},{"date":"2023-03-16T20:06:43.000Z","title":"Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance","file":{"link":"/assets/dotcom/pressreleases/2023/2023-03-16-20-06-43-2629188-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-03-16-20-06-43-2629188","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance","icon":"fasArrowRight"}},{"date":"2023-03-13T06:00:00.000Z","title":"Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)","file":{"link":"/assets/dotcom/pressreleases/2023/2023-03-13-06-00-00-2625367-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)","icon":"fasArrowRight"}},{"date":"2023-03-07T06:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review","file":{"link":"/assets/dotcom/pressreleases/2023/2023-03-07-06-00-00-2621670-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-03-07-06-00-00-2621670","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review","icon":"fasArrowRight"}},{"date":"2023-03-02T07:00:00.000Z","title":"Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children \u003c12 years of age with hemophilia A","file":{"link":"/assets/dotcom/pressreleases/2023/2023-03-02-07-00-00-2618928-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-03-02-07-00-00-2618928","label":"Read the Press Release","target":"_self","title":"Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children \u003c12 years of age with hemophilia A","icon":"fasArrowRight"}},{"date":"2023-02-24T16:16:46.000Z","title":"Press Release: FDA approves once-weekly ALTUVIIIOTM, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive event triggers impairment reversal, impacting 2022 IFRS net income; no change on business net income (non-IFRS)","file":{"link":"/assets/dotcom/pressreleases/2023/2023-02-24-16-16-46-2615419-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-02-24-16-16-46-2615419","label":"Read the Press Release","target":"_self","title":"Press Release: FDA approves once-weekly ALTUVIIIOTM, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive event triggers impairment reversal, impacting 2022 IFRS net income; no change on business net income (non-IFRS)","icon":"fasArrowRight"}},{"date":"2023-02-24T15:31:00.000Z","title":"Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease","file":{"link":"/assets/dotcom/pressreleases/2023/2023-02-24-15-31-00-2615384-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-02-24-15-31-00-2615384","label":"Read the Press Release","target":"_self","title":"Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease","icon":"fasArrowRight"}},{"date":"2023-02-23T22:00:00.000Z","title":"Media Update: New data for tolebrutinib, Sanofi’s investigational brain- penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2023/2023-02-23-22-00-00-2614869-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-02-23-22-00-00-2614869","label":"Read the Media Update","target":"_self","title":"Media Update: New data for tolebrutinib, Sanofi’s investigational brain- penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression","icon":"fasArrowRight"}},{"date":"2023-02-23T21:00:00.000Z","title":"Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection","file":{"link":"/assets/dotcom/pressreleases/2023/2023-02-23-21-00-00-2614759-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-02-23-21-00-00-2614759","label":"Read the Press Release","target":"_self","title":"Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection","icon":"fasArrowRight"}},{"date":"2023-02-21T13:16:26.000Z","title":"Media Update: Pediatric research at ReSViNET 2023 underscores Beyfortus’ potential to prevent RSV disease in infants","category":"media-update","file":{"link":"/assets/dotcom/pressreleases/2023/2023-02-21-13-16-26-2612125-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-02-21-13-16-26-2612125","label":"Read the Media Update","target":"_self","title":"Media Update: Pediatric research at ReSViNET 2023 underscores Beyfortus’ potential to prevent RSV disease in infants","icon":"fasArrowRight"}},{"date":"2023-02-13T07:30:00.000Z","title":"Press Release: Sanofi announces change in R\u0026D leadership","file":{"link":"/assets/dotcom/pressreleases/2023/2023-02-13-07-30-00-2606338-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-02-13-07-30-00-2606338","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi announces change in R\u0026D leadership","icon":"fasArrowRight"}},{"date":"2023-02-03T06:30:00.000Z","title":"Press Release: Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone","file":{"link":"/assets/dotcom/pressreleases/2023/2023-02-03-06-30-00-2601072-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-02-03-06-30-00-2601072","label":"Read the Press Release","target":"_self","title":"Press Release: Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone","icon":"fasArrowRight"}},{"date":"2023-01-30T06:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis","file":{"link":"/assets/dotcom/pressreleases/2023/2023-01-30-06-00-00-2597236-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-01-30-06-00-00-2597236","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis","icon":"fasArrowRight"}},{"date":"2023-01-27T06:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2023/2023-01-27-06-00-00-2596599-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-01-27-06-00-00-2596599","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2023-01-25T22:30:00.000Z","title":"Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A","file":{"link":"/assets/dotcom/pressreleases/2023/2023-01-25-22-30-00-2595681-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-01-25-22-30-00-2595681","label":"Read the Press Release","target":"_self","title":"Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A","icon":"fasArrowRight"}},{"date":"2023-01-11T16:30:00.000Z","title":"Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M","file":{"link":"/assets/dotcom/pressreleases/2023/2023-01-11-16-30-00-2587330-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-01-11-16-30-00-2587330","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M","icon":"fasArrowRight"}},{"date":"2023-01-05T07:00:00.000Z","title":"Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants","file":{"link":"/assets/dotcom/pressreleases/2023/2023-01-05-07-00-00-2583365-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-01-05-07-00-00-2583365","label":"Read the Press Release","target":"_self","title":"Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants","icon":"fasArrowRight"}},{"date":"2023-01-04T06:30:00.000Z","title":"Press Release: Availability of the Q4 2022 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2023/2023-01-04-06-30-00-2582628-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2023/2023-01-04-06-30-00-2582628","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q4 2022 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2022-12-21T22:30:00.000Z","title":"Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine","file":{"link":"/assets/dotcom/pressreleases/2022/2022-12-21-22-30-00-2578278-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-12-21-22-30-00-2578278","label":"Read the Press Release","target":"_self","title":"Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine","icon":"fasArrowRight"}},{"date":"2022-12-19T06:00:00.000Z","title":"Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology","file":{"link":"/assets/dotcom/pressreleases/2022/2022-12-19-06-00-00-2575893-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-12-19-06-00-00-2575893","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology","icon":"fasArrowRight"}},{"date":"2022-12-16T12:30:00.000Z","title":"Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-12-16-12-30-00-2575389-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-12-16-12-30-00-2575389","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis","icon":"fasArrowRight"}},{"date":"2022-12-15T06:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis ","file":{"link":"/assets/dotcom/pressreleases/2022/2022-12-15-06-00-00-2574183-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-12-15-06-00-00-2574183","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis ","icon":"fasArrowRight"}},{"date":"2022-12-11T18:21:50.000Z","title":"Press Release: Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”)","file":{"link":"/assets/dotcom/pressreleases/2022/2022-12-11-18-21-50-2571441-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-12-11-18-21-50-2571441","label":"Read the Press Release","target":"_self","title":"Press Release: Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”)","icon":"fasArrowRight"}},{"date":"2022-12-02T19:30:00.000Z","title":"Media Update: Sanofi to showcase new data from oncology portfolio spanning marketed products and investigational compounds at ASH 2022","file":{"link":"/assets/dotcom/pressreleases/2022/2022-12-02-19-30-00-2566912-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-12-02-19-30-00-2566912","label":"Read the Press Release","target":"_self","title":"Media Update: Sanofi to showcase new data from oncology portfolio spanning marketed products and investigational compounds at ASH 2022","icon":"fasArrowRight"}},{"date":"2022-11-30T12:00:00.000Z","title":"Media Update: Sanofi to present new clinical data reinforcing novel therapies across rare blood disorders at ASH 2022","file":{"link":"/assets/dotcom/pressreleases/2022/2022-11-30-12-00-00-2564784-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-11-30-12-00-00-2564784","label":"Read the Press Release","target":"_self","title":"Media Update: Sanofi to present new clinical data reinforcing novel therapies across rare blood disorders at ASH 2022","icon":"fasArrowRight"}},{"date":"2022-11-30T07:00:00.000Z","title":"Press Release: Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa","file":{"link":"/assets/dotcom/pressreleases/2022/2022-11-30-07-00-00-2564640-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-11-30-07-00-00-2564640","label":"Read the Press Release","target":"_self","title":"Press Release: Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa","icon":"fasArrowRight"}},{"date":"2022-11-28T09:00:00.000Z","title":"Press Release: Sanofi moves into its new Paris global headquarters","file":{"link":"/assets/dotcom/pressreleases/2022/2022-11-28-09-00-00-2562820-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-11-28-09-00-00-2562820","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi moves into its new Paris global headquarters","icon":"fasArrowRight"}},{"date":"2022-11-17T17:50:00.000Z","title":"Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease","file":{"link":"/assets/dotcom/pressreleases/2022/2022-11-17-17-50-00-2558583-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-11-17-17-50-00-2558583","label":"Read the Press Release","target":"_self","title":"Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease","icon":"fasArrowRight"}},{"date":"2022-11-11T12:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-11-11-12-00-00-2554131-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-11-11-12-00-00-2554131","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis","icon":"fasArrowRight"}},{"date":"2022-11-10T15:36:50.000Z","title":"Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission","file":{"link":"/assets/dotcom/pressreleases/2022/2022-11-10-15-36-50-2553486-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-11-10-15-36-50-2553486","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission","icon":"fasArrowRight"}},{"date":"2022-11-04T07:00:00.000Z","title":"Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants","file":{"link":"/assets/dotcom/pressreleases/2022/2022-11-04-07-00-00-2548492-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-11-04-07-00-00-2548492","label":"Read the Press Release","target":"_self","title":"Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants","icon":"fasArrowRight"}},{"date":"2022-10-28T05:30:00.000Z","title":" Press Release: Continued strong growth in Q3 with key regulatory milestones achieved","file":{"link":"/assets/dotcom/pressreleases/2022/2022-10-28-05-30-00-2543532-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-10-28-05-30-00-2543532","label":"Read the Press Release","target":"_self","title":" Press Release: Continued strong growth in Q3 with key regulatory milestones achieved","icon":"fasArrowRight"}},{"date":"2022-10-26T11:00:00.000Z","title":"Media Update: New two-year efficacy and safety data for tolebrutinib, Sanofi’s investigational, brain-penetrant and bioactive BTK inhibitor, to be presented at ECTRIMS 2022","file":{"link":"/assets/dotcom/pressreleases/2022/2022-10-26-11-00-00-2541624-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-10-26-11-00-00-2541624","label":"Read the Press Release","target":"_self","title":"Media Update: New two-year efficacy and safety data for tolebrutinib, Sanofi’s investigational, brain-penetrant and bioactive BTK inhibitor, to be presented at ECTRIMS 2022","icon":"fasArrowRight"}},{"date":"2022-10-11T05:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old","file":{"link":"/assets/dotcom/pressreleases/2022/2022-10-11-05-00-00-2531406-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-10-11-05-00-00-2531406","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old","icon":"fasArrowRight"}},{"date":"2022-09-28T22:05:26.000Z","title":"Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-09-28-22-05-26-2524764-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-09-28-22-05-26-2524764","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis","icon":"fasArrowRight"}},{"date":"2022-09-28T05:30:00.000Z","title":"Press Release: Availability of the Q3 2022 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2022/2022-09-28-05-30-00-2523916-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-09-28-05-30-00-2523916","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q3 2022 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2022-09-16T15:18:01.000Z","title":"Media Update: CHMP recommends approval of Enjaymo™ (sutimlimab), first and only approved treatment for hemolytic anemia in adult patients with cold agglutinin disease","file":{"link":"/assets/dotcom/pressreleases/2022/2022-09-16-15-18-01-2517753-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-09-16-15-18-01-2517753","label":"Read the Press Release","target":"_self","title":"Media Update: CHMP recommends approval of Enjaymo™ (sutimlimab), first and only approved treatment for hemolytic anemia in adult patients with cold agglutinin disease","icon":"fasArrowRight"}},{"date":"2022-09-16T06:00:00.000Z","title":"Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants","file":{"link":"/assets/dotcom/pressreleases/2022/2022-09-16-06-00-00-2517378-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-09-16-06-00-00-2517378","label":"Read the Press Release","target":"_self","title":"Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants","icon":"fasArrowRight"}},{"date":"2022-09-15T22:37:32.000Z","title":"Media Update: Positive Dupixent® (dupilumab) Phase 3 data in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis published in The Lancet","file":{"link":"/assets/dotcom/pressreleases/2022/2022-09-15-22-37-32-2517340-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-09-15-22-37-32-2517340","label":"Read the Press Release","target":"_self","title":"Media Update: Positive Dupixent® (dupilumab) Phase 3 data in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis published in The Lancet","icon":"fasArrowRight"}},{"date":"2022-09-08T15:30:00.000Z","title":"Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-09-08-15-30-00-2512789-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-09-08-15-30-00-2512789","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis","icon":"fasArrowRight"}},{"date":"2022-09-06T05:00:00.000Z","title":"Media Update: New Dupixent® (dupilumab) data at EADV 2022 adds to body of evidence across multiple inflammatory skin diseases","file":{"link":"/assets/dotcom/pressreleases/2022/2022-09-06-05-00-00-2509982-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-09-06-05-00-00-2509982","label":"Read the Press Release","target":"_self","title":"Media Update: New Dupixent® (dupilumab) data at EADV 2022 adds to body of evidence across multiple inflammatory skin diseases","icon":"fasArrowRight"}},{"date":"2022-09-05T05:30:00.000Z","title":"Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma","file":{"link":"/assets/dotcom/pressreleases/2022/2022-09-05-05-30-00-2509533-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-09-05-05-30-00-2509533","label":"Read the Press Release","target":"_self","title":"Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma","icon":"fasArrowRight"}},{"date":"2022-09-05T05:00:00.000Z","title":"Press Release: Evolution of the Board of Directors","file":{"link":"/assets/dotcom/pressreleases/2022/2022-09-05-05-00-00-2509527-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-09-05-05-00-00-2509527","label":"Read the Press Release","target":"_self","title":"Press Release: Evolution of the Board of Directors","icon":"fasArrowRight"}},{"date":"2022-08-31T18:30:00.000Z","title":"Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)","file":{"link":"/assets/dotcom/pressreleases/2022/2022-08-31-18-30-00-2507978-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-08-31-18-30-00-2507978","label":"Read the Press Release","target":"_self","title":"Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)","icon":"fasArrowRight"}},{"date":"2022-08-30T05:30:00.000Z","title":"Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A","file":{"link":"/assets/dotcom/pressreleases/2022/2022-08-30-05-30-00-2506359-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-08-30-05-30-00-2506359","label":"Read the Press Release","target":"_self","title":"Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A","icon":"fasArrowRight"}},{"date":"2022-08-30T05:00:00.000Z","title":"Media Update: New Dupixent® (dupilumab) data at ERS adds to body of safety and efficacy data in chronic respiratory diseases","file":{"link":"/assets/dotcom/pressreleases/2022/2022-08-30-05-00-00-2506339-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-08-30-05-00-00-2506339","label":"Read the Press Release","target":"_self","title":"Media Update: New Dupixent® (dupilumab) data at ERS adds to body of safety and efficacy data in chronic respiratory diseases","icon":"fasArrowRight"}},{"date":"2022-08-17T05:30:00.000Z","title":"Press Release: Sanofi provides update on amcenestrant clinical development program","file":{"link":"/assets/dotcom/pressreleases/2022/2022-08-17-05-30-00-2499668-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-08-17-05-30-00-2499668","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi provides update on amcenestrant clinical development program","icon":"fasArrowRight"}},{"date":"2022-08-11T16:21:24.000Z","title":"Sanofi Media Update","file":{"link":"/assets/dotcom/pressreleases/2022/2022-08-11-16-21-24-2497005-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-08-11-16-21-24-2497005","label":"Read the Press Release","target":"_self","title":"Sanofi Media Update","icon":"fasArrowRight"}},{"date":"2022-08-08T17:08:40.000Z","title":"Media Update: Tolebrutinib clinical trial program update","file":{"link":"/assets/dotcom/pressreleases/2022/2022-08-08-17-08-40-2494173-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-08-08-17-08-40-2494173","label":"Read the Press Release","target":"_self","title":"Media Update: Tolebrutinib clinical trial program update","icon":"fasArrowRight"}},{"date":"2022-08-04T15:30:00.000Z","title":"Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China","file":{"link":"/assets/dotcom/pressreleases/2022/2022-08-04-15-30-00-2492626-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-08-04-15-30-00-2492626","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China","icon":"fasArrowRight"}},{"date":"2022-07-28T05:30:00.000Z","title":"Press Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R\u0026D news flow in Immunology and Rare Disease ","file":{"link":"/assets/dotcom/pressreleases/2022/2022-07-28-05-30-00-2487474-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-07-28-05-30-00-2487474","label":"Read the Press Release","target":"_self","title":"Press Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R\u0026D news flow in Immunology and Rare Disease ","icon":"fasArrowRight"}},{"date":"2022-07-14T05:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-07-14-05-00-00-2479427-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-07-14-05-00-00-2479427","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis","icon":"fasArrowRight"}},{"date":"2022-07-10T13:45:00.000Z","title":"Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis ","file":{"link":"/assets/dotcom/pressreleases/2022/2022-07-10-13-45-00-2476896-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-07-10-13-45-00-2476896","label":"Read the Press Release","target":"_self","title":"Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis ","icon":"fasArrowRight"}},{"date":"2022-07-10T13:45:00.000Z","title":"Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-07-10-13-45-00-2476897-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-07-10-13-45-00-2476897","label":"Read the Press Release","target":"_self","title":"Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis","icon":"fasArrowRight"}},{"date":"2022-07-04T10:00:00.000Z","title":"Press Release: Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries","file":{"link":"/assets/dotcom/pressreleases/2022/2022-07-04-10-00-00-2473350-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-07-04-10-00-00-2473350","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries","icon":"fasArrowRight"}},{"date":"2022-06-30T05:30:00.000Z","title":"Media Update: Patient enrollment of phase III tolebrutinib trials paused in the U.S.","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-30-05-30-00-2471767-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-30-05-30-00-2471767","label":"Read the Press Release","target":"_self","title":"Media Update: Patient enrollment of phase III tolebrutinib trials paused in the U.S.","icon":"fasArrowRight"}},{"date":"2022-06-28T05:30:00.000Z","title":"Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD ","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-28-05-30-00-2469974-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-28-05-30-00-2469974","label":"Read the Press Release","target":"_self","title":"Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD ","icon":"fasArrowRight"}},{"date":"2022-06-28T05:30:00.000Z","title":"Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease ","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-28-05-30-00-2469979-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-28-05-30-00-2469979","label":"Read the Press Release","target":"_self","title":"Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease ","icon":"fasArrowRight"}},{"date":"2022-06-24T05:32:00.000Z","title":"Press Release: Availability of the Q2 2022 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-24-05-32-00-2468541-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-24-05-32-00-2468541","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q2 2022 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2022-06-24T05:29:02.000Z","title":"Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-24-05-29-02-2468538-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-24-05-29-02-2468538","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine","icon":"fasArrowRight"}},{"date":"2022-06-22T12:00:00.000Z","title":"Media Update: Survey: Physicians and pharmacists would tell CDC to recommend vaccine like Fluzone High-Dose Quadrivalent (Influenza Vaccine) for people 65 years and older","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-22-12-00-00-2467035-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-22-12-00-00-2467035","label":"Read the Press Release","target":"_self","title":"Media Update: Survey: Physicians and pharmacists would tell CDC to recommend vaccine like Fluzone High-Dose Quadrivalent (Influenza Vaccine) for people 65 years and older","icon":"fasArrowRight"}},{"date":"2022-06-13T05:30:00.000Z","title":"Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-13-05-30-00-2460833-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-13-05-30-00-2460833","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron","icon":"fasArrowRight"}},{"date":"2022-06-10T17:00:00.000Z","title":"Media Update: Sanofi, a leader in immune-mediated rare blood disorders, to present latest data at EHA 2022 ","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-10-17-00-00-2460690-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-10-17-00-00-2460690","label":"Read the Press Release","target":"_self","title":"Media Update: Sanofi, a leader in immune-mediated rare blood disorders, to present latest data at EHA 2022 ","icon":"fasArrowRight"}},{"date":"2022-06-08T09:21:33.000Z","title":"Press Release: Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-08-09-21-33-2458434-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-08-09-21-33-2458434","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth","icon":"fasArrowRight"}},{"date":"2022-06-07T20:45:00.000Z","title":"Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-07-20-45-00-2458243-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-07-20-45-00-2458243","label":"Read the Press Release","target":"_self","title":"Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2022-06-07T05:30:00.000Z","title":"Press Release: Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-07-05-30-00-2457270-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-07-05-30-00-2457270","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people","icon":"fasArrowRight"}},{"date":"2022-06-02T11:30:00.000Z","title":"Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-02-11-30-00-2455080-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-02-11-30-00-2455080","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)","icon":"fasArrowRight"}},{"date":"2022-06-01T05:00:00.000Z","title":"Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A","file":{"link":"/assets/dotcom/pressreleases/2022/2022-06-01-05-00-00-2453803-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-06-01-05-00-00-2453803","label":"Read the Press Release","target":"_self","title":"Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A","icon":"fasArrowRight"}},{"date":"2022-05-31T05:00:00.000Z","title":"Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-05-31-05-00-00-2452848-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-05-31-05-00-00-2452848","label":"Read the Press Release","target":"_self","title":"Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis","icon":"fasArrowRight"}},{"date":"2022-05-30T05:30:00.000Z","title":"Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial","file":{"link":"/assets/dotcom/pressreleases/2022/2022-05-30-05-30-00-2452303-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-05-30-05-30-00-2452303","label":"Read the Press Release","target":"_self","title":"Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial","icon":"fasArrowRight"}},{"date":"2022-05-20T19:15:00.000Z","title":"Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-05-20-19-15-00-2447906-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-05-20-19-15-00-2447906","label":"Read the Press Release","target":"_self","title":"Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis","icon":"fasArrowRight"}},{"date":"2022-05-20T05:00:00.000Z","title":"Media Update: CHMP recommends approval of Xenpozyme® (olipudase alfa), the first and only treatment for ASMD","file":{"link":"/assets/dotcom/pressreleases/2022/2022-05-20-05-00-00-2447427-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-05-20-05-00-00-2447427","label":"Read the Press Release","target":"_self","title":"Media Update: CHMP recommends approval of Xenpozyme® (olipudase alfa), the first and only treatment for ASMD","icon":"fasArrowRight"}},{"date":"2022-05-17T05:00:00.000Z","title":"Media Update: New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting ","file":{"link":"/assets/dotcom/pressreleases/2022/2022-05-17-05-00-00-2444487-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-05-17-05-00-00-2444487","label":"Read the Press Release","target":"_self","title":"Media Update: New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting ","icon":"fasArrowRight"}},{"date":"2022-05-15T07:30:00.000Z","title":"Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy","file":{"link":"/assets/dotcom/pressreleases/2022/2022-05-15-07-30-00-2443369-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-05-15-07-30-00-2443369","label":"Read the Press Release","target":"_self","title":"Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy","icon":"fasArrowRight"}},{"date":"2022-05-11T06:00:00.000Z","title":"Press Release: New nirsevimab data analyses reinforce efficacy against RSV","file":{"link":"/assets/dotcom/pressreleases/2022/2022-05-11-06-00-00-2440425-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-05-11-06-00-00-2440425","label":"Read the Press Release","target":"_self","title":"Press Release: New nirsevimab data analyses reinforce efficacy against RSV","icon":"fasArrowRight"}},{"date":"2022-05-04T10:00:00.000Z","title":"Press Release: Foundation S: Sanofi’s new philanthropic spearhead","file":{"link":"/assets/dotcom/pressreleases/2022/2022-05-04-10-00-00-2435408-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-05-04-10-00-00-2435408","label":"Read the Press Release","target":"_self","title":"Press Release: Foundation S: Sanofi’s new philanthropic spearhead","icon":"fasArrowRight"}},{"date":"2022-05-03T17:00:00.000Z","title":"Press Release: Annual General Meeting of May 3, 2022","file":{"link":"/assets/dotcom/pressreleases/2022/2022-05-03-17-00-00-2434935-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-05-03-17-00-00-2434935","label":"Read the Press Release","target":"_self","title":"Press Release: Annual General Meeting of May 3, 2022","icon":"fasArrowRight"}},{"date":"2022-04-28T05:30:00.000Z","title":"Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1","file":{"link":"/assets/dotcom/pressreleases/2022/2022-04-28-05-30-00-2430908-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-04-28-05-30-00-2430908","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1","icon":"fasArrowRight"}},{"date":"2022-04-26T10:47:18.000Z","title":"Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence","file":{"link":"/assets/dotcom/pressreleases/2022/2022-04-26-10-47-18-2428869-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-04-26-10-47-18-2428869","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence","icon":"fasArrowRight"}},{"date":"2022-04-21T05:00:00.000Z","title":"Media Update: Rezurock® (belumosudil) patient-reported outcomes correlated with clinical response in chronic graft-versus-host disease ","file":{"link":"/assets/dotcom/pressreleases/2022/2022-04-21-05-00-00-2426054-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-04-21-05-00-00-2426054","label":"Read the Press Release","target":"_self","title":"Media Update: Rezurock® (belumosudil) patient-reported outcomes correlated with clinical response in chronic graft-versus-host disease ","icon":"fasArrowRight"}},{"date":"2022-04-14T05:00:00.000Z","title":"Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine","file":{"link":"/assets/dotcom/pressreleases/2022/2022-04-14-05-00-00-2422388-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-04-14-05-00-00-2422388","label":"Read the Press Release","target":"_self","title":"Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine","icon":"fasArrowRight"}},{"date":"2022-04-07T05:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation","file":{"link":"/assets/dotcom/pressreleases/2022/2022-04-07-05-00-00-2418107-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-04-07-05-00-00-2418107","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation","icon":"fasArrowRight"}},{"date":"2022-04-04T10:00:00.000Z","title":"Press Release: Sanofi launches first-in-pharma Diversity, Equity \u0026 Inclusion Board","file":{"link":"/assets/dotcom/pressreleases/2022/2022-04-04-10-00-00-2415480-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-04-04-10-00-00-2415480","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi launches first-in-pharma Diversity, Equity \u0026 Inclusion Board","icon":"fasArrowRight"}},{"date":"2022-04-04T05:00:00.000Z","title":"Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-04-04-05-00-00-2415245-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-04-04-05-00-00-2415245","label":"Read the Press Release","target":"_self","title":"Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis","icon":"fasArrowRight"}},{"date":"2022-04-01T05:30:00.000Z","title":"Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022","file":{"link":"/assets/dotcom/pressreleases/2022/2022-04-01-05-30-00-2414527-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-04-01-05-30-00-2414527","label":"Read the Press Release","target":"_self","title":"Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022","icon":"fasArrowRight"}},{"date":"2022-03-31T05:00:00.000Z","title":"Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-31-05-00-00-2413430-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-31-05-00-00-2413430","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines","icon":"fasArrowRight"}},{"date":"2022-03-30T05:30:00.000Z","title":"Press Release: Availability of the Q1 2022 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-30-05-30-00-2412460-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-30-05-30-00-2412460","label":"Read the Press Release","target":"_self","title":"Press Release: Availability of the Q1 2022 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2022-03-29T05:00:00.000Z","title":"Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-29-05-00-00-2411497-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-29-05-00-00-2411497","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets","icon":"fasArrowRight"}},{"date":"2022-03-29T01:00:00.000Z","title":"Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-29-01-00-00-2411464-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-29-01-00-00-2411464","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver","icon":"fasArrowRight"}},{"date":"2022-03-28T07:00:00.000Z","title":"Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-28-07-00-00-2410648-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-28-07-00-00-2410648","label":"Read the Press Release","target":"_self","title":"Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency","icon":"fasArrowRight"}},{"date":"2022-03-26T14:00:00.000Z","title":"Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-26-14-00-00-2410552-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-26-14-00-00-2410552","label":"Read the Press Release","target":"_self","title":"Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis","icon":"fasArrowRight"}},{"date":"2022-03-18T11:48:38.000Z","title":"Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-18-11-48-38-2405963-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-18-11-48-38-2405963","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris","icon":"fasArrowRight"}},{"date":"2022-03-16T10:18:19.000Z","title":"Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-16-10-18-19-2404147-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-16-10-18-19-2404147","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates","icon":"fasArrowRight"}},{"date":"2022-03-15T06:00:00.000Z","title":"Press Release: Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-15-06-00-00-2403030-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-15-06-00-00-2403030","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma","icon":"fasArrowRight"}},{"date":"2022-03-14T06:00:00.000Z","title":"Press Release: Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-14-06-00-00-2402216-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-14-06-00-00-2402216","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer","icon":"fasArrowRight"}},{"date":"2022-03-09T06:00:00.000Z","title":"Press Release: Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-09-06-00-00-2399557-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-09-06-00-00-2399557","label":"Read the Press Release","target":"_self","title":"Press Release: Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment","icon":"fasArrowRight"}},{"date":"2022-03-08T13:25:40.000Z","title":"Press Release: Sanofi recognized by S\u0026P as one of the most sustainability- committed companies","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-08-13-25-40-2398922-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-08-13-25-40-2398922","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi recognized by S\u0026P as one of the most sustainability- committed companies","icon":"fasArrowRight"}},{"date":"2022-03-03T07:00:00.000Z","title":"Nirsevimab Shows 74.5% Reduction in RSV Infections in Phase 3 Trial","file":{"link":"/assets/dotcom/pressreleases/2022/2022-03-03-07-00-00-2395880-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-03-03-07-00-00-2395880","label":"Read the Press Release","target":"_self","title":"Nirsevimab Shows 74.5% Reduction in RSV Infections in Phase 3 Trial","icon":"fasArrowRight"}},{"date":"2022-02-26T17:05:00.000Z","title":"Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-26-17-05-00-2392626-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-26-17-05-00-2392626","label":"Read the Press Release","target":"_self","title":"Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis","icon":"fasArrowRight"}},{"date":"2022-02-26T17:00:00.000Z","title":"Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-26-17-00-00-2392625-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-26-17-00-00-2392625","label":"Read the Press Release","target":"_self","title":"Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria","icon":"fasArrowRight"}},{"date":"2022-02-24T14:01:00.000Z","title":"New preclinical tolebrutinib data demonstrated superior brain penetration and potency ","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-24-14-01-00-2391553-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-24-14-01-00-2391553","label":"Read the Press Release","target":"_self","title":"New preclinical tolebrutinib data demonstrated superior brain penetration and potency ","icon":"fasArrowRight"}},{"date":"2022-02-23T19:16:21.000Z","title":"Filing of the 2021 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-23-19-16-21-2390705-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-23-19-16-21-2390705","label":"Read the Press Release","target":"_self","title":"Filing of the 2021 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report","icon":"fasArrowRight"}},{"date":"2022-02-23T10:15:00.000Z","title":"Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-23-10-15-00-2390091-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-23-10-15-00-2390091","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine","icon":"fasArrowRight"}},{"date":"2022-02-22T17:32:28.000Z","title":"Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-22-17-32-28-2389683-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-22-17-32-28-2389683","label":"Read the Press Release","target":"_self","title":"Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors","icon":"fasArrowRight"}},{"date":"2022-02-18T06:00:00.000Z","title":"Latest Updates on Dupixent® (dupilumab) Chronic Spontaneous Urticaria Clinical Trials","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-18-06-00-00-2387700-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-18-06-00-00-2387700","label":"Read the Press Release","target":"_self","title":"Latest Updates on Dupixent® (dupilumab) Chronic Spontaneous Urticaria Clinical Trials","icon":"fasArrowRight"}},{"date":"2022-02-17T13:00:00.000Z","title":"Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-17-13-00-00-2387084-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-17-13-00-00-2387084","label":"Read the Press Release","target":"_self","title":"Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants","icon":"fasArrowRight"}},{"date":"2022-02-10T06:00:00.000Z","title":"FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-10-06-00-00-2382407-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-10-06-00-00-2382407","label":"Read the Press Release","target":"_self","title":"FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2022-02-09T17:00:00.000Z","title":"Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-09-17-00-00-2382138-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-09-17-00-00-2382138","label":"Read the Press Release","target":"_self","title":"Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD","icon":"fasArrowRight"}},{"date":"2022-02-08T14:00:00.000Z","title":"Nexviazyme® (avalglucosidase alfa) shows sustained improvements in respiratory function and mobility in patients with Pompe disease","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-08-14-00-00-2380936-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-08-14-00-00-2380936","label":"Read the Press Release","target":"_self","title":"Nexviazyme® (avalglucosidase alfa) shows sustained improvements in respiratory function and mobility in patients with Pompe disease","icon":"fasArrowRight"}},{"date":"2022-02-08T13:51:22.000Z","title":"Media Update: Sanofi completes acquisition of Amunix","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-08-13-51-22-2380928-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-08-13-51-22-2380928","label":"Read the Press Release","target":"_self","title":"Media Update: Sanofi completes acquisition of Amunix","icon":"fasArrowRight"}},{"date":"2022-02-04T22:00:00.000Z","title":"FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-04-22-00-00-2379517-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-04-22-00-00-2379517","label":"Read the Press Release","target":"_self","title":"FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease","icon":"fasArrowRight"}},{"date":"2022-02-04T06:30:00.000Z","title":"Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R\u0026D","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-04-06-30-00-2379020-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-04-06-30-00-2379020","label":"Read the Press Release","target":"_self","title":"Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R\u0026D","icon":"fasArrowRight"}},{"date":"2022-02-03T16:00:00.000Z","title":"Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-03-16-00-00-2378702-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-03-16-00-00-2378702","label":"Read the Press Release","target":"_self","title":"Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity","icon":"fasArrowRight"}},{"date":"2022-02-01T21:30:00.000Z","title":"Positive Dupixent® (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting","file":{"link":"/assets/dotcom/pressreleases/2022/2022-02-01-21-30-00-2377180-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-02-01-21-30-00-2377180","label":"Read the Press Release","target":"_self","title":"Positive Dupixent® (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting","icon":"fasArrowRight"}},{"date":"2022-01-31T06:00:00.000Z","title":"CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation","file":{"link":"/assets/dotcom/pressreleases/2022/2022-01-31-06-00-00-2375371-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-01-31-06-00-00-2375371","label":"Read the Press Release","target":"_self","title":"CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation","icon":"fasArrowRight"}},{"date":"2022-01-28T12:00:00.000Z","title":"Sanofi and Regeneron provide regulatory update on Libtayo® (cemiplimab-rwlc) in advanced cervical cancer","file":{"link":"/assets/dotcom/pressreleases/2022/2022-01-28-12-00-00-2374983-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-01-28-12-00-00-2374983","label":"Read the Press Release","target":"_self","title":"Sanofi and Regeneron provide regulatory update on Libtayo® (cemiplimab-rwlc) in advanced cervical cancer","icon":"fasArrowRight"}},{"date":"2022-01-19T06:00:00.000Z","title":"Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis","file":{"link":"/assets/dotcom/pressreleases/2022/2022-01-19-06-00-00-2368986-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-01-19-06-00-00-2368986","label":"Read the Press Release","target":"_self","title":"Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis","icon":"fasArrowRight"}},{"date":"2022-01-07T06:00:00.000Z","title":"Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines","file":{"link":"/assets/dotcom/pressreleases/2022/2022-01-07-06-00-00-2362917-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-01-07-06-00-00-2362917","label":"Read the Press Release","target":"_self","title":"Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines","icon":"fasArrowRight"}},{"date":"2022-01-04T06:30:00.000Z","title":"Availability of the Q4 2021 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2022/2022-01-04-06-30-00-2360386-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2022/2022-01-04-06-30-00-2360386","label":"Read the Press Release","target":"_self","title":"Availability of the Q4 2021 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2021-12-21T04:30:00.000Z","title":"Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics","file":{"link":"/assets/dotcom/pressreleases/2021/2021-12-21-04-30-00-2355740-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-12-21-04-30-00-2355740","label":"Read the Press Release","target":"_self","title":"Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics","icon":"fasArrowRight"}},{"date":"2021-12-16T07:00:00.000Z","title":"Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi","file":{"link":"/assets/dotcom/pressreleases/2021/2021-12-16-07-00-00-2353238-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-12-16-07-00-00-2353238","label":"Read the Press Release","target":"_self","title":"Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi","icon":"fasArrowRight"}},{"date":"2021-12-15T06:30:00.000Z","title":"Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation","file":{"link":"/assets/dotcom/pressreleases/2021/2021-12-15-06-30-00-2352255-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-12-15-06-30-00-2352255","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation","icon":"fasArrowRight"}},{"date":"2021-12-14T14:00:00.000Z","title":"Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions","file":{"link":"/assets/dotcom/pressreleases/2021/2021-12-14-14-00-00-2351761-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-12-14-14-00-00-2351761","label":"Read the Press Release","target":"_self","title":"Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions","icon":"fasArrowRight"}},{"date":"2021-12-13T06:00:00.000Z","title":"Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session","file":{"link":"/assets/dotcom/pressreleases/2021/2021-12-13-06-00-00-2350402-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-12-13-06-00-00-2350402","label":"Read the Press Release","target":"_self","title":"Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session","icon":"fasArrowRight"}},{"date":"2021-12-11T13:30:00.000Z","title":"Sarclisa® (isatuximab) trial is first Phase 3 study to meet primary endpoint of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2021/2021-12-11-13-30-00-2350297-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-12-11-13-30-00-2350297","label":"Read the Press Release","target":"_self","title":"Sarclisa® (isatuximab) trial is first Phase 3 study to meet primary endpoint of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma","icon":"fasArrowRight"}},{"date":"2021-12-08T22:30:00.000Z","title":"New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma","file":{"link":"/assets/dotcom/pressreleases/2021/2021-12-08-22-30-00-2348703-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-12-08-22-30-00-2348703","label":"Read the Press Release","target":"_self","title":"New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma","icon":"fasArrowRight"}},{"date":"2021-12-06T13:00:00.000Z","title":"EMA accepts regulatory submission for olipudase alfa, the first potential therapy for ASMD","file":{"link":"/assets/dotcom/pressreleases/2021/2021-12-06-13-00-00-2346501-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-12-06-13-00-00-2346501","label":"Read the Press Release","target":"_self","title":"EMA accepts regulatory submission for olipudase alfa, the first potential therapy for ASMD","icon":"fasArrowRight"}},{"date":"2021-12-01T06:30:00.000Z","title":"Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates","file":{"link":"/assets/dotcom/pressreleases/2021/2021-12-01-06-30-00-2343730-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-12-01-06-30-00-2343730","label":"Read the Press Release","target":"_self","title":"Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates","icon":"fasArrowRight"}},{"date":"2021-12-01T06:00:00.000Z","title":"Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy ","file":{"link":"/assets/dotcom/pressreleases/2021/2021-12-01-06-00-00-2343720-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-12-01-06-00-00-2343720","label":"Read the Press Release","target":"_self","title":"Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy ","icon":"fasArrowRight"}},{"date":"2021-11-18T06:30:00.000Z","title":"Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline","file":{"link":"/assets/dotcom/pressreleases/2021/2021-11-18-06-30-00-2336966-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-11-18-06-30-00-2336966","label":"Read the Press Release","target":"_self","title":"Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline","icon":"fasArrowRight"}},{"date":"2021-11-12T11:38:38.000Z","title":"Sanofi announces results of CHMP re-examination of the New Active Substance status for avalglucosidase alfa, a potential new standard of care for the treatment of Pompe disease","file":{"link":"/assets/dotcom/pressreleases/2021/2021-11-12-11-38-38-2333221-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-11-12-11-38-38-2333221","label":"Read the Press Release","target":"_self","title":"Sanofi announces results of CHMP re-examination of the New Active Substance status for avalglucosidase alfa, a potential new standard of care for the treatment of Pompe disease","icon":"fasArrowRight"}},{"date":"2021-11-09T14:05:00.000Z","title":"Sanofi completes acquisition of Kadmon","file":{"link":"/assets/dotcom/pressreleases/2021/2021-11-09-14-05-00-2330525-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-11-09-14-05-00-2330525","label":"Read the Press Release","target":"_self","title":"Sanofi completes acquisition of Kadmon","icon":"fasArrowRight"}},{"date":"2021-11-04T15:30:00.000Z","title":"New data in blood cancers, hemophilia, and other hematological disorders to be presented at ASH 2021","file":{"link":"/assets/dotcom/pressreleases/2021/2021-11-04-15-30-00-2327804-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-11-04-15-30-00-2327804","label":"Read the Press Release","target":"_self","title":"New data in blood cancers, hemophilia, and other hematological disorders to be presented at ASH 2021","icon":"fasArrowRight"}},{"date":"2021-10-28T05:30:00.000Z","title":"Sanofi: Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)","file":{"link":"/assets/dotcom/pressreleases/2021/2021-10-28-05-30-00-2322319-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-10-28-05-30-00-2322319","label":"Read the Press Release","target":"_self","title":"Sanofi: Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)","icon":"fasArrowRight"}},{"date":"2021-10-25T05:00:00.000Z","title":"Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease","file":{"link":"/assets/dotcom/pressreleases/2021/2021-10-25-05-00-00-2319486-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-10-25-05-00-00-2319486","label":"Read the Press Release","target":"_self","title":"Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease","icon":"fasArrowRight"}},{"date":"2021-10-22T05:00:00.000Z","title":"Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease","file":{"link":"/assets/dotcom/pressreleases/2021/2021-10-22-05-00-00-2318876-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-10-22-05-00-00-2318876","label":"Read the Press Release","target":"_self","title":"Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease","icon":"fasArrowRight"}},{"date":"2021-10-20T21:30:00.000Z","title":"Press Release: FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma","file":{"link":"/assets/dotcom/pressreleases/2021/2021-10-20-21-30-00-2317854-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-10-20-21-30-00-2317854","label":"Read the Press Release","target":"_self","title":"Press Release: FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma","icon":"fasArrowRight"}},{"date":"2021-10-13T07:00:00.000Z","title":"New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021","file":{"link":"/assets/dotcom/pressreleases/2021/2021-10-13-07-00-00-2313117-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-10-13-07-00-00-2313117","label":"Read the Press Release","target":"_self","title":"New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021","icon":"fasArrowRight"}},{"date":"2021-10-12T16:16:27.000Z","title":"Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022","file":{"link":"/assets/dotcom/pressreleases/2021/2021-10-12-16-16-27-2312865-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-10-12-16-16-27-2312865","label":"Read the Press Release","target":"_self","title":"Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022","icon":"fasArrowRight"}},{"date":"2021-10-07T05:00:00.000Z","title":"Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations","file":{"link":"/assets/dotcom/pressreleases/2021/2021-10-07-05-00-00-2309981-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-10-07-05-00-00-2309981","label":"Read the Press Release","target":"_self","title":"Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations","icon":"fasArrowRight"}},{"date":"2021-09-30T12:30:00.000Z","title":"Press Release: New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-30-12-30-00-2306183-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-30-12-30-00-2306183","label":"Read the Press Release","target":"_self","title":"Press Release: New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2021-09-28T16:44:47.000Z","title":"Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-28-16-44-47-2304800-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-28-16-44-47-2304800","label":"Read the Press Release","target":"_self","title":"Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate","icon":"fasArrowRight"}},{"date":"2021-09-28T06:00:00.000Z","title":"Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-28-06-00-00-2304069-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-28-06-00-00-2304069","label":"Read the Press Release","target":"_self","title":"Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate","icon":"fasArrowRight"}},{"date":"2021-09-27T05:00:00.000Z","title":"New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline and commitment to advancing public health protection","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-27-05-00-00-2303270-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-27-05-00-00-2303270","label":"Read the Press Release","target":"_self","title":"New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline and commitment to advancing public health protection","icon":"fasArrowRight"}},{"date":"2021-09-24T05:30:00.000Z","title":"Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-24-05-30-00-2302708-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-24-05-30-00-2302708","label":"Read the Press Release","target":"_self","title":"Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2021-09-21T05:00:00.000Z","title":"New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-21-05-00-00-2300187-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-21-05-00-00-2300187","label":"Read the Press Release","target":"_self","title":"New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV","icon":"fasArrowRight"}},{"date":"2021-09-19T15:30:00.000Z","title":"ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-19-15-30-00-2299392-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-19-15-30-00-2299392","label":"Read the Press Release","target":"_self","title":"ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC","icon":"fasArrowRight"}},{"date":"2021-09-14T13:26:25.000Z","title":"Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-14-13-26-25-2296830-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-14-13-26-25-2296830","label":"Read the Press Release","target":"_self","title":"Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics","icon":"fasArrowRight"}},{"date":"2021-09-09T05:00:00.000Z","title":"Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-09-05-00-00-2293920-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-09-05-00-00-2293920","label":"Read the Press Release","target":"_self","title":"Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus","icon":"fasArrowRight"}},{"date":"2021-09-08T05:00:00.000Z","title":"Sanofi to acquire Kadmon to further strengthen growth of transplant business","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-08-05-00-00-2293017-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-08-05-00-00-2293017","label":"Read the Press Release","target":"_self","title":"Sanofi to acquire Kadmon to further strengthen growth of transplant business","icon":"fasArrowRight"}},{"date":"2021-09-03T11:00:00.000Z","title":"Dupixent® (dupilumab) efficacy and quality of life data in asthma patients across multiple age groups to be presented at 2021 ERS international congress","file":{"link":"/assets/dotcom/pressreleases/2021/2021-09-03-11-00-00-2291359-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-09-03-11-00-00-2291359","label":"Read the Press Release","target":"_self","title":"Dupixent® (dupilumab) efficacy and quality of life data in asthma patients across multiple age groups to be presented at 2021 ERS international congress","icon":"fasArrowRight"}},{"date":"2021-08-30T05:00:00.000Z","title":"Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months","file":{"link":"/assets/dotcom/pressreleases/2021/2021-08-30-05-00-00-2288011-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-08-30-05-00-00-2288011","label":"Read the Press Release","target":"_self","title":"Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months","icon":"fasArrowRight"}},{"date":"2021-08-06T15:42:21.000Z","title":"FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease","file":{"link":"/assets/dotcom/pressreleases/2021/2021-08-06-15-42-21-2276588-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-08-06-15-42-21-2276588","label":"Read the Press Release","target":"_self","title":"FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease","icon":"fasArrowRight"}},{"date":"2021-08-05T10:00:00.000Z","title":"Press Release: Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non- small cell lung cancer","file":{"link":"/assets/dotcom/pressreleases/2021/2021-08-05-10-00-00-2275303-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-08-05-10-00-00-2275303","label":"Read the Press Release","target":"_self","title":"Press Release: Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non- small cell lung cancer","icon":"fasArrowRight"}},{"date":"2021-08-03T05:00:00.000Z","title":"Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development","file":{"link":"/assets/dotcom/pressreleases/2021/2021-08-03-05-00-00-2273307-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-08-03-05-00-00-2273307","label":"Read the Press Release","target":"_self","title":"Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development","icon":"fasArrowRight"}},{"date":"2021-07-29T16:24:31.000Z","title":"Online availability of Sanofi’s half-year financial report for 2021","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-29-16-24-31-2271617-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-29-16-24-31-2271617","label":"Read the Press Release","target":"_self","title":"Online availability of Sanofi’s half-year financial report for 2021","icon":"fasArrowRight"}},{"date":"2021-07-29T05:31:00.000Z","title":"Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-29-05-31-00-2270884-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-29-05-31-00-2270884","label":"Read the Press Release","target":"_self","title":"Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI","icon":"fasArrowRight"}},{"date":"2021-07-29T05:30:00.000Z","title":"Sales growth accelerated - Full-year guidance raised","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-29-05-30-00-2270868-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-29-05-30-00-2270868","label":"Read the Press Release","target":"_self","title":"Sales growth accelerated - Full-year guidance raised","icon":"fasArrowRight"}},{"date":"2021-07-29T05:00:00.000Z","title":"Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients ","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-29-05-00-00-2270858-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-29-05-00-00-2270858","label":"Read the Press Release","target":"_self","title":"Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients ","icon":"fasArrowRight"}},{"date":"2021-07-27T17:23:10.000Z","title":"Sanofi provides update on avalglucosidase alfa EU submission for patients with Pompe Disease","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-27-17-23-10-2269762-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-27-17-23-10-2269762","label":"Read the Press Release","target":"_self","title":"Sanofi provides update on avalglucosidase alfa EU submission for patients with Pompe Disease","icon":"fasArrowRight"}},{"date":"2021-07-22T12:00:00.000Z","title":"Sanofi continues streamlining of established products with sale of dental care brands to Septodont","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-22-12-00-00-2267219-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-22-12-00-00-2267219","label":"Read the Press Release","target":"_self","title":"Sanofi continues streamlining of established products with sale of dental care brands to Septodont","icon":"fasArrowRight"}},{"date":"2021-07-19T05:30:00.000Z","title":"Media Update: US FDA approves fexinidazole as the first all-oral treatment for sleeping sickness","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-19-05-30-00-2264542-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-19-05-30-00-2264542","label":"Read the Press Release","target":"_self","title":"Media Update: US FDA approves fexinidazole as the first all-oral treatment for sleeping sickness","icon":"fasArrowRight"}},{"date":"2021-07-15T16:45:00.000Z","title":"Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-15-16-45-00-2263834-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-15-16-45-00-2263834","label":"Read the Press Release","target":"_self","title":"Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings","icon":"fasArrowRight"}},{"date":"2021-07-13T06:00:00.000Z","title":"Sanofi streamlines Consumer Healthcare portfolio in Latin America with divestiture of eight brands to Hypera Pharma","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-13-06-00-00-2261594-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-13-06-00-00-2261594","label":"Read the Press Release","target":"_self","title":"Sanofi streamlines Consumer Healthcare portfolio in Latin America with divestiture of eight brands to Hypera Pharma","icon":"fasArrowRight"}},{"date":"2021-07-10T17:30:00.000Z","title":"Media Update: MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-10-17-30-00-2260818-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-10-17-30-00-2260818","label":"Read the Press Release","target":"_self","title":"Media Update: MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers","icon":"fasArrowRight"}},{"date":"2021-07-02T13:00:00.000Z","title":"Sanofi highlights scientific innovations in the field of rare blood disorders at ISTH 2021","file":{"link":"/assets/dotcom/pressreleases/2021/2021-07-02-13-00-00-2257163-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-07-02-13-00-00-2257163","label":"Read the Press Release","target":"_self","title":"Sanofi highlights scientific innovations in the field of rare blood disorders at ISTH 2021","icon":"fasArrowRight"}},{"date":"2021-06-29T08:00:40.000Z","title":"Sanofi launches dedicated vaccines mRNA Center of Excellence","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-29-08-00-40-2254458-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-29-08-00-40-2254458","label":"Read the Press Release","target":"_self","title":"Sanofi launches dedicated vaccines mRNA Center of Excellence","icon":"fasArrowRight"}},{"date":"2021-06-28T14:00:00.000Z","title":"Media Update: New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin ","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-28-14-00-00-2254031-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-28-14-00-00-2254031","label":"Read the Press Release","target":"_self","title":"Media Update: New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin ","icon":"fasArrowRight"}},{"date":"2021-06-28T06:00:00.000Z","title":"Press Release: Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-28-06-00-00-2253567-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-28-06-00-00-2253567","label":"Read the Press Release","target":"_self","title":"Press Release: Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial","icon":"fasArrowRight"}},{"date":"2021-06-28T05:30:00.000Z","title":"Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-28-05-30-00-2253551-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-28-05-30-00-2253551","label":"Read the Press Release","target":"_self","title":"Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA","icon":"fasArrowRight"}},{"date":"2021-06-28T05:00:00.000Z","title":"Press Release: Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-28-05-00-00-2253546-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-28-05-00-00-2253546","label":"Read the Press Release","target":"_self","title":"Press Release: Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2021-06-25T05:30:00.000Z","title":"Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-25-05-30-00-2253000-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-25-05-30-00-2253000","label":"Read the Press Release","target":"_self","title":"Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2021-06-25T05:15:26.000Z","title":"Press Release: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-25-05-15-26-2252997-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-25-05-15-26-2252997","label":"Read the Press Release","target":"_self","title":"Press Release: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma","icon":"fasArrowRight"}},{"date":"2021-06-25T05:00:00.000Z","title":"Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-25-05-00-00-2252992-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-25-05-00-00-2252992","label":"Read the Press Release","target":"_self","title":"Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression","icon":"fasArrowRight"}},{"date":"2021-06-22T05:00:00.000Z","title":"Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-22-05-00-00-2250633-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-22-05-00-00-2250633","label":"Read the Press Release","target":"_self","title":"Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine","icon":"fasArrowRight"}},{"date":"2021-06-18T13:45:00.000Z","title":"European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-18-13-45-00-2249701-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-18-13-45-00-2249701","label":"Read the Press Release","target":"_self","title":"European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis","icon":"fasArrowRight"}},{"date":"2021-06-11T07:00:00.000Z","title":"New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia ","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-11-07-00-00-2245658-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-11-07-00-00-2245658","label":"Read the Press Release","target":"_self","title":"New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia ","icon":"fasArrowRight"}},{"date":"2021-06-11T05:00:00.000Z","title":"Sanofi provides update on Aubagio® (teriflunomide) submission for children and adolescents with relapsing-remitting multiple sclerosis in the U.S.","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-11-05-00-00-2245628-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-11-05-00-00-2245628","label":"Read the Press Release","target":"_self","title":"Sanofi provides update on Aubagio® (teriflunomide) submission for children and adolescents with relapsing-remitting multiple sclerosis in the U.S.","icon":"fasArrowRight"}},{"date":"2021-06-07T16:00:00.000Z","title":"Sanofi launches its new global employee share ownership plan","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-07-16-00-00-2242990-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-07-16-00-00-2242990","label":"Read the Press Release","target":"_self","title":"Sanofi launches its new global employee share ownership plan","icon":"fasArrowRight"}},{"date":"2021-06-04T05:00:00.000Z","title":"Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-04-05-00-00-2241809-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-04-05-00-00-2241809","label":"Read the Press Release","target":"_self","title":"Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer","icon":"fasArrowRight"}},{"date":"2021-06-03T12:00:00.000Z","title":"Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-03-12-00-00-2241238-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-03-12-00-00-2241238","label":"Read the Press Release","target":"_self","title":"Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects","icon":"fasArrowRight"}},{"date":"2021-06-01T05:00:00.000Z","title":"Sanofi provides update on venglustat clinical program","file":{"link":"/assets/dotcom/pressreleases/2021/2021-06-01-05-00-00-2239122-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-06-01-05-00-00-2239122","label":"Read the Press Release","target":"_self","title":"Sanofi provides update on venglustat clinical program","icon":"fasArrowRight"}},{"date":"2021-05-27T05:30:00.000Z","title":"Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate","file":{"link":"/assets/dotcom/pressreleases/2021/2021-05-27-05-30-00-2236989-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-05-27-05-30-00-2236989","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate","icon":"fasArrowRight"}},{"date":"2021-05-24T05:00:00.000Z","title":"Libtayo® (cemiplimab) receives positive CHMP opinion for the treatment in Europe of two advanced cancers","file":{"link":"/assets/dotcom/pressreleases/2021/2021-05-24-05-00-00-2234433-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-05-24-05-00-00-2234433","label":"Read the Press Release","target":"_self","title":"Libtayo® (cemiplimab) receives positive CHMP opinion for the treatment in Europe of two advanced cancers","icon":"fasArrowRight"}},{"date":"2021-05-19T21:45:00.000Z","title":"Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting","file":{"link":"/assets/dotcom/pressreleases/2021/2021-05-19-21-45-00-2232905-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-05-19-21-45-00-2232905","label":"Read the Press Release","target":"_self","title":"Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting","icon":"fasArrowRight"}},{"date":"2021-05-19T21:00:00.000Z","title":"Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer","file":{"link":"/assets/dotcom/pressreleases/2021/2021-05-19-21-00-00-2232867-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-05-19-21-00-00-2232867","label":"Read the Press Release","target":"_self","title":"Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer","icon":"fasArrowRight"}},{"date":"2021-05-17T14:00:00.000Z","title":"Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children","file":{"link":"/assets/dotcom/pressreleases/2021/2021-05-17-14-00-00-2230876-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-05-17-14-00-00-2230876","label":"Read the Press Release","target":"_self","title":"Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children","icon":"fasArrowRight"}},{"date":"2021-05-17T05:30:00.000Z","title":"Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial","file":{"link":"/assets/dotcom/pressreleases/2021/2021-05-17-05-30-00-2230312-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-05-17-05-30-00-2230312","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial","icon":"fasArrowRight"}},{"date":"2021-05-12T19:00:00.000Z","title":"New data to be featured at EHA 2021 Congress highlight Sanofi’s ongoing commitment to rare blood disorders","file":{"link":"/assets/dotcom/pressreleases/2021/2021-05-12-19-00-00-2228607-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-05-12-19-00-00-2228607","label":"Read the Press Release","target":"_self","title":"New data to be featured at EHA 2021 Congress highlight Sanofi’s ongoing commitment to rare blood disorders","icon":"fasArrowRight"}},{"date":"2021-05-12T17:35:00.000Z","title":"Positive Phase 3 Libtayo® (cemiplimab) results in advanced cervical cancer presented at ESMO Virtual Plenary","file":{"link":"/assets/dotcom/pressreleases/2021/2021-05-12-17-35-00-2228565-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-05-12-17-35-00-2228565","label":"Read the Press Release","target":"_self","title":"Positive Phase 3 Libtayo® (cemiplimab) results in advanced cervical cancer presented at ESMO Virtual Plenary","icon":"fasArrowRight"}},{"date":"2021-05-06T05:00:00.000Z","title":"Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research","file":{"link":"/assets/dotcom/pressreleases/2021/2021-05-06-05-00-00-2224038-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-05-06-05-00-00-2224038","label":"Read the Press Release","target":"_self","title":"Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research","icon":"fasArrowRight"}},{"date":"2021-04-30T15:56:48.000Z","title":"Annual General Meeting of April 30, 2021","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-30-15-56-48-2220769-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-30-15-56-48-2220769","label":"Read the Press Release","target":"_self","title":"Annual General Meeting of April 30, 2021","icon":"fasArrowRight"}},{"date":"2021-04-29T05:00:00.000Z","title":" Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-29-05-00-00-2219237-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-29-05-00-00-2219237","label":"Read the Press Release","target":"_self","title":" Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer","icon":"fasArrowRight"}},{"date":"2021-04-28T05:30:00.000Z","title":"Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-28-05-30-00-2218251-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-28-05-30-00-2218251","label":"Read the Press Release","target":"_self","title":"Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER","icon":"fasArrowRight"}},{"date":"2021-04-26T16:00:00.000Z","title":"Delisting of Kiadis will be effective on 25 May 2021","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-26-16-00-00-2217065-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-26-16-00-00-2217065","label":"Read the Press Release","target":"_self","title":"Delisting of Kiadis will be effective on 25 May 2021","icon":"fasArrowRight"}},{"date":"2021-04-26T11:00:00.000Z","title":"Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-26-11-00-00-2216648-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-26-11-00-00-2216648","label":"Read the Press Release","target":"_self","title":"Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands","icon":"fasArrowRight"}},{"date":"2021-04-26T06:00:00.000Z","title":"Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-26-06-00-00-2216474-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-26-06-00-00-2216474","label":"Read the Press Release","target":"_self","title":"Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial","icon":"fasArrowRight"}},{"date":"2021-04-23T14:05:00.000Z","title":"New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-23-14-05-00-2216083-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-23-14-05-00-2216083","label":"Read the Press Release","target":"_self","title":"New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years","icon":"fasArrowRight"}},{"date":"2021-04-19T05:00:00.000Z","title":"European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-19-05-00-00-2212005-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-19-05-00-00-2212005","label":"Read the Press Release","target":"_self","title":"European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma","icon":"fasArrowRight"}},{"date":"2021-04-16T16:00:00.000Z","title":"Sanofi completes Kiadis acquisition","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-16-16-00-00-2211767-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-16-16-00-00-2211767","label":"Read the Press Release","target":"_self","title":"Sanofi completes Kiadis acquisition","icon":"fasArrowRight"}},{"date":"2021-04-13T05:00:00.000Z","title":"Sanofi declares the offer for Kiadis unconditional","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-13-05-00-00-2208732-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-13-05-00-00-2208732","label":"Read the Press Release","target":"_self","title":"Sanofi declares the offer for Kiadis unconditional","icon":"fasArrowRight"}},{"date":"2021-04-09T17:45:00.000Z","title":"Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-09-17-45-00-2207664-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-09-17-45-00-2207664","label":"Read the Press Release","target":"_self","title":"Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas","icon":"fasArrowRight"}},{"date":"2021-04-09T05:00:00.000Z","title":"Sanofi completes Kymab acquisition","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-09-05-00-00-2207173-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-09-05-00-00-2207173","label":"Read the Press Release","target":"_self","title":"Sanofi completes Kymab acquisition","icon":"fasArrowRight"}},{"date":"2021-04-09T04:01:00.000Z","title":"Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-09-04-01-00-2207165-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-09-04-01-00-2207165","label":"Read the Press Release","target":"_self","title":"Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2","icon":"fasArrowRight"}},{"date":"2021-04-07T21:15:00.000Z","title":"Positive results from the sutimlimab pivotal trial for people with cold agglutinin disease published in New England Journal of Medicine","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-07-21-15-00-2206283-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-07-21-15-00-2206283","label":"Read the Press Release","target":"_self","title":"Positive results from the sutimlimab pivotal trial for people with cold agglutinin disease published in New England Journal of Medicine","icon":"fasArrowRight"}},{"date":"2021-04-07T07:03:41.000Z","title":"Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines ","file":{"link":"/assets/dotcom/pressreleases/2021/2021-04-07-07-03-41-2205543-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-04-07-07-03-41-2205543","label":"Read the Press Release","target":"_self","title":"Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines ","icon":"fasArrowRight"}},{"date":"2021-03-31T21:15:00.000Z","title":"FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2021/2021-03-31-21-15-00-2202919-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-03-31-21-15-00-2202919","label":"Read the Press Release","target":"_self","title":"FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma","icon":"fasArrowRight"}},{"date":"2021-03-31T14:05:00.000Z","title":"Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine ","file":{"link":"/assets/dotcom/pressreleases/2021/2021-03-31-14-05-00-2202566-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-03-31-14-05-00-2202566","label":"Read the Press Release","target":"_self","title":"Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine ","icon":"fasArrowRight"}},{"date":"2021-03-23T09:00:00.000Z","title":"Sanofi continues streamlining of established products with sale of anti-inflammatory drugs to Fidia Farmaceutici","file":{"link":"/assets/dotcom/pressreleases/2021/2021-03-23-09-00-00-2197396-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-03-23-09-00-00-2197396","label":"Read the Press Release","target":"_self","title":"Sanofi continues streamlining of established products with sale of anti-inflammatory drugs to Fidia Farmaceutici","icon":"fasArrowRight"}},{"date":"2021-03-19T06:30:00.000Z","title":"Availability of the Q1 2021 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2021/2021-03-19-06-30-00-2195917-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-03-19-06-30-00-2195917","label":"Read the Press Release","target":"_self","title":"Availability of the Q1 2021 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2021-03-15T06:00:00.000Z","title":"Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival ","file":{"link":"/assets/dotcom/pressreleases/2021/2021-03-15-06-00-00-2192446-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-03-15-06-00-00-2192446","label":"Read the Press Release","target":"_self","title":"Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival ","icon":"fasArrowRight"}},{"date":"2021-03-12T06:00:00.000Z","title":"Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate","file":{"link":"/assets/dotcom/pressreleases/2021/2021-03-12-06-00-00-2191846-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-03-12-06-00-00-2191846","label":"Read the Press Release","target":"_self","title":"Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate","icon":"fasArrowRight"}},{"date":"2021-03-04T17:18:34.000Z","title":"Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report","file":{"link":"/assets/dotcom/pressreleases/2021/2021-03-04-17-18-34-2187459-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-03-04-17-18-34-2187459","label":"Read the Press Release","target":"_self","title":"Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report","icon":"fasArrowRight"}},{"date":"2021-03-04T06:00:00.000Z","title":"FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma","file":{"link":"/assets/dotcom/pressreleases/2021/2021-03-04-06-00-00-2186746-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-03-04-06-00-00-2186746","label":"Read the Press Release","target":"_self","title":"FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma","icon":"fasArrowRight"}},{"date":"2021-03-03T17:00:00.000Z","title":"Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members","file":{"link":"/assets/dotcom/pressreleases/2021/2021-03-03-17-00-00-2186513-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-03-03-17-00-00-2186513","label":"Read the Press Release","target":"_self","title":"Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members","icon":"fasArrowRight"}},{"date":"2021-02-26T06:00:00.000Z","title":"Media Update: CHMP recommends approval of Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-26-06-00-00-2183074-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-26-06-00-00-2183074","label":"Read the Press Release","target":"_self","title":"Media Update: CHMP recommends approval of Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma","icon":"fasArrowRight"}},{"date":"2021-02-22T18:00:00.000Z","title":"FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-22-18-00-00-2179862-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-22-18-00-00-2179862","label":"Read the Press Release","target":"_self","title":"FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%","icon":"fasArrowRight"}},{"date":"2021-02-22T10:40:00.000Z","title":"Sanofi to provide manufacturing support to Johnson \u0026 Johnson for their COVID-19 vaccine to help address global supply demands","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-22-10-40-00-2179318-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-22-10-40-00-2179318","label":"Read the Press Release","target":"_self","title":"Sanofi to provide manufacturing support to Johnson \u0026 Johnson for their COVID-19 vaccine to help address global supply demands","icon":"fasArrowRight"}},{"date":"2021-02-22T10:40:00.000Z","title":"Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-22-10-40-00-2179319-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-22-10-40-00-2179319","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate","icon":"fasArrowRight"}},{"date":"2021-02-18T06:00:00.000Z","title":"Efanesoctocog alfa granted FDA Fast Track Designation for treatment of hemophilia A","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-18-06-00-00-2177630-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-18-06-00-00-2177630","label":"Read the Press Release","target":"_self","title":"Efanesoctocog alfa granted FDA Fast Track Designation for treatment of hemophilia A","icon":"fasArrowRight"}},{"date":"2021-02-12T06:00:00.000Z","title":"Sanofi and Kiadis collaboration: Exploring the offer memorandum for advancing healthcare innovation!","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-12-06-00-00-2174663-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-12-06-00-00-2174663","label":"Read the Press Release","target":"_self","title":"Sanofi and Kiadis collaboration: Exploring the offer memorandum for advancing healthcare innovation!","icon":"fasArrowRight"}},{"date":"2021-02-12T06:00:00.000Z","title":"Sanofi launches recommended cash offer for all shares in Kiadis","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-12-06-00-00-2174665-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-12-06-00-00-2174665","label":"Read the Press Release","target":"_self","title":"Sanofi launches recommended cash offer for all shares in Kiadis","icon":"fasArrowRight"}},{"date":"2021-02-12T06:00:00.000Z","title":"The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-12-06-00-00-2174676-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-12-06-00-00-2174676","label":"Read the Press Release","target":"_self","title":"The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%","icon":"fasArrowRight"}},{"date":"2021-02-09T22:15:00.000Z","title":"FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-09-22-15-00-2172711-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-09-22-15-00-2172711","label":"Read the Press Release","target":"_self","title":"FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma","icon":"fasArrowRight"}},{"date":"2021-02-09T06:00:00.000Z","title":"New indication for Plavix® (clopidogrel) now approved in the European Union","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-09-06-00-00-2171820-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-09-06-00-00-2171820","label":"Read the Press Release","target":"_self","title":"New indication for Plavix® (clopidogrel) now approved in the European Union","icon":"fasArrowRight"}},{"date":"2021-02-05T16:30:00.000Z","title":"Sanofi presents amended protocols in fitusiran clinical studies at EAHAD 2021","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-05-16-30-00-2170841-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-05-16-30-00-2170841","label":"Read the Press Release","target":"_self","title":"Sanofi presents amended protocols in fitusiran clinical studies at EAHAD 2021","icon":"fasArrowRight"}},{"date":"2021-02-05T06:30:00.000Z","title":"Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER ","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-05-06-30-00-2170436-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-05-06-30-00-2170436","label":"Read the Press Release","target":"_self","title":"Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER ","icon":"fasArrowRight"}},{"date":"2021-02-05T06:30:00.000Z","title":"Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-05-06-30-00-2170437-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-05-06-30-00-2170437","label":"Read the Press Release","target":"_self","title":"Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology","icon":"fasArrowRight"}},{"date":"2021-02-02T17:00:00.000Z","title":"Kiadis shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-02-17-00-00-2168492-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-02-17-00-00-2168492","label":"Read the Press Release","target":"_self","title":"Kiadis shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi","icon":"fasArrowRight"}},{"date":"2021-02-02T13:00:00.000Z","title":"Media Update: Data presented at WORLDSymposiumTM reinforces robust rare disease pipeline and highlights additional clinical data for investigational avalglucosidase alfa in Pompe disease","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-02-13-00-00-2168087-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-02-13-00-00-2168087","label":"Read the Press Release","target":"_self","title":"Media Update: Data presented at WORLDSymposiumTM reinforces robust rare disease pipeline and highlights additional clinical data for investigational avalglucosidase alfa in Pompe disease","icon":"fasArrowRight"}},{"date":"2021-02-01T15:00:00.000Z","title":"Media Update: New Dupixent® (dupilumab) data showcasing improvements across four type 2 inflammatory diseases to be presented at 2021 AAAAI Annual Meeting ","file":{"link":"/assets/dotcom/pressreleases/2021/2021-02-01-15-00-00-2167462-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-02-01-15-00-00-2167462","label":"Read the Press Release","target":"_self","title":"Media Update: New Dupixent® (dupilumab) data showcasing improvements across four type 2 inflammatory diseases to be presented at 2021 AAAAI Annual Meeting ","icon":"fasArrowRight"}},{"date":"2021-01-27T06:30:00.000Z","title":"Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs","file":{"link":"/assets/dotcom/pressreleases/2021/2021-01-27-06-30-00-2164797-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-01-27-06-30-00-2164797","label":"Read the Press Release","target":"_self","title":"Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs","icon":"fasArrowRight"}},{"date":"2021-01-12T13:30:00.000Z","title":"SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer","file":{"link":"/assets/dotcom/pressreleases/2021/2021-01-12-13-30-00-2157086-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-01-12-13-30-00-2157086","label":"Read the Press Release","target":"_self","title":"SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer","icon":"fasArrowRight"}},{"date":"2021-01-11T07:30:00.000Z","title":"Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L","file":{"link":"/assets/dotcom/pressreleases/2021/2021-01-11-07-30-00-2155914-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2021/2021-01-11-07-30-00-2155914","label":"Read the Press Release","target":"_self","title":"Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L","icon":"fasArrowRight"}},{"date":"2020-12-17T21:30:00.000Z","title":"Availability of the Q4 2020 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2020/2020-12-17-21-30-00-2147427-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-12-17-21-30-00-2147427","label":"Read the Press Release","target":"_self","title":"Availability of the Q4 2020 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2020-12-15T06:00:00.000Z","title":"Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030 ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-12-15-06-00-00-2144970-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-12-15-06-00-00-2144970","label":"Read the Press Release","target":"_self","title":"Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030 ","icon":"fasArrowRight"}},{"date":"2020-12-11T06:00:00.000Z","title":"Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly","file":{"link":"/assets/dotcom/pressreleases/2020/2020-12-11-06-00-00-2143517-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-12-11-06-00-00-2143517","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly","icon":"fasArrowRight"}},{"date":"2020-12-10T22:00:00.000Z","title":"Sanofi to resume dosing in fitusiran clinical studies in the U.S.","file":{"link":"/assets/dotcom/pressreleases/2020/2020-12-10-22-00-00-2143446-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-12-10-22-00-00-2143446","label":"Read the Press Release","target":"_self","title":"Sanofi to resume dosing in fitusiran clinical studies in the U.S.","icon":"fasArrowRight"}},{"date":"2020-12-09T06:00:00.000Z","title":"Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities","file":{"link":"/assets/dotcom/pressreleases/2020/2020-12-09-06-00-00-2141881-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-12-09-06-00-00-2141881","label":"Read the Press Release","target":"_self","title":"Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities","icon":"fasArrowRight"}},{"date":"2020-12-09T05:45:00.000Z","title":"Sanofi and Kiadis satisfy competition condition related to the tender offer","file":{"link":"/assets/dotcom/pressreleases/2020/2020-12-09-05-45-00-2141874-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-12-09-05-45-00-2141874","label":"Read the Press Release","target":"_self","title":"Sanofi and Kiadis satisfy competition condition related to the tender offer","icon":"fasArrowRight"}},{"date":"2020-11-30T06:00:00.000Z","title":"Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2020/2020-11-30-06-00-00-2136067-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-11-30-06-00-00-2136067","label":"Read the Press Release","target":"_self","title":"Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2020-11-30T05:45:00.000Z","title":"Press Release: Update on the intended offer by Sanofi for Kiadis","file":{"link":"/assets/dotcom/pressreleases/2020/2020-11-30-05-45-00-2136061-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-11-30-05-45-00-2136061","label":"Read the Press Release","target":"_self","title":"Press Release: Update on the intended offer by Sanofi for Kiadis","icon":"fasArrowRight"}},{"date":"2020-11-23T09:00:00.000Z","title":"European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older","file":{"link":"/assets/dotcom/pressreleases/2020/2020-11-23-09-00-00-2131477-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-11-23-09-00-00-2131477","label":"Read the Press Release","target":"_self","title":"European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older","icon":"fasArrowRight"}},{"date":"2020-11-18T18:12:36.000Z","title":"European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older","file":{"link":"/assets/dotcom/pressreleases/2020/2020-11-18-18-12-36-2129521-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-11-18-18-12-36-2129521","label":"Read the Press Release","target":"_self","title":"European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older","icon":"fasArrowRight"}},{"date":"2020-11-18T06:15:00.000Z","title":"Press Release: Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia","file":{"link":"/assets/dotcom/pressreleases/2020/2020-11-18-06-15-00-2128828-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-11-18-06-15-00-2128828","label":"Read the Press Release","target":"_self","title":"Press Release: Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia","icon":"fasArrowRight"}},{"date":"2020-11-18T06:00:00.000Z","title":"FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease","file":{"link":"/assets/dotcom/pressreleases/2020/2020-11-18-06-00-00-2128825-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-11-18-06-00-00-2128825","label":"Read the Press Release","target":"_self","title":"FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease","icon":"fasArrowRight"}},{"date":"2020-11-14T00:00:00.000Z","title":"FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease","file":{"link":"/assets/dotcom/pressreleases/2020/2020-11-14-00-00-00-2126796-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-11-14-00-00-00-2126796","label":"Read the Press Release","target":"_self","title":"FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease","icon":"fasArrowRight"}},{"date":"2020-11-05T14:00:00.000Z","title":"New clinical and health-related quality of life data in multiple myeloma and rare blood disorders to be presented at ASH 2020","file":{"link":"/assets/dotcom/pressreleases/2020/2020-11-05-14-00-00-2121130-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-11-05-14-00-00-2121130","label":"Read the Press Release","target":"_self","title":"New clinical and health-related quality of life data in multiple myeloma and rare blood disorders to be presented at ASH 2020","icon":"fasArrowRight"}},{"date":"2020-11-02T06:15:00.000Z","title":"Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products","file":{"link":"/assets/dotcom/pressreleases/2020/2020-11-02-06-15-00-2118122-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-11-02-06-15-00-2118122","label":"Read the Press Release","target":"_self","title":"Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products","icon":"fasArrowRight"}},{"date":"2020-11-02T06:00:00.000Z","title":"Sanofi offers to acquire Kiadis for €308 million","file":{"link":"/assets/dotcom/pressreleases/2020/2020-11-02-06-00-00-2118110-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-11-02-06-00-00-2118110","label":"Read the Press Release","target":"_self","title":"Sanofi offers to acquire Kiadis for €308 million","icon":"fasArrowRight"}},{"date":"2020-10-29T13:50:00.000Z","title":"European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)","file":{"link":"/assets/dotcom/pressreleases/2020/2020-10-29-13-50-00-2117063-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-10-29-13-50-00-2117063","label":"Read the Press Release","target":"_self","title":"European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)","icon":"fasArrowRight"}},{"date":"2020-10-29T06:30:00.000Z","title":"Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER","file":{"link":"/assets/dotcom/pressreleases/2020/2020-10-29-06-30-00-2116519-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-10-29-06-30-00-2116519","label":"Read the Press Release","target":"_self","title":"Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER","icon":"fasArrowRight"}},{"date":"2020-10-29T06:15:00.000Z","title":"Safety and efficacy of Dupixent® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis further reinforced by new data analyses presented at EADV","file":{"link":"/assets/dotcom/pressreleases/2020/2020-10-29-06-15-00-2116516-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-10-29-06-15-00-2116516","label":"Read the Press Release","target":"_self","title":"Safety and efficacy of Dupixent® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis further reinforced by new data analyses presented at EADV","icon":"fasArrowRight"}},{"date":"2020-10-29T06:00:00.000Z","title":"Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology","file":{"link":"/assets/dotcom/pressreleases/2020/2020-10-29-06-00-00-2116498-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-10-29-06-00-00-2116498","label":"Read the Press Release","target":"_self","title":"Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology","icon":"fasArrowRight"}},{"date":"2020-10-28T06:00:00.000Z","title":"Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine","file":{"link":"/assets/dotcom/pressreleases/2020/2020-10-28-06-00-00-2115626-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-10-28-06-00-00-2115626","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine","icon":"fasArrowRight"}},{"date":"2020-10-26T12:00:00.000Z","title":"Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings","file":{"link":"/assets/dotcom/pressreleases/2020/2020-10-26-12-00-00-2114216-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-10-26-12-00-00-2114216","label":"Read the Press Release","target":"_self","title":"Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings","icon":"fasArrowRight"}},{"date":"2020-10-16T12:00:00.000Z","title":" CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2020/2020-10-16-12-00-00-2109815-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-10-16-12-00-00-2109815","label":"Read the Press Release","target":"_self","title":" CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2020-10-15T12:00:00.000Z","title":"Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies","file":{"link":"/assets/dotcom/pressreleases/2020/2020-10-15-12-00-00-2109121-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-10-15-12-00-00-2109121","label":"Read the Press Release","target":"_self","title":"Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies","icon":"fasArrowRight"}},{"date":"2020-10-13T05:00:00.000Z","title":"Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-10-13-05-00-00-2107178-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-10-13-05-00-00-2107178","label":"Read the Press Release","target":"_self","title":"Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial ","icon":"fasArrowRight"}},{"date":"2020-10-02T05:00:00.000Z","title":"EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease","file":{"link":"/assets/dotcom/pressreleases/2020/2020-10-02-05-00-00-2102719-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-10-02-05-00-00-2102719","label":"Read the Press Release","target":"_self","title":"EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease","icon":"fasArrowRight"}},{"date":"2020-09-28T13:30:00.000Z","title":"Sanofi completes Principia Biopharma Inc. acquisition ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-28-13-30-00-2099966-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-28-13-30-00-2099966","label":"Read the Press Release","target":"_self","title":"Sanofi completes Principia Biopharma Inc. acquisition ","icon":"fasArrowRight"}},{"date":"2020-09-25T05:30:00.000Z","title":"Availability of the Q3 2020 Memorandum for modelling purposes","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-25-05-30-00-2099103-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-25-05-30-00-2099103","label":"Read the Press Release","target":"_self","title":"Availability of the Q3 2020 Memorandum for modelling purposes","icon":"fasArrowRight"}},{"date":"2020-09-22T16:50:50.000Z","title":"CHMP recommends approval of Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-22-16-50-50-2097511-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-22-16-50-50-2097511","label":"Read the Press Release","target":"_self","title":"CHMP recommends approval of Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older","icon":"fasArrowRight"}},{"date":"2020-09-22T16:30:00.000Z","title":"Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-22-16-30-00-2097496-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-22-16-30-00-2097496","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine","icon":"fasArrowRight"}},{"date":"2020-09-22T14:49:16.000Z","title":"CHMP recommends approval of MenQuadfi® for active immunization of individuals from the age of 12 months and older against invasive meningococcal ACWY disease","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-22-14-49-16-2097408-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-22-14-49-16-2097408","label":"Read the Press Release","target":"_self","title":"CHMP recommends approval of MenQuadfi® for active immunization of individuals from the age of 12 months and older against invasive meningococcal ACWY disease","icon":"fasArrowRight"}},{"date":"2020-09-22T05:00:00.000Z","title":"Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-22-05-00-00-2096915-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-22-05-00-00-2096915","label":"Read the Press Release","target":"_self","title":"Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.","icon":"fasArrowRight"}},{"date":"2020-09-21T12:25:00.000Z","title":"Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-21-12-25-00-2096500-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-21-12-25-00-2096500","label":"Read the Press Release","target":"_self","title":"Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%","icon":"fasArrowRight"}},{"date":"2020-09-18T10:52:46.000Z","title":"Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-18-10-52-46-2095745-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-18-10-52-46-2095745","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union","icon":"fasArrowRight"}},{"date":"2020-09-18T07:05:00.000Z","title":"Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-18-07-05-00-2095658-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-18-07-05-00-2095658","label":"Read the Press Release","target":"_self","title":"Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO ","icon":"fasArrowRight"}},{"date":"2020-09-18T05:00:00.000Z","title":"Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-18-05-00-00-2095616-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-18-05-00-00-2095616","label":"Read the Press Release","target":"_self","title":"Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation","icon":"fasArrowRight"}},{"date":"2020-09-14T05:00:00.000Z","title":"FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-14-05-00-00-2092666-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-14-05-00-00-2092666","label":"Read the Press Release","target":"_self","title":"FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis","icon":"fasArrowRight"}},{"date":"2020-09-10T05:00:00.000Z","title":"New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-10-05-00-00-2091410-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-10-05-00-00-2091410","label":"Read the Press Release","target":"_self","title":"New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A","icon":"fasArrowRight"}},{"date":"2020-09-08T05:00:00.000Z","title":"Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-08-05-00-00-2089711-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-08-05-00-00-2089711","label":"Read the Press Release","target":"_self","title":"Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma ","icon":"fasArrowRight"}},{"date":"2020-09-03T05:00:00.000Z","title":"Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-03-05-00-00-2088150-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-03-05-00-00-2088150","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate","icon":"fasArrowRight"}},{"date":"2020-09-01T05:00:00.000Z","title":"Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.","file":{"link":"/assets/dotcom/pressreleases/2020/2020-09-01-05-00-00-2086564-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-09-01-05-00-00-2086564","label":"Read the Press Release","target":"_self","title":"Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.","icon":"fasArrowRight"}},{"date":"2020-08-28T05:00:00.000Z","title":"Sanofi to commence tender offer for acquisition of Principia Biopharma Inc. ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-08-28-05-00-00-2085199-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-08-28-05-00-00-2085199","label":"Read the Press Release","target":"_self","title":"Sanofi to commence tender offer for acquisition of Principia Biopharma Inc. ","icon":"fasArrowRight"}},{"date":"2020-08-17T05:00:00.000Z","title":"Sanofi to acquire Principia Biopharma","file":{"link":"/assets/dotcom/pressreleases/2020/2020-08-17-05-00-00-2078993-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-08-17-05-00-00-2078993","label":"Read the Press Release","target":"_self","title":"Sanofi to acquire Principia Biopharma","icon":"fasArrowRight"}},{"date":"2020-07-31T19:20:00.000Z","title":"Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine","file":{"link":"/assets/dotcom/pressreleases/2020/2020-07-31-19-20-00-2071304-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-07-31-19-20-00-2071304","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine","icon":"fasArrowRight"}},{"date":"2020-07-31T11:00:00.000Z","title":"Press Release: Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine","file":{"link":"/assets/dotcom/pressreleases/2020/2020-07-31-11-00-00-2071010-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-07-31-11-00-00-2071010","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine","icon":"fasArrowRight"}},{"date":"2020-07-30T06:15:00.000Z","title":"Positive Phase 2b Clinical Trial: Nirsevimab reduces lower respiratory tract infections by 70 percent","file":{"link":"/assets/dotcom/pressreleases/2020/2020-07-30-06-15-00-2070026-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-07-30-06-15-00-2070026","label":"Read the Press Release","target":"_self","title":"Positive Phase 2b Clinical Trial: Nirsevimab reduces lower respiratory tract infections by 70 percent","icon":"fasArrowRight"}},{"date":"2020-07-29T15:29:13.000Z","title":"Online availability of Sanofi’s half-year financial report for 2020","file":{"link":"/assets/dotcom/pressreleases/2020/2020-07-29-15-29-13-2069605-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-07-29-15-29-13-2069605","label":"Read the Press Release","target":"_self","title":"Online availability of Sanofi’s half-year financial report for 2020","icon":"fasArrowRight"}},{"date":"2020-07-29T05:30:00.000Z","title":"Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation","file":{"link":"/assets/dotcom/pressreleases/2020/2020-07-29-05-30-00-2069158-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-07-29-05-30-00-2069158","label":"Read the Press Release","target":"_self","title":"Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation","icon":"fasArrowRight"}},{"date":"2020-07-29T05:00:00.000Z","title":"Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine","file":{"link":"/assets/dotcom/pressreleases/2020/2020-07-29-05-00-00-2069151-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-07-29-05-00-00-2069151","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine","icon":"fasArrowRight"}},{"date":"2020-07-06T20:30:00.000Z","title":"Availability of the Pre-quarterly Results Communication","file":{"link":"/assets/dotcom/pressreleases/2020/2020-07-06-20-30-00-2058185-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-07-06-20-30-00-2058185","label":"Read the Press Release","target":"_self","title":"Availability of the Pre-quarterly Results Communication","icon":"fasArrowRight"}},{"date":"2020-07-02T20:30:00.000Z","title":"Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients","file":{"link":"/assets/dotcom/pressreleases/2020/2020-07-02-20-30-00-2057183-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-07-02-20-30-00-2057183","label":"Read the Press Release","target":"_self","title":"Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients","icon":"fasArrowRight"}},{"date":"2020-06-23T05:00:00.000Z","title":"Sanofi’s virtual R\u0026D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-23-05-00-00-2051688-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-23-05-00-00-2051688","label":"Read the Press Release","target":"_self","title":"Sanofi’s virtual R\u0026D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients","icon":"fasArrowRight"}},{"date":"2020-06-23T04:59:00.000Z","title":"Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-23-04-59-00-2051681-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-23-04-59-00-2051681","label":"Read the Press Release","target":"_self","title":"Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas","icon":"fasArrowRight"}},{"date":"2020-06-19T13:00:00.000Z","title":"Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-19-13-00-00-2050713-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-19-13-00-00-2050713","label":"Read the Press Release","target":"_self","title":"Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors ","icon":"fasArrowRight"}},{"date":"2020-06-19T11:30:00.000Z","title":"Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-19-11-30-00-2050647-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-19-11-30-00-2050647","label":"Read the Press Release","target":"_self","title":"Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2020-06-16T12:00:00.000Z","title":"Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-16-12-00-00-2048709-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-16-12-00-00-2048709","label":"Read the Press Release","target":"_self","title":"Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease","icon":"fasArrowRight"}},{"date":"2020-06-16T10:00:00.000Z","title":"Sanofi invests to make France its world class center of excellence in vaccine research and production","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-16-10-00-00-2048583-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-16-10-00-00-2048583","label":"Read the Press Release","target":"_self","title":"Sanofi invests to make France its world class center of excellence in vaccine research and production","icon":"fasArrowRight"}},{"date":"2020-06-11T05:00:00.000Z","title":"Understanding Dupixent® (dupilumab)'s Growth Strategy and Mechanism of Action | Sanofi","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-11-05-00-00-2046612-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-11-05-00-00-2046612","label":"Read the Press Release","target":"_self","title":"Understanding Dupixent® (dupilumab)'s Growth Strategy and Mechanism of Action | Sanofi","icon":"fasArrowRight"}},{"date":"2020-06-08T05:00:00.000Z","title":"Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-08-05-00-00-2044631-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-08-05-00-00-2044631","label":"Read the Press Release","target":"_self","title":"Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease","icon":"fasArrowRight"}},{"date":"2020-06-03T16:00:00.000Z","title":"Press Release: Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-03-16-00-00-2043122-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-03-16-00-00-2043122","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan","icon":"fasArrowRight"}},{"date":"2020-06-02T13:00:00.000Z","title":"Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-02-13-00-00-2042255-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-02-13-00-00-2042255","label":"Read the Press Release","target":"_self","title":"Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma","icon":"fasArrowRight"}},{"date":"2020-06-02T10:47:38.000Z","title":"European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-02-10-47-38-2042068-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-02-10-47-38-2042068","label":"Read the Press Release","target":"_self","title":"European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma","icon":"fasArrowRight"}},{"date":"2020-06-02T05:00:00.000Z","title":"Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline","file":{"link":"/assets/dotcom/pressreleases/2020/2020-06-02-05-00-00-2041884-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-06-02-05-00-00-2041884","label":"Read the Press Release","target":"_self","title":"Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline","icon":"fasArrowRight"}},{"date":"2020-05-29T20:01:00.000Z","title":"Press Release: Sanofi announces closing of Regeneron stock sale","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-29-20-01-00-2041137-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-29-20-01-00-2041137","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi announces closing of Regeneron stock sale","icon":"fasArrowRight"}},{"date":"2020-05-29T12:00:00.000Z","title":"Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-29-12-00-00-2040886-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-29-12-00-00-2040886","label":"Read the Press Release","target":"_self","title":"Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time","icon":"fasArrowRight"}},{"date":"2020-05-29T05:00:00.000Z","title":"Sanofi names new leaders to Executive Committee","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-29-05-00-00-2040657-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-29-05-00-00-2040657","label":"Read the Press Release","target":"_self","title":"Sanofi names new leaders to Executive Committee","icon":"fasArrowRight"}},{"date":"2020-05-28T16:05:00.000Z","title":"Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-28-16-05-00-2040458-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-28-16-05-00-2040458","label":"Read the Press Release","target":"_self","title":"Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director","icon":"fasArrowRight"}},{"date":"2020-05-26T23:55:00.000Z","title":"Sanofi announces pricing of Regeneron stock offering","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-26-23-55-00-2039026-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-26-23-55-00-2039026","label":"Read the Press Release","target":"_self","title":"Sanofi announces pricing of Regeneron stock offering","icon":"fasArrowRight"}},{"date":"2020-05-26T15:40:00.000Z","title":"Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-26-15-40-00-2038798-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-26-15-40-00-2038798","label":"Read the Press Release","target":"_self","title":"Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2020-05-25T16:45:00.000Z","title":"Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-25-16-45-00-2038217-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-25-16-45-00-2038217","label":"Read the Press Release","target":"_self","title":"Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration","icon":"fasArrowRight"}},{"date":"2020-05-22T22:25:00.000Z","title":"Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-22-22-25-00-2037859-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-22-22-25-00-2037859","label":"Read the Press Release","target":"_self","title":"Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints","icon":"fasArrowRight"}},{"date":"2020-05-18T05:00:00.000Z","title":"Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R\u0026D day event","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-18-05-00-00-2034674-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-18-05-00-00-2034674","label":"Read the Press Release","target":"_self","title":"Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R\u0026D day event","icon":"fasArrowRight"}},{"date":"2020-05-14T05:00:00.000Z","title":"FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-14-05-00-00-2033186-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-14-05-00-00-2033186","label":"Read the Press Release","target":"_self","title":"FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease","icon":"fasArrowRight"}},{"date":"2020-05-12T05:00:00.000Z","title":"Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-12-05-00-00-2031604-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-12-05-00-00-2031604","label":"Read the Press Release","target":"_self","title":"Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma","icon":"fasArrowRight"}},{"date":"2020-05-05T05:00:00.000Z","title":"Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma","file":{"link":"/assets/dotcom/pressreleases/2020/2020-05-05-05-00-00-2027187-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-05-05-05-00-00-2027187","label":"Read the Press Release","target":"_self","title":"Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma","icon":"fasArrowRight"}},{"date":"2020-04-28T16:06:08.000Z","title":"Sanofi: Annual General Meeting of April 28, 2020","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-28-16-06-08-2023557-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-28-16-06-08-2023557","label":"Read the Press Release","target":"_self","title":"Sanofi: Annual General Meeting of April 28, 2020","icon":"fasArrowRight"}},{"date":"2020-04-27T11:00:00.000Z","title":"Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-27-11-00-00-2022295-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-27-11-00-00-2022295","label":"Read the Press Release","target":"_self","title":"Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival","icon":"fasArrowRight"}},{"date":"2020-04-27T10:58:00.000Z","title":"Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-27-10-58-00-2022288-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-27-10-58-00-2022288","label":"Read the Press Release","target":"_self","title":"Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients","icon":"fasArrowRight"}},{"date":"2020-04-24T05:00:00.000Z","title":"FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-24-05-00-00-2021445-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-24-05-00-00-2021445","label":"Read the Press Release","target":"_self","title":"FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination ","icon":"fasArrowRight"}},{"date":"2020-04-23T05:00:00.000Z","title":"Press Release: Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-23-05-00-00-2020541-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-23-05-00-00-2020541","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis","icon":"fasArrowRight"}},{"date":"2020-04-17T05:00:00.000Z","title":"Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-17-05-00-00-2017780-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-17-05-00-00-2017780","label":"Read the Press Release","target":"_self","title":"Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis","icon":"fasArrowRight"}},{"date":"2020-04-16T12:00:00.000Z","title":"Press Release: Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-16-12-00-00-2017250-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-16-12-00-00-2017250","label":"Read the Press Release","target":"_self","title":"Press Release: Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution","icon":"fasArrowRight"}},{"date":"2020-04-14T11:00:00.000Z","title":"Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-14-11-00-00-2015521-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-14-11-00-00-2015521","label":"Read the Press Release","target":"_self","title":"Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 ","icon":"fasArrowRight"}},{"date":"2020-04-10T05:55:20.000Z","title":"COVID-19: Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-10-05-55-20-2014764-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-10-05-55-20-2014764","label":"Read the Press Release","target":"_self","title":"COVID-19: Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries ","icon":"fasArrowRight"}},{"date":"2020-04-06T21:00:00.000Z","title":"Sanofi finalizes Praluent® (alirocumab) restructuring with Regeneron","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-06-21-00-00-2012457-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-06-21-00-00-2012457","label":"Read the Press Release","target":"_self","title":"Sanofi finalizes Praluent® (alirocumab) restructuring with Regeneron","icon":"fasArrowRight"}},{"date":"2020-04-06T18:11:51.000Z","title":"Sanofi successfully prices taps on outstanding bond issues for EUR 500 million ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-06-18-11-51-2012382-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-06-18-11-51-2012382","label":"Read the Press Release","target":"_self","title":"Sanofi successfully prices taps on outstanding bond issues for EUR 500 million ","icon":"fasArrowRight"}},{"date":"2020-04-03T05:30:00.000Z","title":"Sanofi: Availability of the Pre-quarterly Results Communication","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-03-05-30-00-2011228-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-03-05-30-00-2011228","label":"Read the Press Release","target":"_self","title":"Sanofi: Availability of the Pre-quarterly Results Communication","icon":"fasArrowRight"}},{"date":"2020-04-03T05:00:00.000Z","title":"Sanofi: Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-03-05-00-00-2011217-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-03-05-00-00-2011217","label":"Read the Press Release","target":"_self","title":"Sanofi: Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years","icon":"fasArrowRight"}},{"date":"2020-04-01T05:00:00.000Z","title":"Sanofi: Information on Sanofi’s Shareholder General Meeting of Tuesday, April 28, 2020","file":{"link":"/assets/dotcom/pressreleases/2020/2020-04-01-05-00-00-2009709-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-04-01-05-00-00-2009709","label":"Read the Press Release","target":"_self","title":"Sanofi: Information on Sanofi’s Shareholder General Meeting of Tuesday, April 28, 2020","icon":"fasArrowRight"}},{"date":"2020-03-30T05:00:00.000Z","title":"Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19","file":{"link":"/assets/dotcom/pressreleases/2020/2020-03-30-05-00-00-2008040-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-03-30-05-00-00-2008040","label":"Read the Press Release","target":"_self","title":"Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19","icon":"fasArrowRight"}},{"date":"2020-03-27T06:05:00.000Z","title":"Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2020/2020-03-27-06-05-00-2007411-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-03-27-06-05-00-2007411","label":"Read the Press Release","target":"_self","title":"Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma","icon":"fasArrowRight"}},{"date":"2020-03-27T06:00:00.000Z","title":"Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19","file":{"link":"/assets/dotcom/pressreleases/2020/2020-03-27-06-00-00-2007404-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-03-27-06-00-00-2007404","label":"Read the Press Release","target":"_self","title":"Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19","icon":"fasArrowRight"}},{"date":"2020-03-24T21:00:00.000Z","title":"Sanofi successfully prices EUR 1.5 billion of bond issue","file":{"link":"/assets/dotcom/pressreleases/2020/2020-03-24-21-00-00-2005874-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-03-24-21-00-00-2005874","label":"Read the Press Release","target":"_self","title":"Sanofi successfully prices EUR 1.5 billion of bond issue","icon":"fasArrowRight"}},{"date":"2020-03-05T22:28:30.000Z","title":"Sanofi : Filing of the 2019 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report","file":{"link":"/assets/dotcom/pressreleases/2020/2020-03-05-22-28-30-1996225-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-03-05-22-28-30-1996225","label":"Read the Press Release","target":"_self","title":"Sanofi : Filing of the 2019 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report","icon":"fasArrowRight"}},{"date":"2020-03-04T17:38:20.000Z","title":"Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors","file":{"link":"/assets/dotcom/pressreleases/2020/2020-03-04-17-38-20-1995299-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-03-04-17-38-20-1995299","label":"Read the Press Release","target":"_self","title":"Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors","icon":"fasArrowRight"}},{"date":"2020-03-02T18:51:16.000Z","title":"Sanofi : FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma","file":{"link":"/assets/dotcom/pressreleases/2020/2020-03-02-18-51-16-1993727-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-03-02-18-51-16-1993727","label":"Read the Press Release","target":"_self","title":"Sanofi : FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma","icon":"fasArrowRight"}},{"date":"2020-02-24T15:03:59.000Z","title":"Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*)","file":{"link":"/assets/dotcom/pressreleases/2020/2020-02-24-15-03-59-1989360-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-02-24-15-03-59-1989360","label":"Read the Press Release","target":"_self","title":"Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*)","icon":"fasArrowRight"}},{"date":"2020-02-18T15:00:00.000Z","title":"Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine","file":{"link":"/assets/dotcom/pressreleases/2020/2020-02-18-15-00-00-1986380-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-02-18-15-00-00-1986380","label":"Read the Press Release","target":"_self","title":"Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine","icon":"fasArrowRight"}},{"date":"2020-02-06T06:30:00.000Z","title":"Sanofi delivers strong 2019 business EPS growth of 6.8% at CER","file":{"link":"/assets/dotcom/pressreleases/2020/2020-02-06-06-30-00-1980751-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-02-06-06-30-00-1980751","label":"Read the Press Release","target":"_self","title":"Sanofi delivers strong 2019 business EPS growth of 6.8% at CER","icon":"fasArrowRight"}},{"date":"2020-02-06T06:00:00.000Z","title":"Sanofi : Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-02-06-06-00-00-1980729-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-02-06-06-00-00-1980729","label":"Read the Press Release","target":"_self","title":"Sanofi : Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis ","icon":"fasArrowRight"}},{"date":"2020-01-30T06:00:00.000Z","title":"Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency ","file":{"link":"/assets/dotcom/pressreleases/2020/2020-01-30-06-00-00-1977201-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-01-30-06-00-00-1977201","label":"Read the Press Release","target":"_self","title":"Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency ","icon":"fasArrowRight"}},{"date":"2020-01-28T06:00:00.000Z","title":"Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis","file":{"link":"/assets/dotcom/pressreleases/2020/2020-01-28-06-00-00-1975855-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-01-28-06-00-00-1975855","label":"Read the Press Release","target":"_self","title":"Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis","icon":"fasArrowRight"}},{"date":"2020-01-23T13:52:33.000Z","title":"Sanofi : Sanofi Completes Acquisition of Synthorx, Inc.","file":{"link":"/assets/dotcom/pressreleases/2020/2020-01-23-13-52-33-1974331-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-01-23-13-52-33-1974331","label":"Read the Press Release","target":"_self","title":"Sanofi : Sanofi Completes Acquisition of Synthorx, Inc.","icon":"fasArrowRight"}},{"date":"2020-01-20T06:00:00.000Z","title":"Sanofi : Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Synthorx","file":{"link":"/assets/dotcom/pressreleases/2020/2020-01-20-06-00-00-1972241-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-01-20-06-00-00-1972241","label":"Read the Press Release","target":"_self","title":"Sanofi : Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Synthorx","icon":"fasArrowRight"}},{"date":"2020-01-09T06:30:00.000Z","title":"Sanofi : Availability of the Pre-quarterly Results Communication","file":{"link":"/assets/dotcom/pressreleases/2020/2020-01-09-06-30-00-1968186-en.pdf"},"cta":{"type":"pressrelease","url":"/en/media-room/press-releases/2020/2020-01-09-06-30-00-1968186","label":"Read the Press Release","target":"_self","title":"Sanofi : Availability of the Pre-quarterly Results Communication","icon":"fasArrowRight"}}],"isCategoryFilter":true,"years":["2025","2024","2023","2022","2021","2020"],"pagination":20,"htmlId":"prlist"},{"cmsComponentType":"content-block","headingLevel":"h2","title":"Press Statements ","videoPlay":"Play the video","variation":"text-alone","cta":{"type":"internal","url":"/en/media-room/press-statements","label":"See more","target":"_self","title":"Press Statements","icon":"fasArrowRight"},"tableLines":[],"htmlId":"85615052-acfb-46db-9d35-52bb11d44bfe","imageContentAlignement":"flex-start","imageContentGridRatio":{"mobile":"4-4","tablet":"8-8","desktop":"7-5"},"imageRatio":"16/9","display":{"type":"none"},"linkVariation":"standalone","borderRadius":1,"textToWhite":false}],"bottom":[]}}}}},"actionData":null,"errors":null}};</script><script type="module" async="">import "/static/manifest-A69F9EC4.js"; import * as route0 from "/static/root-PCUIZQI5.js"; import * as route1 from "/static/routes/$-KESNOA4U.js"; window.__remixRouteModules = {"root":route0,"routes/$":route1}; import("/static/entry.client-G3JUSURV.js");</script></body></html>